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ABSTRACT 
The insulin-like growth factors, IGF-I and IGF-II, are ubiquitous polypeptide molecules 
that have mitogenic and metabolic actions in a wide variety of cell types, and 
consequently play a major role in mammalian growth and development. Unlike many 
other peptide hormones, IGF levels and their bioactivity are highly dependent upon the 
secretion of a family of six specific binding proteins, named IGFBPs. In this thesis, we 
have developed a normal human fibroblast in vitro cell culture model to investigate both 
factors that affect IGFBP secretion, the mechanisms behind such regulation, and also the 
effect of IGFBP modulation upon subsequent IGF-I mitogenic activity. 
Firstly, we have examined the possible role that the recently discovered IGFBP proteases 
may have in determining the effect of IGF-I on IGFBP-3 abundance in fibroblast 
conditioned media. We show that IGF-I increased IGFBP-3 when assessed by ligand 
blotting, but did not increase immunoreactive IGFBP-3, a discrepancy that could be 
explained by further data showing an inhibitory effect of IGF-I on the activity of the 
fibroblast IGFBP-3 protease. Thus, IGF-I protection of IGFBP-3 from enzymatic 
degradation may help explain the post-transcriptional, non-receptor mediated 'stimulation' 
of IGFBP-3 by IGF-I in these cells. 
We also show for the first time the ability of a number of cytokines to regulate IGFBP 
secretion, perhaps indicating a novel pathway of communication between these immune 
cell molecules and the IGFs. The inflammatory cytokine interleukin 113 (]L-16) inhibited 
Hs68 fibroblast IGFBP-3 secretion by down-regulating its gene expression, whilst tumour 
necrosis factor oc (TNF(x) had a similar inhibitory effect on IGFBP-3 and IGFBP-4 but 
acted via a post-transcriptional mechanism. The exact nature of the TNF(x effect remains 
to be determined as no evidence was found to suggest TNF(x increased IGFBP protease 
activity, or that TNF(x removed IGFBPs from the conditioned media by increasing the 
proportion immobilised on the cell surface. The inhibition of IGFBP secretion by TNF(x 
was observed to have marked effects upon the mitogenic activity of IGF-I in these cells, 
with a five-fold increase in sensitivity to the growth factor seen in a novel cytochemical 
bioassay. 
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Inhibition of fibroblast IGFBP secretion appeared to be restricted to certain cytokines as 
IL-6 had no effect, whilst high doses of interferon gamma abolished the TNF(X effect. 
Conversely, transforming growth factor 6 (TGFB) directly stimulated fibroblast IGFBP-3 
secretion, via an increase in gene expression, and subsequently resulted in the reduction 
in the mitogenic activity of IGF-I. 
These data indicate that a variety of mechanisms can be employed by a number of factors 
to elicit changes in fibroblast IGFBP secretion, and that these changes may have direct 
consequences in determining IGF-I bioactivity. Such is the importance given to the IGFs 
in maintaining normal somatic growth, changes in IGFBP secretion may contribute to the 
altered cellular growth and metabolism seen associated with cytokines in conditions as 
diverse as chronic infection, rheumatoid arthritis, cancer and the wound healing process. 
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CHAPTERL 
SECTION A. IGF CHARACTERISATION 
1.1. Historical perspectives 
The first evidence for a secondary mediator of growth hormone (GH) action came in 1957 
from Salmon and Daughaday, with their discovery that while GH in vivo stimulated the 
incorporation of sulphate into cartilage, it was inactive in vitro. They then presented 
evidence for an active factor in serum, under the control of GH, that stimulated in vitro 
sulphate incorporation into chrondroitin sulphate in rat costal cartilage segments. 
Accordingly they named this mediator of GH action 'sulphation factor'. 
Further research demonstrated that 'sulphation factor' also stimulated synthesis in 
chondrocytes of DNA, RNA, protein and hydroxyproline (Daughaday and Reeder, 1966), 
and promoted the proliferation of cultured cells in serum-free media. In recognition of 
these properties, the limiting term 'sulphation factor' was replaced by the name 
somatomedin (Sm) to reflect what was thought to be its primary function, the mediation 
of the growth promoting effect of GH (Salmon and DuVall, 1970). Three somatomedins 
were originally described, somatomedin-A (Sm-A) being defined by classical sulphation 
activity in chick cartilage (Sievertsson et al, 1975), somatomedin-B (Sm-B) by its ability 
to stimulate DNA synthesis in glial cells (Uthne, 1973), and somatomedin-C (Sm-C) by 
sulphation activity in a rat cartilage assay (Van Wyk et al, 1974). However, subsequent 
amino acid sequence analysis has since shown that Sm-A was a deaminated form of Sm-C 
(Enberg et al, 1984), whilst the original Sm-B preparation was found to be contaminated 
with epidermal growth factor (Heldin et al, 1981). 
At a similar time to the discovery of the somatomedins, another group was studying the 
nature of the insulin-like activity in serum detected in bioassay but absent in an insulin 
immunoassay (Froesch et al, 1963). The addition of saturating amounts of insulin 
antibodies to serum failed to affect the insulin-like bioactivity, namely glucose uptake, by 
more than 10%. The remaining 90% was thus termed the non-suppressible insulin-like 
activity (NSILA), and was found to consist of a low molecular weight acid-ethanol soluble 
fraction (NSILA-s) and a high molecular weight precipitable fraction (NSILA-p) (Froesch 
16 
1967). This seems to be the first description of the binding protein complex. The NSILA-s 
of approximately 8000 kDa was later found to possess similar properties to the 
somatomedins; stimulating sulphate incorporation into cartilage (Zingg and Froesch 1973), 
and DNA synthesis in fibroblasts (Morell and Froesch 1973, Zapf et al, 1978). 
As evidence for somatomedins and NSILA was emerging, another circulating peptide that 
also had the ability to stimulate DNA synthesis in cultured chicken embryo fibroblasts 
was partially purified from calf serum (Pierson and Temin, 1972). They named this 
somatomedin-like peptide multiplication- stimulating activity or MSA, and later showed 
it to be secreted by the rat liver cell line designated BRL-3A (Dulak and Temin, 1973). 
Confusion surrounding these early descriptions was finally resolved following analysis of 
the primary structure of the somatomedins, NSILA and MSA showing the activity of all 
these peptides could be ascribed to one of two factors which were then designated insulin- 
like growth factor (IGF) -I or IGF-H, Daughaday et al (1987). This remains the present 
day nomenclature, see Table 1. 
Tckhis- I 
ORIGINAL DESCRIPTION PRESENT CLASSIFICATION 
SULPHATION FACTOR 
SOMATOMEDIN-C IGF-I 
SOMATOMEDIN-A 
NSILA 
NSILA IGF-11 
MSA 
1.2. IGF peptide structure 
The primary structures of IGF-I and IGF-II were first characterised from adult human 
plasma by Rindernecht and Humbel (1978,1978a). They are both single chain peptides 
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with three interchain disulphide bridges and are comprised of either 70 (IGF-1) or 67 
(IGF-11) amino acids, with molecular weights of 7646 and 7471 Daltons, respectively. The 
IGF structures functionally consist of an A-domain and an amino terminal B-domain 
separated by a connecting C-region (figure 11). IGF-l and IGF-111 share identical amino 
acids at 45 positions, a 64% homology, whilst the A and B regions show a 42% sequence 
homology with proinsulin. Unlike proinsulin however, the IGFs have an additional D- 
domain which extends from from the C-terminal end of the peptide. 
The primary structure of the IGFs has also been characterised in a number of other 
species, including rat (Murphy et al, 1987), mouse (Bell et al, 1986), cow (Honneger & 
Humbel, 1986) and pig (Tavakkol et al, 1988). Human, bovine and porcine IGF-l were 
seen to be identical demonstrating the highly conserved nature of the peptide. Rat and 
mouse IGF-I differ from the human form by only three and four amino acids, respectively. 
Sequence analysis of isolated IGF cDNA clones has predicted that both IGF-I and IGF-11 
are initially synthesized as large 18 kDa precursors, with additional E-domain regions at 
the carboxy termini (figure Li and figure IGF-I can have a 35 JGF-IA) or 77 
(IGF-IB) amino acid extension, while IGF-11 exists with an extra 89 amino acids. 
Certain other altered forms of IGFs have also been described. A truncated IGF-I peptide 
named Des[I-3]-IGF-1, with a deletion of the first three amino acids at the N-terminus, 
has been isolated from both human brain (Sara et al, 1986) and bovine colostrum (Francis 
et al, 1988). This IGF-I peptide whilst having normal affinity for the type I IGF receptor, 
has a greatly reduced affinity for the IGFBPs. 
A number of circulating precursor IGF-11 peptides have also been observed. For example, 
Daughaday et al (1988) reported a 15 kDa form in normal plasma and also in patients 
with non-islet cell tumour associated hypoglycemia. Its biological activity was similar to 
the mature 7.5 kDa form. A 10 kDa IGF-11 peptide, witha 21 amino acid extension, has 
also been purified from human serum (Zumstein et al, 1985). 
1.3. Gene structure 
The genomic sequences for IGF-I and IGF-11 have been mapped to the long arm of human 
chromosome 12 and the short arm of chromosome II respectively (Brissendon et al, 1984) 
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Figure Li. 
DNA: 
Exon I Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 
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050100150200 
1111 
Amino AMINO ACID NUMBER Carboxyl 
terminus terminus 
Schematic representation of mammalian IGF-I DNA, mRNA 
transcripts and precursor proteins. Adapted from Holthuizen 
et al, 1991. 
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Figure I. H. 
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Schematic representation of mammalian IGF-Il DNA, 
mRNA transripts and precursor proteins. Adapted from 
Holthuizen et al, 1991. 
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Recent molecular cloning studies have indicated that 
in mammals the single-copy IGF-I gene has both a complex structure and a complicated 
pattern of expression. 
In rats and humans there are six IGF-I exons and at least four promoters distributed over 
more than 70 kb of chromosomal DNA. The first two leader exons at the 5-part of the 
human IGF-I gene, designated IB and IC, contain alternative initiation sites of 
transcription. The mature IGF-I peptide is encoded by exons 2 and 3. The variable E 
domains seen in the IGF-I precursor peptides arise from alternative splicing of the classl 
mRNA; exon 3 to 4 in IGF-IA and exon 3 to 5 in IGF-IB. Northern blot analysis has 
subsequently shown that exon 4 is only present in the 1.3 kb mRNA, while exon 5 is 
found in the 7.6 and 1.1 kb mRNA species. 
Each of these mRNAs encode IGF-I precursors with different carboxyl-terminal 
extensions, perhaps giving a subtle range of different biological activities. Moreover, there 
are indications in the rat that the shorter mRNA species are preferentially associated with 
polysomes and have a higher stability. The 7.6 kb mRNA also has several putative 
destabilisation signals, thought to be important in determining its half-life. 
The 30 kb IGF-11 gene is similarly complex, with nine exons and four different promoters 
generating five or more mRNA species, ranging from 2.2 - 6.0 kb in size (figure I. H. ). 
It is also notable that the IGF-H gene is located very close to the insulin gene, being 
separated by only 1.4 kb of intergenic cDNA. 
1.4. IGF function 
Despite the wide range of activities that have been described for the IGFs, most fan into 
three broad categories: those affecting mitogenesis, insulin-like metabolic actions and 
those involved in modulating cellular differentiation. 
1.41 Mitogenic effects 
Perhaps the most widely acknowledged function of the IGFs is to stimulate cell 
proliferation. This ability of IGF was first demonstrated in vitro by Salmon and Hosse 
(1971) who showed that a serum fraction rich in 'sulphation activity' could partially 
21 
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substitute for serum in stimulating the growth of HeLa cell populations. The partially 
purified NSILA and MSA (Pierson and Temin, 1972) was then shown to stimulate the 
incorporation of '[H]thymidine into cellular DNA in vitro, a now well established 
indicator of mitogenesis. 
Demonstration of the ubiquitous nature of the mitogenic IGF response has subsequently 
come from a large number of studies measuring thymidine uptake in a variety of cell 
types. These include foreskin fibroblasts (DeMellow and Baxter, 1988), thyroid epithelial 
cells (Tramontano et al, 1986), myoblasts (Florini et al, 1986), and hepatoma cells 
(Verspohl et al, 1988). Despite such widespread target cell types however, the IGFs only 
appear to be effective at certain points in the cell cycle. For example, cells that have 
become quiescent and have entered into Go of the cycle, usually through the removal of 
the serum component in the culture medium, are often insensitive to the mitogenic action 
of the IGFs. The addition of 'competence factors' are often required, such as platelet 
derived growth factor (PDGF) and fibroblast growth factor (FGF), which initiate the cell 
cycle and take the cells into G1. Thus stimulated, the IGFs can then act as 'progression 
factors' taking the cells into the DNA synthesis stage (S) and then through stages G2 and 
M, ending in cell division (Clemmons and Van Wyk et al, 1981). 
The wide ranging mitogenic effects of the IGFs seen in vitro are thought to be seen in 
vivo translating GH signals into effects on normal body growth. IGF-I for instance 
stimulates the clonal. expansion of prechondrocytes in the germinal layer of the epiphyseal 
growth plate, which after degenerating allows increased cartilage matrix to be ossified by 
osteoblasts, resulting in new bone formation. Close correlations between the GH / IGF 
axis and body height scores during development from neonate to adult have been well 
documented, with increased circulating IGF-I levels seen during the pubertal growth spurt. 
Moreover, abnormalities of growth such as those caused by GH excess (acromegaly) and 
GH insensitivity (Laron) syndrome are characterised by correspondingly altered IGF-I 
levels (Clemmons et al, 1979, Laron et al, 1980). 
22 
MAL Insulin-like metabolic effects 
Early studies using the so named 'fat pad assay' (Froesch et al, 1963) described the ability 
of IGF to stimulate glucose uptake and net gas exchange in rat epididymal fat pad 
sections. Purified IGF-I and IGF-][[ were shown to be approximately sixty-fold less potent 
than insulin in this assay (Zapf et al, 1978), although the potential for IGF controlled 
glucose regulation would appear great due to its vastly higher concentration in serum. 
Similarly, the IGFs were shown to stimulate "CO2production and `C incorporation into 
lipid (lipogenesis) in isolated fat cells, with IGF-II two to three-fold more potent than 
IGF-I. 
A number of other IGF bioassays have also employed the use of radiolabelled metabolites 
as indices of metabolic activity. These include IGF stimulated cellular uptake of D-[I- 
'H]glucose and its incorporation into glycogen, the uptake of the non-metabolised 2- 
deoxy-D- [I -'H] glucose, the incorporation of L-[4,5-'H]Ieucine into Sertoli cell protein 
(Borland et al, 1984), and the uptake of the non-metabolised 2-amino[ 1_14C]isobutyric acid 
by human fibroblasts (Kaplowitz, 1987) and rat thyroid cells (Rotella et al, 1989). Despite 
early suggestions that such effects were due to IGF cross-reacting with the insulin 
receptor, many of the above actions can be asigned to the IGF receptors themselves, 
although the overall IGF contribution to the acute regulation of glucose metabolism in 
vivo is unclear at present. 
Certain metabolic enzymatic activities can also be regulated by the IGFs, such as 
increased glucose-6-phosphate dehydrogenase activity in human osteosarcoma cells 
(Farquharson et al, 1992), and increased glycogen synthase activity in isolated soleus 
muscle (Poggi et al, 1979). 
1.4. iii. Cellular differentiation 
The IGFs have been demonstrated to stimulate the differentiation of myoblasts (Florini 
et al, 1986), osteoblasts (Schmid et al, 1984), and adipocytes (Smith, 1988). They also 
appear to be differentiating factors for both ovarian (Adashi et al, 1985) and testicular 
function (Chatelain et al, 1987), amplifying the actions of the respective steroid hormones. 
The IGFs can induce erythropoiesis (Claustres et al, 1987) and also stimulate 
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granulopoiesis and chernotaxis in endothelial. and melanoma cells (Stracke et al, 1988). 
Differentiated effects under IGF control also include the stimulation of sulphate uptake 
into costal cartilage and the synthesis and deposition of glycosaminoglycans into the 
extracellular matrix (Kemp and Hintz, 1980). 
1.5. Control of IGF secretion 
Historically, studies investigating the regulation of IGF activity have tended to follow the 
same route used for other established peptide hormones, largely focussing therefore on the 
alteration of IGF gene expression and peptide levels in the circulation. A number of 
factors and conditions which are capable of mediating these parameters have now been 
identified and are described below. 
Daughaday et al (1976) first demonstrated that IGF-I secretion from isolated rat liver, 
since recognised as the main source of circulating IGF-I, was particulary sensitive to GH. 
Since this initial discovery, GH has been established as the primary regulator of IGF-I 
gene expression (Mathews et al, 1986), not only of hepatic origin but also in many other 
tissues, such as heart, lung and pancreas. 
The GH dependency of circulating IGF-I levels is also evident in a number of clinical 
conditions involving altered GH status, such as puberty, acromegaly and hypopituitarism, 
whilst the lack of functional GH receptors in fetal tissues and Laron syndrome has been 
suggested to be responsible for their low IGF-I levels. Unlike the pulsatile nature of GH 
secretion however, IGF-I levels do not undergo any marked diurnal rhythm. 
There is also evidence to suggest other trophic hormones can regulate IGF biosynthesis, 
particularly that of extrahepatic: origin. For example, increased IGF-I gene expression can 
result from treatment with platelet derived growth factor (PDGF) and fibroblast growth 
factor (FGF) in human fibroblast cultures (Clemmons & Shaw, 1983), thyroid hormones 
in the liver (Tollet et al, 1990), epidermal growth factor in the kidney (Rogers et al, 
1991), and parathyroid hormone in cultured foetal rat bone cells (McCarthy et al, 1989). 
The effects of these hormones do appear to be tissue specific however, as demonstrated 
by oestradiol stimulating IGF-I in the uterus (Murphy and Friesen, 1988), whilst generally 
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inhibiting the hepatic IGF output. Follicle stimulating hormone (FSH), luteinising hormone 
(LH), and adrenocorticotrophic hormone (ACTH) act on their respective target organs to 
stimulate paracrine production of IGF-I. 
Nutrition is also an imPortant regulator of circulating IGFs, with severe fasting, such as 
that seen in patients with anorexia nervosa, reducing IGF-I levels to those associated with 
GH deficiency (Clemmons et al, 1981). In these states, GH is rendered ineffective and 
only refeeding can restore IGF-I levels to normal. 
An enhancement of IGF-I levels is seen at sites of local tissue injury. An elevation in 
IGF-I immunoreactivity during regeneration after injury has been observed in rat 
peripheral nerves, skeletal muscle, and endothelial cells of arteries (Jennische et al, 1987). 
Although the precise mechanism behind such an effect is unclear, a possible source of 
IGF other than from an autocrine origin may be from invading cells involved in the 
inflammatory response, such as platelets and peripheral blood mononucleocytes. 
1.6. Cell membrane IGF receptors 
Another area of IGF physiology which is crucial to the regulation of the activity of this 
growth factor is the nature and tissue distribution of the cell membrane IGF receptor 
family. Like most peptide hormones and growth factors the IGFs require association with 
one of a group of cell surface receptors to elicit their biological actions. Early competitive 
binding experiments demonstrated the presence of two subtypes of IGF receptors quite 
distinct from the insulin receptor and have subsequently been designated as Type I and 
Type H IGF receptors. 
1.61 Type I IGF receptors 
Type I IGF receptors were characterised by Ulrich et al (1986) and are closely related to 
the insulin receptor, with about a 40% homology. They are initially synthesised as 150 
kDa precursor proteins, which are subsequently glycosylated, proteolytically cleaved and 
dimerized to form the 300 - 350 kDa heterotetrameric receptor structure. This consists of 
two extracellular ot subunits (135 kDa) anchored to the plasma membrane and two 
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transmembrane 6 subunits by disulphide bonds. 
The 6 subunits (90 kDa) contain an intracellular portion with an adenosine triphosphate 
(ATP) binding region, autophosphorylation sites and intrinsic tyrosine- specific protein 
kinase activity (Roth et al, 199 1). Although the precise biochemical cascade of events that 
follows activation of these tyrosine kinases upon IGF receptor ligand interaction is largely 
unknown, certain phoshatidylinositol kinases (type I PtdIns kinase) appear to be closely 
involved in a similar manner to insulin. 
Unlike the rather ubiquitous insulin receptor, Type I IGF-I receptors can exist in varying 
quantities on cell surfaces or be present in specific cell type subpopulations. Scatchard 
analysis of IGF-I binding data has demonstrated the presence of such receptors on normal 
human fibroblasts (Rosenfeld and Dollar, 1982) with a high affinity for the IGF-I peptide 
(Ka Of 1.07 x 10' M-') similar to that seen in IM-9 human lymphocytes and BRL 3A2 rat 
liver cells. They also strongly bind IGF-H with a K. approximately ten-fold reduced 
(Ritvos et al, 1988) and to a lesser degree insulin. 
1.6. ii. Hybrid IGF-I receptors 
The characteristic modular structure of the Type I IGF receptor and its similarity with the 
insulin receptor can apparently give rise to the existence of hybrids. Essentially, these 
consist of one pair of (x and 6 subunits from each of the respective receptors, thus 
retaining the tetramic tertiary structure (Soos and Siddle, 1989), and have been found in 
various tissues, including hepatoma and fibroblast cells. 
Their binding affinity appears greater for IGF-I than insulin, although it is not known 
which of the tyrosine kinase domains within the hybrids becomes activated when either 
ligand binds. As the IGF and insulin components of these receptors are independently 
regulated however it seems likely that they may serve to increase the flexibility of cellular 
responses to certain extracellular stimuli. 
1.6. iii. Type 11 IGF receptors 
The primary structure of the Type H IGF receptor was first characterised in human 
hepatorna (HepG2) cells by Morgan et al (1987). These single-chain 220-300 kDa 
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receptors were thus found to be structurally unrelated to both type I IGF and insulin 
receptors, with high binding affinity for IGF-H (Kd of 0.1 nM, Beukers et al, 1991) and 
little or no affinity for either IGF-I or insulin. 
They consist of a large extracellular domain, which accounts for approximately 93% of 
the total receptor protein, comprising fifteen hydrophobic cysteine-rich repeat sequences. 
This is linked by a single transmembrane region to a small cytoplasmic domain, which 
unlike the Type I IGF receptor has no protein kinase activity, although can be 
phosphorylated in intact cells. 
More recent evidence has suggested that secondary signalling by IGF-111 through this 
receptor may involve the activation of certain calcium channels mediated via a network 
of pertussis toxin-sensitive G proteins, such as Gi-2 (Nishimoto et al, 1989). 
Perhaps the most intriguing discovery about the Type H IGF receptor came however from 
its cloning analysis which showed it to be identical to the cation independent mannose-6- 
phosphate (Man-6P) receptor (Oshima et al, 1988). Ligand binding studies demonstrated 
that each receptor could bind both IGF-11 and molecules containing the Man-6P residue 
without inhibiting the binding of each other, indicating separate binding sites. Moreover, 
as the Man-6P receptor has been implicated in targeting molecular traffic to cytoplasmic 
lysosomes for degradation, possible IGF-11 modulation of such a process, although as yet 
unproven, remains a possibilty. 
1.6. iv. IGF receptor regulation 
The dynamic nature of cell membrane receptor populations, such as those for the IGFs, means that 
their regulation can take a number of forms. Essentially, regulation of receptor activity 
may be achieved by alteration of receptor affinity or number, the latter reflecting changes 
in receptor biosynthesis (principally gene expression), degradative processing and 
internalisation. Altered Type I IGF receptor gene expression has been recorded in response 
to a variety of conditions. Nutritional deprivation, for example, can cause reversible 
increases in steady state mRNA and receptor number in lung, stomach, kidney and heart 
tissues (Lowe et al, 1989). Developmental stage also determines the mRNA levels of this 
receptor, with a general reduction seen in many rat tissues following embryonic 
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advancement and postnatal development. 
Certain hormonal regulators have also been observed to alter Type I IGF receptor gene 
expression. Estradiol increases mRNA levels 6.5 fold in a human breast cancer cells 
(MCF-7), whilst there is some evidence that diabetes can lead to significant increases in 
some rat tissues. 
Down regulation of Type I IGF receptor numbers by IGF-1, IGF-H and insulin, in 
proportion to their relative binding affinities, has been observed in vitro using human 
lymphocytes and fibroblasts (Rosenfeld and Dollar, 1982). This effect is not however seen 
in Type 11 IGF receptors, once again reflecting their markedly different nature. Indeed, 
insulin appears to acutely upregulate Type 11 receptors in rat adipocyte tissue, the most 
likely mechanism being an alteration in its rapid turnover and recycling, possibly by 
inhibiting kinase activity (Corvera and Czech, 1985). GH similarly affects adipocyte Type 
H receptors (Unnroth et al, 1987). 
1.6. v. Functional aspects of 1GF receptors 
Initially, largely due to the ease at which IGFs cross-reacted with the insulin receptor, it 
was assumed that the IGFs mediated their insulin-like metabolic actions through this 
receptor. However, a number of studies have now shown that whilst most of the growth- 
promoting action of the IGFs (and insulin) are mediated via the Type I IGF receptor, 
many metabolic IGF actions also result from the interaction with the receptor in a number 
of tissue types. For example, IGF metabolic activity such as glucose and amino acid 
uptake has been recorded to occur through Type I IGF receptors in human skin fibroblasts 
(Knight et al, 198 1), human choriocarcinoma cells (Ritvos et al, 1988a), human hepatoma 
cells (Vershpohl et al, 1988) and even mouse muscle (Poggi et al, 1979). 
The role of the Type R IGF receptors is more unclear however. In many cell types IGF-11 
mitogenesis can be inhibited by the addition of Type I IGF receptor monoclonal antibodies 
(Conover et al, 1986), whilst anti-Type I IGF receptor antibodies have mostly been 
ineffective. In a few tissues, such as the human erythroleukaernic cell line K562 which 
lacks the Type I receptors, IGF-11 can stimulate cell growth via its own receptor however 
(Tally and Hall, 1990), indicating that this receptor can transmit well recognised IGF 
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signalling functions, in some cells at least. As outlined earlier, the significance of the 
Man-6P receptor homology is unknown at present. 
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CHAPTERL 
SECTION B. THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS 
The most unique aspect which characterises IGF physiology compared to other peptide 
hormones and growth factors is the existence of a closely related family of soluble 
binding proteins. The six species of IGFBPs so far identified seem to share a common 
ancestry, as demonstrated by the high degree of homology in their amino acid sequences 
(figure 1AH. ), notably in that part of the molecule thought to be important in IGF binding, 
the N and C termini. Despite such close structural similarities the IGFBPs have variable 
IGF binding affinities, often greater or of the same magnitude as the cell membrane IGF 
receptors, and unlike GH binding protein they are not simply soluble components of the 
membrane receptors but arise from distinct genes. It has also become increasingly 
apparent that individual IGFBP species are often localised to particular tissues or cell 
types and may be regulated by their own specific factors, suggesting that they are not 
merely simple carrier proteins but may have a more active role in determining IGF 
physiology. An overview of the current knowledge on the IGFBPs is now given below. 
1.7. Insulin-like growth factor-binding protein 3 
Characterisation 
The majority of circulating IGFs in man, especially IGF-I, are found in a ternary complex 
of approximately 140 kDa. This comprises an acid-labile (a) subunit of about 85 kDa, the 
IGFBP-3 acid stable binding (3) subunit of 50 kDa and the growth factor subunit of about 
7.5 kDa, either IGF-I or IGF-H (Furlanetto, 1980). The a-subunit appears on non-reduced 
SDS-PAGE as a glycoprotein doublet between 84-86 kDa, with binding to the IGFBP-3 
only possible when the IGFBP-3 is occupied by the IGF peptide (Baxter, 1988). 
The 6-subunit of this complex, the IGFBP-3 peptide, also appears on non-reduced SDS 
PAGE as a doublet of approximately 53 and 47 kDa, both with IGF binding activity. 
These two bands represent differentially glycosylated forms of the same 29 kDa core 
peptide which has been cloned and sequenced (Wood et al, 1988). The complete cDNA 
for human IGFBP-3 is approximately 2500 bp in length, containing a 120 bp 5' 
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untranslated region, an 873 bp coding region and approximately 1400 bp of 3' 
untranslated sequence. The mature binding protein comprises 264 amino acids and 
contains 18 cysteines, all of which are thought to be involved in forming disulphide bonds 
(Sommer et al, 1991), suggesting a potentially complex folding pattern. The IGFBP-3 has 
a 33% homology with IGFBP-l but lacks an Arg-Gly-Asp (RGD) sequence suggesting 
no potential interaction with cell surface integrin receptors. The gene for IGFBP-3 has 
been located on chromosome 7 (Cubage et al, 1990). 
Tissue expression and production 
A 2.4 kb IGFBP-3 mRNA species has been detected in many human and rat tissues, with 
particularly high levels of the gene observed in liver, ovary, spleen and prostate 
(Shimasaki et al, 1989; Naya et al, 1991). IGFBP-3 peptide has also been demonstrated 
in vitro in numerous cell types, including fetal, neonatal and adult human skin fibroblasts 
(Martin & Baxter, 1988, Camacho-Hubner et al, 1992), vascular endothelial cells (Bar et 
al, 1989), breast carcinoma (Adamo et al, 1992), and porcine and human ovarian 
granulosa cells (Mohan et al, 1989). 
Regulation of IGFBP-3 
In vivo observations 
The growth hormone (GH)-dependence of the 150 kDa complex has been known for a 
number of years, due to various chromatographic studies (Zapf et al, 1981), and a study 
demonstrating the reappearance of IGFBP-3 in hypophysectomised rats upon GH treatment 
(Moses et al, 1976). There is also a large body of evidence detailing a very close 
correlation between circulating IGFBP-3 levels and GH secretory status (Blum & Ranke 
1991). For example, congenital and idiopathic hypopituitarism show reduced IGFBP-3 
levels in line with their GH deficiency, whilst growth hormone excess in acromegalic 
patients is associated with markedly increased IGFBP-3, which decrease upon treatment 
(Hardouin et al, 1987). 
As described earlier however, GH appears to be the primary mediator of IGF-I secretion, 
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particularly from the liver, and a series of more recent experiments has suggested that it 
may be the IGF-I peptide that directly mediates IGFBP-3 levels. Zapf et al (1989) showed 
IGF-I infusion into hypophysectornised rats (thus GH deficient) could itself restore 
IGFBP-3 to normal levels. IGF-I infusion into protein deficient (Clemmons et al, 1989) 
and diabetic rats, both GH resistant syndromes, can also significantly increase IGFBP-3 
serum concentrations. Crucially, GH treatment was without effect in both of these models. 
Each of the above models do introduce additional variables other than GH deficiency 
however, such as removal of all anterior pituitary hormones, dietary imbalance, and 
potential disruption of insulin-mediated metabolic processes. To overcome these possible 
problems Camacho-Hubner et al, (199 1) utilised a model consisting of four genotypically 
distinct groups of sibling transgenic mice that differed in respect to their expression of GH 
and IGF-I (Behringer et al, 1990). Low IGFBP-3 levels seen in their GH-deficient mice 
(caused by genetic ablation of somatotrophs) could be restored to near normal in similar 
animals expressing IGF-I having lost its GH dependence. Further to this, normal mice 
with genetically manipulated over-expression of IGF-I showed increased IGFBP-3, despite 
slightly reduced GH (probably due to an IGF-I negative feedback pathway acting on the 
pituitary). Thus, these experiments strongly implicated IGF-I as being the main regulator 
of IGFBP-3, at least in the rat. 
Regulation of the 80 kDa acid-labile subunit however appears to be under direct control 
of GH itself. In the transgenic mouse model described earlier (Camacho-Hubner et al, 
1991) those animals genetically GH deficient, but with normal expression of IGF-I, lacked 
the ternary 150 kDa complex despite having about two-thirds normal levels of IGF-I and 
IGFBP-3. More recent data has shown that synthesis of ALS by rat hepatocytes in vitro 
can be directly increased by the addition of GH (Scott and Baxter, 1991). 
The in vitro fibroblast model. 
Although a wide variety of cultured cell types have been shown to secrete IGFBP-3, 
human skin fibroblasts have been used most extensively in studies investigating the 
regulation of this binding protein. There are a number of reasons for this, including the 
ease at which they can be obtained, notably from the foreskins of newborn donors, their 
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successful maintenance in vitro, including serum-free environments, and their 
undifferentiated non-transformed phenotype. 
The production and characterisation of IGFBPs released by human dermal fibroblasts has 
thus been well described over the last decade. Originally Adams et al (1984) reported the 
presence of an IGFBP complex of 150 kDa in fibroblast conditioned medium, which upon 
acidification became a lower molecular mass of between 50 - 60 kDa. This was consistent 
with the presence of the IGFBP-3 complex as seen in serum, with the IGFBP-3 peptide 
coupled to the 80 kDa acid labile subunit. 
A more detailed study by Martin and Baxter (1988) revealed that in the absence of serum, 
neonatal skin fibroblasts secreted at least three IGFBPs. The largest and most abundant 
of these was indeed seen to cross-react with a specific antibody raised against the human 
plasma IGFBP-3, whilst not to a specific IGFBP- I antiserum. Further, IGF binding studies 
showed the affinity of this peptide for IGF-I to be similar to that of plasma IGFBP-3. Its 
size estimation determined by affinity labelling and SDS Page also matched serum 
IGFBP-3, with the appearance of doublet between Mr 43,000 and 39,000 representing the 
two glycosylated forms of the binding protein. 
Final confirmation of the presence of fibroblast derived IGFBP-3 was subsequently shown 
through recognition of IGFBP-3 mRNA using a full length human cDNA probe and 
Northern blotting (Camacho-Hubner et al,, 1992). This study also clarified the identity of 
the other fibroblast IGFBP species. The 31,000 kDa IGFBP was shown to be IGFBP-5 
whilst the smaller 24,000 kDa form corresponded to IGFBP-4. 
Data from the initial experiments investigating the regulation of IGFBP-3 in these cells 
seemed to confirm many observations seen in vivo, with little or no change in IGFBP-3 
secretion (measured by Western ligand blot) in response to GH. As outlined earlier there 
has been described in vivo a very close correlation between circulating IGF-l status and 
levels of IGFBP-3. Experiments analysing the conditioned medium from IGF-I and IGF-11 
treated fibroblasts indicated dose-dependent increases in IGFBP-3 levels (Clemmons et 
al, 1991), as was expected in view of the in vivo data . 
An IGFBP-3 radioimmunoassay 
confirmed these findings (Martin and Baxter, 1991) although increases of only fifty 
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percent were seen even after 72 hour incubations. 
During these early studies it became apparent that despite the consistent increases in 
fibroblast IGFBP-3 in response to IGF, such an effect was not mediated via cell 
membrane receptors. Evidence against type-I IGF receptor involvement came from 
experiments using supraphysiological doses of insulin, capable of cross-reacting with this 
receptor, that were shown to be largely without effect (Clemmons et al, 1991). In 
addition, more recent studies using [QAYL]IGF-1, an IGF-I analogue with normal IGF 
receptor affinity but up to a six hundred fold reduced affinity for the IGFBPs, showed no 
effect of this peptide upon IGFBP-3 levels (Conover, 1991). Moreover, the type-I IGF 
receptor blocking antibody WR-3 caused no change in the native IGF-I effect. This 
apparently novel mechanism of IGFBP-3 regulation has now been reported to occur in a 
number of cell types, such as human and rat osteoblast-like cell cultures. 
Data on the effect of IGF-I upon fibroblast IGFBP-3 gene expression has been more 
equivocal. One report has described IGF-I to inconsistantly increase IGFBP-3 mRNA 20- 
60% but largely have no effect in human adult fibroblasts (Bale and Conover, 1992), thus 
supporting the mechanism described above for IGFBP-3 peptide regulation. However, 
another study has recorded a 2-fold increase in IGFBP-3 mRNA in response to IGF-I 
(Camacho-Hubner et al, 1992), although the cells were derived from a fetal source 
possibly explaining the descrepancy. 
Certain other growth factors have also been shown to regulate IGFBP-3 secretion from 
fibroblast cells. Martin and Baxter (1991) demonstrated that epidermal growth factor 
(EGF) and transforming growth factor B (TGFf3) induced increases in IGFBP-3 production 
from neonatal human skin fibroblasts during 72 hour incubations. Platelet derived growth 
factor (PDGF) similarly enhanced IGFBP-3 secretion in mouse 3T3 fibroblasts (Corps and 
Brown, 199 1). 
IGFBP proteases 
The assumption that the above regulators of IGFBP-3 operate by altering the molar 
amounts of secreted binding protein has been brought into question by the discovery of 
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proteolytic activity capable of degrading the IGFBPs (Hossenlopp et al, 1990). Such 
activity was initially described in the circulation of pregnant women and appeared to lead 
to the structural degradation of the IGFBPs, such that they exhibited a considerable 
reduction in affinity for 1251-IGF. Consequently, these patients gave low serum IGFBP-3 
levels when assessed by Western ligand blotting, despite normal or even elevated values 
in immunological assays. 
The presence of circulating proteolytic activity affecting IGFBP-3 has since been 
described in prostate cancer patients (Cohen et al, 1992), in children suffering GH 
deficiency (Cotterill et al, 1992) and in patients in a catabolic state (Davies et al, 1991). 
There is also evidence to suggest that this activity can be produced by a wide variety of 
transformed and non-transformed cells in vitro (Holly et al, 1993). Activity produced by 
rat prostate cells has been identified as a urokinase-type plasminogen activator 
(Koutsilieris et A 1993), whilst in primates 72 and 96 kDa gellatinases have been 
implicated (Giudice et al, 1993). 
At present, the functional significance of the IGFBP protease(s) is unknown and somewhat 
controversial, indeed at present there is little data suggesting specificity for the IGFBPs. 
However, studies in some in vitro systems have now shown that IGF bioactivity can be 
increased in the presence of IGFBP protease (Holly et al, 1993), perhaps indicating the 
potential importance of such a system for regulating IGFBPs. 
Functions of IGFBP-3 
Endocrine 
In normal human adults IGFBP-3 is the most abundant IGF binding protein in the 
circulation, with typical concentrations of 5 mg/l or 150 nmols/l (Baxter and Martin, 
1986). Approximately 90% is found in the ternary complex of 140 kDa, resulting in 
restricted transport of the IGF peptide across the endothelial barrier (Binoux and 
Hossenlopp, 1988) and also a reduction in its renal clearance. Thus, the association of IGF 
with IGFBP-3 / ALS has been shown experimentally to greatly stabilise the IGF peptide, 
with its half-life in serum increasing over 50-fold, from about 10 minutes to 10 - 15 hours 
(Guler et al, 1989). 
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Moreover, as the formation of this complex is dependent upon the presence of the IGF 
peptide (on an equimolar basis), it follows that IGFBP-3 functions as a large circulating 
reservoir of IGF. Unlike most endocrine hormones the IGFs are synthesized and secreted 
somewhat constitutively from a wide variety of sources, rather than secreted acutely on 
demand from an inactive source stored in secretory granules. This has prompted the 
attractive hypothesis that the circulating reservoir of IGF held by the IGFBP-3 complex 
may act as a mobile endocrine 'gland', releasing the active peptide as required. 
When one considers the difference between the resultant concentrations of the IGFs and 
those of insulin (some 100 : 1, in respective molarities) we must assume that most of the 
IGFs within the IGFBP-3 complex have been inactivated, otherwise severe hypoglycaemia 
would surely occur. Increases in IGF activity however, are observed in cases of high 
IGFBP-3 levels, such as acromegaly, due to the parallel increase in IGF peptide. Indeed, 
an in vivo animal model of wound repair found that treatment with IGF and IGFBP-3, 
when compared with IGF-1 given alone, resulted in enhanced tissue formation (Sommer 
et al, 1991). This suggests that although IGFBP-3 seems to act as an IGF inhibitor, the 
rate of IGF release from the complex to the tissues remains constant allowing alterations 
in steady state IGF levels, dependent upon IGFBP levels, to be reflected in concommitant 
changes in bioactivity. The specific mechanisms which regulate the release of IGF from 
the IGFBP-3 are at present largely unknown, although heparin and certain 
glycosaminoglycans have been shown to dissociate the binary IGF/IGFBP-3 complex from 
the acid labile subunit (Baxter, 1990). 
Autocrine / paracrine 
In addition to extravascular IGFBP-3 derived from an hepatic origin and transported 
across the endothelium, a large amount of IGFBP-3 found amongst the tissues is likely 
to be from a more local source, either autocrine or paracrine. Moreover, whilst certain 
interpretations on the function of circulating IGFBP-3 can be made from the large number 
of in vitro studies carried out on this binding protein, the data obtained is perhaps more 
pertinent towards our understanding of this more local source of IGFBP-3. 
Most of the IGFBP-3 data from cell culture in vitro studies have been in agreement with 
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its supposed function in the circulation, i. e. an inhibitor of IGF activity. Initial studies 
using impure preparations of serum IGFBPs (mostly IGFBP-3 therefore) found inhibition 
of IGF actions ranging from stimulation of glucose transport in adipocytes (Chochinov et 
al, 1977), sulphate incorporation by chondrocytes (Zapf et al, 1979), and thymidine 
incorporation in fibroblasts (Drop et al, 1979). A later study by DeMellow and Baxter 
(1988) also observed IGF-I inhibition when the peptide was co-incubated with pure 
IGFBP-3, presumably by preventing it from associating with the IGF cell membrane 
receptors. 
Such a simplistic understanding of the function of IGFBP-3 was however brought into 
question from other data presented in this same study. A pre-incubation of the fibroblast 
cells with the pure IGFBP-3 preparation prior to the addition of IGF-I, was found to result 
in up to a 50% increase in subsequent IGF-I activity. Others have now reported similar 
IGF-I responses, following these particular incubation conditions, with both glycosylated 
and non-glycosylated IGFBP-3 (Conover, 1991). Although the precise mechanism 
involved is unknown, IGFBP-3 sensitisation of cells by blocking endogenous IGFs from 
down-regulating membrane receptors has been suggested, as has cell bound IGFBP-3 
directly modulating the presentation of the IGF molecule to its receptor. 
1.8. Insulin-like growth factor binding-protein 1 
Characterisation 
IGFBP- I was first detected in and purified from amniotic fluid (Chochinov et al, 1977; 
Drop et al, 1979). It was also the first IGFBP to be cloned (Lee et al, 1988) and its gene 
characterised (Brinkman et al, 1988). In humans this binding protein consists of 259 
amino acids with a calculated molecular weight of approximately 28.1 kDa, is highly 
negatively charged and rich in cysteine residues. 
The IGFBP- I gene spanning 5.2 kb is found on chromosome 7, located just 20 kb from 
the IGFBP-3 gene. This is reflected in their respective protein coding regions, with 
homologous exons 1,3 and 4, and a dissimilar exon 2. The N-terminal portion of IGFBP- I 
is thought to be responsible for IGF binding whereas the hydrophylic C-terminal region 
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contains an RGD sequence (Arg-Gly-Asp tripeptide) which represents a potential cell 
attachment site similar to that found in the integrin family of proteins (Brewer et al, 
1988). 
Although having no glycosylation sites, IGFBP- I is at present thought to be unique 
amongst IGFBPs in that it can exist in a number of differentially phosphorylated forms 
(Jones et al, 1991). Human hepatoma (HepG2) cells and human decidual cells secrete at 
least four different isoforms, with binding affinities for IGF-I between 3 and 7-fold greater 
than the non-phosphorylated form. The presence of a specific phosphatase in amniotic 
fluid and fetal serum has been suggested after the appearance of non-phosphorylated and 
phosphorylated forms, and may be an important regulator of IGFBP-1 function (see 
below). 
Tissue expression and production 
The main site of IGFBP-1 production is the liver, and although the peptide is widely 
distributed throughout many other tissues, other sources of IGFBP- I mRNA are restricted. 
It has been identified in human amniotic fluid as a 35 - 40 kDa binding protein (named 
AFBP), in tissue extracts of fetal and maternal placenta (placental protein 12, Koistinen 
et al, 1986) and in the conditioned medium of human HepG2 hepatoma cells (BP-25, Lee 
et al, 1988). 
Due to its early discovery and description IGFBP-1 has historically been assigned a 
multitude of pseudonyms. IGFBP- I in human pregnancy endometrium has been variously 
described as pregnancy-associated endometrial oc' globulin (cc'-PEG), chorionic ocl- 
microglobulin (CAG-1), placental-specific (x'-microglobulin (PAMG-1) and endometrial 
protein 14 (EP14). Analysis demonstrating the homology between these independently 
isolated proteins together with the introduction of a standardised nomenclature (Ballard 
et al, 1989) brought all these terminolgies under the single designation of IGFBP-1. 
Regulation of IGFBP-1 
In vivo 
In normal human adults IGFBP-1 has the third highest serum concentration amongst the 
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IGF binding proteins in normal human adults, although its typical levels (5 nmol/1) are 
approximately 50-fold less than IGFBP-3. Unlike IGFBP-3 however, this binding protein 
is not regulated by GH and undergoes a marked diurnal variation with its highest levels 
detected in the morning (Cotterill et al, 1988) reaching a typical peak of 100 nmol/l. This 
acute variation has since been shown to be inversely related to the secretory pattern of 
insulin (Holly et al, 1988). Insulin dependence of IGFBP- I has now been observed in a 
number of metabolic disorders characterised by abnormal insulin status. Increased serum 
IGFBP-1 has been described in GH deficiency and anorexia, conditions of low insulin, 
while raised IGFBP- I has been recorded in obesity, polycystic ovarian syndrome, 
acromegaly and diabetes. 
In vitro 
Much of the in vitro data on the regulation of IGFBP- I has come from studies involving 
the HepG2 human hepatoma cell line. In agreement with the in vivo data, the prodigous 
secretion of IGFBP-1 by these cells is reduced when incubated with insulin (Cotterill et 
al, 1989) and IGF-I, both apparently operating through their respective receptors. 
Conversely, increased hepatic IGFBP-1 secretion can be found in conditions of low 
glucose, such as the specific inhibition of hexose uptake by cytochalasin B. Factors which 
stimulate intracellular cyclic nucleotide accumulation also have this effect. 
Functions of IGFBP-1 
Endocrine 
The regulatory patterns of IGFBP- 1 seen in vivo suggest that this binding protein is 
important in controlling the acute actions of the IGFs. Moreover, its response to glucose 
administration and experimentally induced hypoglycaemia are consistent with a role in 
glucose counter-regulation, principally through the its inhibitory effect on IGF bioactivity, 
as seen in the in vitro studies. As approximately 98% of circulating IGF is held within 
the 140 kDa IGFBP-3 complex, it has been hypothesized that the effect of acute increases 
in IGFBP- I is to block the 'free' IGF fraction (some 2 nmol/1) thus preventing its insulin- 
like activity. Other studies have ascribed the role of an IGF transport molecule to IGFBP- 
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1, carrying the IGF from the circulation to the tissues. Primarily this has arisen from data 
describing the ability of IGFBP-1 to traverse the endothelial barrier (Bar et al, 1990), 
thereby explaining the widespread nature of the peptide when compared to its sites of 
mRNA expression. 
Autocrine / Paracrine 
The precise function of non-hepatic IGFBP- 1, such as that from endometrial tissue, is 
controversial. Most in vitro studies have shown that exogenous IGFBP- I inhibits both the 
metabolic and mitogenic actions of the IGFs, an effect thought to be due to its ability to 
compete with the cell membrane receptors (Ritvos et al, 1988). 
Conversely however, others have described IGFBP-1 mediated enhancement of IGF 
bioactivity (Elgin et al, 1987), and unlike that seen in response to IGFBP-3 this can occur 
when both peptides are co-incubated. This effect has been associated with the adherence 
of the binding protein to target cell surfaces (Busby et al, 1988), perhaps working through 
its RGD amino acid sequence interacting with the integrin receptor family. Interesting data 
has also suggested that the degree of phosphorylation of IGFBP- I may play a central role 
in affecting its function as an IGF regulator at the tissue level (Clemmons et al, 1991). 
The HepG2 cell line, for example, secretes at least four differentially phosphorylated 
isoforms, each consistently inhibiting the mitogenic effect of IGF-I. Dephosphorylated 
IGFBP- I however potentiates IGF-I action, possibly through a reduction in affinity for the 
growth factor, indicating that a potential mechanism of regulating its cellular activity may 
indeed be via dephosphorylation, by a specific phosphatase for example. 
As more data is obtained on this dichotomous function of IGFBP-1 the role of this 
binding protein in regulating IGF bioactivity, at least at the tissue level, seems certain to 
be modified from the simple inhibitor as it was first ascribed. 
1.9. Insulin-like growth factor binding-protein 2 
Characterisation 
One of the earliest IGFBPs to be discovered was IGFBP-2, first identified as a binding 
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protein for Multiplication Stimulating Activity (MSA), or rat IGF-H, in culture media 
conditioned by the rat liver cell line BRL-3A (Romanus et al, 1986). The precise primary 
structure was subsequently determined from cDNA clones isolated from the adult rat liver 
(Margot et al, 1989, Binkert et al, 1989). The mature peptide is comprised of 270 amino 
acids, with no glycosylation sites, resulting in a molecular weight of 29.5 kDa. Cysteine 
rich domains are present however, and like IGFBP-1 it contains the RGD sequence of 
amino acids, suggesting possible association with the integrin receptor family. The 
primary structure of IGFBP-2 is conserved amongst species, with human and rat species 
sharing 90% sequence homology. Its gene has been located on chromosome 2 (Shimasaki 
et A 1990) and codes for a single mRNA transcript of 1.6 kb. 
Tissue expression and production 
As perhaps expected from its initial discovery in rat hepatocytes in vitro, the major source 
of circulating IGFBP-2 is from the liver. Typically, this binding protein is the second most 
abundant IGFBP in the circulation, with levels of 20 nmol/l, and remains fairly constant 
throughout the day (Clemmons et al, 1991). The production of IGFBP-2, both from a 
developmental perspective and in its restriction to certain cell types other than those of 
hepatic origin, seems to be linked to the presence of IGF-11. For example, this binding 
protein is especially predominant in early fetal life and subsequently declines into adult 
life, thus following the pattern of IGF-11. It is also associated with a number of IGF-11 
secreting tumours such as rhabdomyosarcomas (Roghani et al, 1989), human breast 
carcinoma (DeLeon et al, 1989), and also in non-islet cell tumour hypoglycaemia (Zapf 
et al, 1990). IGFBP-2 is the predominant IGFBP found in human cerebro-spinal 
fluid 
(CSF), and has also been observed in medium conditioned by cultured fetal neuronal and 
astroglial cells (Lamson et al, 1989). 
Regulation 
Due to its close correlation with circulating IGF-11 levels, it has been suggested that this 
growth factor may be the primary regulator of this binding protein. 
Despite certain 
similarities with IGFBP -1, its pattern of regulation appears to 
be distinct. In the human 
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subject acute stimulation of insulin has little or no effect upon circulating levels of 
IGFBP-2, although in severe insulin deficiency (such as fasting) levels can be increased. 
Moreover, in rats (where IGF-II is perhaps of greater importance) raised hepatic IGFBP-2 
is found in diabetic animals, reducing upon treatment with insulin (Boni-Schnetzler et al, 
1990). 
Functions of IGFBP-2 
The precise function of IGFBP-2 is unclear. It has also been suggested that IGFBP-2 
seems to be a 'reserve' binding protein in the circulation, acting to provide replacement 
IGF binding sites in conditions where the IGFBP-3 ternary complex is reduced. Thus, its 
circulating levels are high in hypopituitarism and fasting patients, reflecting the distinct 
mode of regulation seen with this particular IGFBP. Its close association and preferential 
affinity for IGF-IL some ten fold greater than that for IGF-I in the rat (Forbes et al, 
1988), also suggests that it may have a specific role in mediating the physiology of this 
IGF species. However, as the function of IGF-II itself is still largely unknown we can 
only speculate as to its importance. As with both IGFBP-1 and IGFBP-3, exogenous 
IGFBP-2 can inhibit IGF activity in vitro (Han et al, 1988), although no data has yet been 
presented on its potential capacity to enhance such activity. 
1.10. Insuhn-like growth factor binding-protein 4 
Characterisation 
The low molecular weight IGFBP-4 was first identified in human serum (Hardouin et al, 
1987) and has subsequently been isolated and sequenced from human and rat sources 
(Shimasaki et al, 1990; LaTour et al, 1990). The human cDNA is 1899 base pairs in size 
and encodes a 237 amino acid mature protein, with a predicted molecular weight of 
25,970 daltons. Its gene is found on chromosome 17 and results in the expression of a 
single 2.2 kb mRNA transcript. The 18 cysteine residues common to IGFBP-1, -2, and - 
3 are retained, but there also exists an additional two cysteines at the mid portion of the 
molecule. The molecule has the potential to exist in a glycosylated form, with a single N- 
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linked glycosylation site, but does not contain the RGD amino acid sequence seen in both 
IGFBP- I and -2. Historically, IGFBP-4 has been named both Binding Protein 24 (BP24) 
and Bone-Cell Derived Binding Protein. 
Tissue expression and production 
IGFBP-4 was originally identified in the conditioned media from human osteosarcoma and 
prostatic turnour cells (Mohan et al, 1989; Perkel et al, 1990). It has since been described 
from a number of other cell types in vitro, including human skin fibroblasts (Conover et 
al, 1991) and human breast cancer cells (De Leon et al, 1989). In the rat neuroblastoma 
cell line B 104 a 28 kDa glycosylated IGFBP-4 varient has been observed in addition to 
the more usual non-glycosylated 24 kDa peptide (Ceda et al, 1991). IGFBP-4 mRNA 
expression is most abundant in the liver, although has been recorded in many other tissues 
such as adrenal, testis, spleen, heart, lung, kidney and stomach (Shimasaki et al, 1990). 
V'M 
Irvegulation of 1GFBP-4 
Parathyroid hormone (PTE), which inhibits the formation of bone both in vivo and in 
vitro, can regulate IGFBP-4 by enhancing mRNA and subsequent protein levels in cultures 
of normal human osteoblast-like cells (La Tour et al, 1990). In contrast, the IGFs can 
inhibit the appearance of IGFBP-4 in the conditioned media of human fibroblast cultures 
(Neely and Rosenfeld, 1992) although in a similar fashion to the IGF induced 
enhancement of IGFBP-3 in these cells, this effect is not mediated via the type I or type 
11 IGF receptors, and does not involve modulation of IGFBP-4 gene expression (Camacho- 
Hubner et al, 1992). 
Functions of IGFBP-4 
Little is known of the fuction of IGFBP-4. Its enhancement by PTH which can be 
catabolic in bone may be consistent with the generally held view of IGFBPs, that of 
acting as inhibitors of IGF (anabolic) activity. However, certain in vivo studies have also 
indicated that PTH may actually increase osteoblast growth and have an overall anabolic 
action in new bone formation, possibly through the mediation of secondary factors such 
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as the IGFs (Tam et al, 1982). To clarify the role of IGFBP-4 in this system more studies 
are required to determine if IGFBP-4 can enhance IGF actions in a similar fashion to 
IGFBP- I and -3, as described earlier. 
Although the function of glycosylated residues on IGFBP-3 has yet to be determined, their 
presence on certain IGFBP-4 molecules has prompted some to suggest that these may be 
serum IGFBPs, with non-glycosylated subpopulations serving different functions at the 
tissue level. 
1.11. Insulin-like growth factor binding-protein 5 
Characterisation 
IGFBP-5 consists of 252 amino acids, with the 18 cysteine residues characteristic of other 
IGFBPs evident, giving a predicted molecular weight of 28.5 kDa. The RGD amino acid 
sequence is lacking although the protein may exist in an 0-glycosylated form. The gene 
for IGFBP-5 is located on chromosome 5, and gives rise to a single mRNA species of 6.0 
kb (Shimasaki et al, 1991). 
Tissue expression and production 
IGFBP-5 mRNA is most abundant in the kidney, but is also found in the intestine, 
adrenal, heart, lung, brain, spleen. It is almost absent from the liver, resulting in 
undetectable levels in serum. A number of cells in vitro also produce this IGFBP, 
including a human glioblastoma tumour cell line designated T98G (from which the 
peptide was originally purified and sequenced), osteoblast-like cells (Andress and 
Birnbaum, 199 1) and also human fetal fibroblasts (Camacho-Hubner et al, 1992). It is also 
the only IGFBP to be produced by the untransformed. rat thyroid cell line FRTL-5 
(Backeljauw et al, 1993). 
Regulation of IGFBP-5 
Levels of IGFBP-5 increase by six to eight-fold in media conditioned by human 
fibroblasts following 24 hour incubations with maximal doses of IGF-l or IGF-11 
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(Camacho-Hubner et al, 1992). This effect was not however mediated through either IGF 
or insulin cell membrane receptors, but was directly dependent upon the IGF peptide 
binding to the IGFBP. Such post-transcriptional regulation has also been observed for 
IGFBP-3, and may involve the IGF displacing IGFBP-5 from the cell membrane or 
protection from proteolytic activity. IGF-I increases IGFBP-5 mRNA and peptide in the 
non-transformed rat thyroid cell line FRTL-5, and insulin, via its own receptor, also seems 
to increase IGFBP-5 in these cells. 
Functions of IGFBP-5 
Due to its absence from serum the function of IGFBP-5 is presumed to be limited to 
affecting the IGFs at the tissue level. In fibroblasts it is preferentially localised in the 
extracellular matrix (Jones et al, 1993), apparently binding to specific components, despite 
lacking the RGD amino acid sequence recognised by the integrin receptor family. The 
precise function of these additional sites for cell surface localisation of the IGF peptides 
is unknown at present. In the osteoblast-like cells however IGFBP-5 has been 
demonstrated to potentiate the mitogenic activity of IGF-1. 
1.12. Insulin-like growth factor binding-protein 6 
Characterisation 
The last IGFBP to be discovered, termed IGFBP-6, was originally isolated from human 
cerebrospinal fluid (CSF) where it constitutes the predominant binding protein (Roghani 
et al, 1989). Subsequently, it was cloned and characterised by Shimasaki et al (1991), 
using porcine follicular fluid and adult rat serum. Human IGFBP-6 consists of 216 amino 
acids, with a predicted molecular weight of 22.8 kDa, and lacks both the short RGD 
sequence recognised by the integrin cell surface receptors, and 2 of the 18 cysteines 
characteristic of all other IGFBPs (figure I. M. ). IGFBP-6 typically exists in a 
glycosylated form similar to IGFBP-3 and -4, although unlike the latter it is 0- 
glycosylated rather than N-glycosylated (Bach et al, 1993). Rat IGFBP-6 is similar in 
structure (201 amino acids) and size (21.5 kDa) but lacks 4 cysteines. The gene for 
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IGFBP-6 is located on chromosome 12, and encodes for a single 1.3 kb mRNA transcript 
Tissue expression and production 
IGFBP-6 mRNA has been found in a wide range of tissues, including the liver, resulting 
in typical serum peptide levels in normal human adults of approximately 10 nmol/l 
(Baxter and Saunders, 1992), comparable to those of IGFBP-2 and higher than baseline 
IGFBP-1. In addition, it has been purified from ovarian follicular fluid, CSF, and from 
the conditioned media from transformed and non-transformed human lung fibroblasts. 
Rxe-egulation of IGFBP-6 
Little attention has been given to the regulation of IGFBP-6 in vivo, perhaps due in part 
to its relatively recent discovery and its identity on Western ligand blots obscured by 
similar sized IGFBPs. Data from a specific radioimmunoassay (Baxter and Saunders, 
1992) has revealed levels of IGFBP-6 are generally higher in men than women, and are 
significantly reduced in pregnancy and in patients with active acromegaly. 
Functions of IGFBP-6 
IGFBP-6 has up to a 30-fold lower affinity for IGF-I compared to IGF-11 (Kiefer et al, 
1993). Data from in vitro studies, using exogenous recombinant non-glycosylated IGFBP- 
6,, has shown that this results in the binding protein being much more effective at 
inhibiting the mitogenic activity of the latter growth factor. The functional significance 
of the unique 0-glycosylation pattern is unknown. 
SUMMARY 
The large number of studies described above demonstrate that the IGFBP family provides 
us with a complex network of potential IGF regulators, in addition to the more usual 
pathways of altered IGF gene expression and IGF cell membrane receptors. However, 
whilst our knowledge of IGFBP structure is now fairly well defined, with gene structure, 
sites of expression and amino acid sequences deduced, there is certainly more scope for 
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studies investigating regulation of IGFBP secretion and their biological function, 
particularly at the tissue level. The recent discovery of IGFBP protease activity may also 
implicate certain novel regulators hitherto overlooked. It is these aspects of IGFBP 
physiology that we have tried to address in the following thesis, principally through the 
development of a human fibroblast in vitro model and investigation of potential IGFBP 
and/or IGFBP protease regulators. In this model we have therefore studied certain 
members of a large group of peptides, the cytokine family, that have well recognised 
effects upon both tissue growth and protease activity. A brief introduction to these 
peptides is now given. 
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CHAPTERL 
SECTION C. THE CYTOKINE FAMILY 
(Ivprvipw 
As I have described in the previous section, an increasing number of hormones and 
growth factors have been shown to affect the production of IGFBPs both in vitro and in 
vivo. However, little data exists on their possible regulation by a major group of 
regulatory peptides known as the cytokines. This is rather surprising because contained 
within this group are a number of factors which have a dramatic impact upon the growth 
of a wide range of cell and tissue types. Moreover, many of their actions can be 
considered to be indirect, often being ascribed to the stimulation of secondary factors in 
the given cell type, and frequently involve the alteration in the secretion of globular 
proteins, such as albumin and various extracellular matrix components. In addition, they 
also often modulate metalloproteinase production and their associated inhibitors in many 
in vitro cell culture models. These characteristics thus make them good candidates to be 
IGFBP regulators. 
There is some recent evidence that at least one member of this family, which includes the 
inflammatory lymphokines, the transforming growth factors and the ever expanding 
interleukin group, is capable of affecting IGFBP production in vitro. Specifically, 
treatment of normal human skin fibroblasts with transforming growth factor B (TGFB) was 
seen to lead to a significant increase in IGFBP-3 secretion from such cells (Martin and 
Baxter, 1991). In the following study this response has been further characterised and the 
effects of tumour necrosis factor (x (TNF(x), interleukins 1a and IB (]]L- 1 cc and IL- I B) and 
interleukin-6 (IL-6) investigated. An introduction to these factors is given below. 
1.13. Transforming growth factor B (TGFB) 
Background 
Transforming growth factor (TGF) was a term originally applied to describe an activity 
present in media conditioned by a murine sarcoma virus -transformed cell line (DeLarco 
and Todaro, 1976). This activity was characterised by its ability to induce the growth of 
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normally anchorage-dependent cells in soft agar, a hallmark of in vitro transformation. 
Although it is now apparent that this effect is but one of their many functions, it has been 
accepted as the operational definition of the family of TGF-like peptides. 
Two classes of TGF exist, designated TGFoc and TGF6, although other structurally related 
polypeptides include the inhibins and the Mullerian inhibitory substance. Although given 
similar names TGRX, an epidermal growth factor-like peptide, and TGFB are however 
distinct molecules in structure and function. In the context of the present study we are 
concerned only with TGFB, a brief introduction of which is now given. 
Primary stucture 
TGFB is a dimeric polypeptide comprised of identical 112 amino acid subunits, linked by 
a series of disulphide bonds. A number of isoforms, all retaining this characteristic feature, 
have now been identified and are designated TGF61,2,1.2,3 and 4. The first of these 
was purified from human platelets (Assoian et al, 1983) and human cDNA clones 
subsequently isolated (Derynck et al, 1985). It exists as a 25 kDa dimer comprising the 
two identical 12.5 kDa subunits, each derived from cleaved 390 precursor peptides. 
TGF62 is a similar diirneric peptide with subunits showing a 72 % sequence homology 
with TGFBl. TGF31.2 is a heterodimer containing one TGF31 and one TGFB2 chain. At 
present their is little evidence to suggest functional divergence among the various 
isoforms. 
Tissue expression and production 
TGFB mRNA and peptide has been detected in a wide range of normal and transformed 
tissues and cell types both in vivo and in vitro. In adult mammals TGFB is particularly 
high in platelets and bone chondrocytes (Robey et al, 1987), whilst circulating levels may 
typically reach 5 [tgll (Shirai et al, 1992). TGFB can also be found in macrophages and 
peripheral blood monocytes, and its expression seems to correlate with tissue 
developmental stage, with highest levels observed during periods of morphogenesis 
Akhurst et al, 1990). 
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Biological functions 
Like many other cytokines TGFB is a multifunctional regulator of cellular activity. 
Responses are mediated via three structurally distinct cell membrane high affinity 
receptors, designated type 1, H and 111, with molecular weights of 65,85-110 and 560 
kDA respectively. All three may be expressed simultaneously, usually in a constitutive 
manner, in epithelial, mesenchymal and haernatopoietic cells of both normal and tumoural 
origin. Although not fully elucidated, signal transduction appears to involve one or more 
GTP-binding proteins (Kataoka et al, 1993). 
Generally, TGF6 is a potent, but reversible, inhibitor of normal cell growth in vitro 
stimulated by serum or growth factors, including the IGFs (Zugmaier et al, 1989). The 
effect of TGF8 on cell proliferation is however often bifunctional and can be markedly 
influenced by other growth factors. In normal fibroblasts for example, inhibition may be 
seen with picomolar doses in subconfluent cultures, although conversely may actually 
stimulate growth in quiescent monolayers. A similar bimodal effect is also seen in bone 
osteoblast cultures. 
Other functions include a pronounced effect on extracellular matrix production (for review 
see: Noble et al, 1992). It causes an increase in collagen, fibronectin and proteoglycan 
expression, an increase in integrin expression, a decrease in proteinase secretion, including 
collagenase and transin, and also increases proteinase inhibitors such as plasminogen 
activator inhibitor (PAI-1) and tissue inhibitor of metalloproteinases (TIMP). It has been 
suggested that such a co-ordinated effect is designed to aid the process of wound healing, 
a hypothesis encouraged by the high TGF6 expression in platelets, and its ability to 
enhance epidermal keratinisation and chemotaxis. TGFB also has marked 
immunoregulatory functions, generally acting as a down-regulatory stimulus in immune 
responses. 
1.14. TUMOUR NECROSIS FACTOR 
Background 
For over 100 years there have been reports in the cancer literature of tumour necrosis and 
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regression after spontaneous or experimentally induced bacterial infection. Indeed, 
'Coley's mixed toxins', a filtrate of of bacterial cultures, were described by the American 
Medical Association in 1934 as the only known systemic therapy for cancer (Old, 1986). 
Further research identified the factor responsible for eliciting such tumour necrosis as the 
lipopolysaccharide constituent of bacterial cell walls, named endotoxin. Carswell et al (1975) 
subsequently described the cytokine tumour necrosis factor (x (TNFcc) as the serum factor 
produced by the host in response to bacterial endotoxin. 
Structure 
Isolated TNF(x cDNA is a 233 amino acid chain, containing a 76 residue pre-sequence 
which is lost upon maturation and thought to be important in macrophage secretory 
processes. TNF(x peptide is first produced as a propeptide, which is cleaved to yield the 
active peptide. The mature protein therefore consists of 157 amino acids with no 
glycosylation sites, resulting in a molecular weight of 17,356 daltons. Cysteine residues 
are present however, forming a number of interchain disulphide bonds. Its gene is found 
on human chromosome 6 mapped in the major histocompatibility complex (MHQ 
encoding region. 
Tissue expression and production 
TNF(x was first purified from the culture supernatant of the human pro-myelocytic 
leukaemic cell line HL-60, although it is now known to be produced by a wide variety 
of immune cells including macrophages, T cells, thymocytes, B cells and natural killer 
(NK) cells. When suitably induced monocytes can secrete large amounts of TNF(X, up to 
1% of their total secretory product for 8 hours or more (Gifford and Flick, 1987). 
TNF(x can be induced by a number of agents other than endotoxin, including a number 
of different viruses and the turnour-promoting agent PMA. In addition, certain other 
cytokines can stimulate or augment the secretion of TNF(x. 
Biological actions of TNF(x 
To exert their cell regulatory or cytotoxic effects, TNF(x must first interact with specific 
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cell surface membrane receptors. Two classes of high-affinity receptors, TNF-R-75 and 
TNF-R-55, have now been reported to exist on a variety of normal and transformed cells 
(Kull et al, 1985). The nature and second messenger of the signal transduced by these 
receptors is not fully understood and is the subject of intense interest. Recent reports have 
however suggested the involvement of certain protein kinase cascades, phosphorylating 
specific receptor proteins (Kalthoff et al, 1993). Depending on the particular cell type, 
binding of TNF(x to the membrane receptors can result in a multiplicity of effects. For 
convenience only, we can asign these into three groups, although they are most certainly 
inter-related. 
A major function of TNF(x, and the one which lead to its initial discovery, is to mediate 
immune directed cytotoxicity. It causes lysis of certain tumours in vivo, such as Meth-A 
sarcomas (Gray et al, 1984), and also a number of transformed cell lines, including mouse 
L-929 fibroblasts, in vitro (Matthews, 1978). TNFoc cytotoxicity can be independent of 
protein synthesis and can be blocked by protease inhibitors, suggesting that one or more 
proteases induced by TNF(x may either directly cause cell damage or may activate other 
lytic enzymes (Ruggiero et al, 1987). The presence of metabolic inhibitors or interferon 
cc and cy seem to enhance the cytotoxic: effect of TNFcc in a wide range of cell types. It 
is also notable that many cell types that fully express TNFCc receptors are not killed by 
the cytokine, although receptor number on susceptible cells is proportional to the amount 
of cell lysis. 
Contrasting with the effects described above, TNFoc can also act as a growth factor in 
vitro, stimulating mitogenesis in normal diploid fibroblasts and certain tumour cells 
(Vilcek et al, 1986; Dealtry et al, 1987). Although TNF(X may function as a direct 
mitogen, there is evidence in a normal human skin fibroblast model that it may act 
synergistically with other serum growth factors, particularly insulin (Vilcek et al, 1986). 
TNF(x stimulation of cell growth has been demonstrated at concentrations comparable to 
those shown to produce cytotoxicity in many transformed cell lines. 
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In addition to its effect on cell proliferation TNF(x is also thought to have profound efects 
on the secretion of a wide range of proteins involved in inflammation and immunity. It 
can for example induce interleukin- I and-6, interleukin 2 receptors, prostaglandin E2, and 
a number of metalloproteinases. It can also inhibit the production of albumin, transferfin, 
lipoprotein lipase and collagen, implicating it in the mediation of connective tissue 
imbalance. 
1.15. INTERLEUKIN-1 and 6 
The term interleukin was originally coined to describe molecules that sent signals between 
leucocytes. However, further understanding of these cytokines has proved this definition 
to be rather limiting, as they can often be produced by and have regulatory effects upon 
a wide variety of other cell types. Consequently, since 1986 all newly discovered 
cytokines have also been ascribed an interleukin number, provided amino acid sequence 
analysis has proven them to be novel. At present, this large and expanding family of 
cytokines now spans interleukin I to 13, and includes a whole variety of isoforms and 
subtypes. Obviously, in the context of this thesis it is impractical to examine the effects 
of each interleukin on the IGF / IGFBP axis, so experiments were restricted to the study 
of those that have been shown to have close functional similarity with TNF(x, namely 
interleukin-I and -6. 
1.15. i. Interleukin 1 
Structure 
There are two different IL-I genes coding for two proteins, named IL-1(x and IL-16, 
which bind to the same cell surface receptor and consequently have identical biological 
actions (Lomedico et al, 1987). Both arise from large 35 kDa precursor molecules 
comprising 271 (IL-loc) and 269 (IL-W) amino acids, and are processed into 17.5 kDa 
mature peptides of 159 and 153 amino acids, respectively. Sequence homology between 
the two species is however restricted to 27%, although as this is contained in the carboxy- 
terminus it seems sufficient to confer identical receptor recognition sites. 
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Tissue expression and production 
In addition to the traditional haematopoietic sources of IL- 1, such as that from monocytes, 
macrophages, T and B lymphocytes and NK cells, it is now accepted that most cell types 
can produce certain amounts of both IL-1 species, although often only when stimulated 
by mitogens (Oppenheim et al, 1986). In a similar manner to TNF(x, IL- I oc and IL- 16 can 
be induced by antigen, toxins, injury, inflammatory processes, and other cytokines 
including TNF(X and the interferons. 
Biological actions 
Membrane receptors for IL- 1 have been found on a wide range of cell types, with binding 
to a 80 kDa species mediating the biological actions of the cytokine. Signal transduction 
is similar to that of the TNF(x receptors and appears to involve the activation of serine / 
threonine kinase activity independent of protein kinase A or C. Such similarity may help 
explain its close functional relationship with TNF(x. 
The biological effects of 11L-1 are largely dependent upon the particular cell type in 
question. It plays a major role in positively regulating the activity of many haematopoietic 
cells involved in mediating immunity, including T and B lymphocytes, and is thus 
responsible for many of the systemic manifestations of infection (Dinarello and Mier, 
1986). However, it also has wide ranging actions in other cell types perhaps more closely 
linked with the IGFs. In bone, for example, IL-IB is an osteoclast- activating factor and 
leads to the inhibition of new proteoglycan synthesis in cartilage. In a similar manner to 
TNF(x, IL-1 also has the conflicting property of being mitogenic for some cells and 
cytostatic or cytotoxic for others. In fibroblasts, 11L-l is an extremely potent mitogen 
(Schmidt et al, 1982) and also increases the synthesis of procollagen, collagenase, tissue 
inhibitor of metalloproteinases (TIMP) and prostaglandin E2, perhaps suggesting an 
involvement in tissue repair. It can be both mitogenic and cytotoxic in tumour cells. 
1.15. ii. Interleukin 6 
Structure 
IL-6 has previously been known as B cell stimulatory factor (BSF-2), interferon-62,26 
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kDa protein, and hepatocyte stimulating factor (HSF). The cDNAs code for a protein 
consisting of 212 amino acids (22 - 29 kDa) that has two potential glycosylation sites and 
four cysteine residues (Hirano et al, 1989). 
Tissue expression and production 
Although the major source of circulating IL-6 is of haernatopoeitic origin, principally from 
the mononuclear T-cells, it now appears that it may also be produced by a wide range of 
other cell types, such as fibroblasts (Van-Damme et al, 1987) and epithelial keratinocytes. 
The IL-6 gene can be induced by inflammation-associated cytokines, such as TNF(x and 
IL-1, bacterial products, viral infections, and activation of either cAMP, calcium ion or 
diacylglycerol signal transduction pathways. 
Biological actions 
IL-6 activity is mediated via its own specific cell receptors. These consist of two 
membrane proteins, a ligand-binding chain (designated IL-6R) and a non-ligand binding 
signal transducer (designated gpl30) which associate once in the presence of IL-6 and 
activate protein kinases (Kishimoto, 1992). 
IL-6 acts on a wide variety of cells regulating the immune response, acute phase reaction 
and haernatopoiesis. That made by activated T cells for example has the capacity to act 
as B-cell differentiation factor by stimulating human B cells to secrete antibody. At 
present, little data exists on the relationship between ]IL-6 and the IGFs. 
56 
CHAPTERL 
SECTION D. AIMS OF THESIS 
The principle objectives of this thesis were to investigate three aspects of IGFBP 
physiology at the cellular level. 
1. To establish the possible mechanisms involved in the regulation of IGFBP-3 
secretion, in vitro. 
In addition to the classical pathway of modulating- IGFBPs, that of altered gene 
expression, it is becoming increasingly apparent that a number of post-translational 
mechanisms may also exist. In the normal human fibroblast cell culture model, such 
mechanisms may be involved in IGF-I regulation of IGFBP-3, as this appears to be a 
non-receptor mediated event. Using a normal neonatal human foreskin fibroblast cell 
line, designated Hs68, the effect of IGF-I on IGFBP-3 has been analysed by Western 
ligand blotting, radioimmunoassay and Northern blotting, and assessment made of the 
role that the recently discovered IGFBP proteases may have in mediating this effect. 
2. To investigate the effect of cytokines on IGFBP production in vitro, and to define the 
regulatory mechanisms involved. 
Despite the cytokine family having a major impact, both physiologically and 
pathologically, upon cellular growth, metabolism and differentiated function very little 
data exists on their role in IGFBP regulation. In this study the fibroblast cell culture 
model has been used to clarify the stimulating effect of TGFB upon IGFBP-3 (Martin 
& Baxter, 1991) and also to analyse for the first time the effect on the IGFBPs of the 
inflammatory cytokines TNF(x, IL-16 and IL-6. As a function of these cytokines 
appears to be mediation of metalloproteinase production, notably in fibroblasts, their 
possible role in mediating IGFBP proteolytic activity was also investigated. 
3. To develop a precise bioassay capable of measuring the effects of endogenous IGFBP 
regulation on IGF-I mitogenic activity. 
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The role that the IGFBPs play in mediating IGF activity at the cellular level is 
controversial. Based upon experiments using either purified or recombinant exogenous 
IGFBPs most in vitro data suggest that they are inhibitory, although they may also 
potentiate both the mitogenic and metabolic actions of the IGFs under certain 
incubation conditions. In an attempt to clarify this situation we have developed a 
precise mitogenic bioassay based upon the Hs68 fibroblast model described above to 
investigate the effect on IGF-I bioactivity of endogenous IGFBP regulation by TGF6, 
and TNF(x. To distinguish those effects mediated via IGFBPs rather than membrane 
receptor or intracellular processes, comparison was made between the mitogenic 
activity of both native IGF-1 and a synthetic IGF-I peptide with minimal affinity for 
the IGFBPs- 
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CHAPTER 2. 
MATERIALS 
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2.1. Peptides 
i. Human IGF-I (recombinant) 
ii. LongR' IGF-I (recombinant) 
iii. Human IGFBP-3 (glycosylated and 
non-glycosylated, recombinant) 
iv. Human insulin (recombinant, 'Actrapid') 
v. Human TNF(x (recombinant) 
vi. Human IL-16 (recombinant, 
code 86/680) 
vii. Human IL- Ia (recombinant, 
code 86/632) 
viii. Human IL-6 (recombinant, 
code 88/514) 
ix. Human interferon gamma (recombinant) 
x. Human TGFBj (purified, platelets) 
GroPep Pty Ltd., Adelaide, Australia. 
Kabi Phannacia, Milton Keynes, Bucks, 
UK. 
GroPep Pty Ltd., Adelaide, Australia. 
Celtrix Inc., La Jolla, California, USA. 
Calbiochem, Nottingham, UK. 
Bachern (UK) Ltd., Saffron Walden, 
Essex, UK. 
National Institute for Biological 
Standards and Control (NMSC), Potters 
B ar, Herts., UK. 
NIBSC, Potters Bar, Herts., UK. 
NIBSC, Potters Bar, Herts., UK. 
Bachem (UK) Ltd., Saffron Walden, 
Essex, UK. 
British Biotechnology Ltd., Oxford, 
Oxon, UK. 
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xi. Prostaglandin 
E2 (synthetic) 
xii. Bovine fibronectin (purified, plasma) 
xii. Gly-Arg-Gly-Asp fibronectin fragment 
(synthetic) 
2.2. MaLior Equipment 
Centrifuges 
Sorvall RT 6000b Benchtop 
MSE Coolspin 
MSE Centaur Il 
MSE Microcentaur 
Beckman J-6B 
Power Supply Units 
LKB Bromma 2197 
Sigma Chemical Co. Ltd., Poole, Dorsa 
UK. 
Sigma Chemical Co. Ltd., Poole, DorseL 
UK. 
Sigma Chemical Co. Ltd., Poole, DorseL 
UK. 
Du Pont (UK) Ltd, 
Wedgewood Way, Stevenage, 
Herts., UK. 
MSE Scientific Instruments, Manor 
Royal, Crawley, Sussex, UK. 
MSE Scientific Instruments, Manor 
Royal, Crawley, Sussex, UK. 
MSE Scientific Instruments, Manor 
Royal, Crawley, Sussex, UK. 
Beckman Instruments, Beverley, 
Califomia, USA 
LKB Instruments Ltd, Selsdon, 
Croydon, Sussex, UK. 
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Gamma Counter 
NE 1600 Multihead 
Gel Electrophoresis Tank 
BRL V16-2 
Transfer Unit 
LKB 2005 
Vacuum Dessicator 
GyroVap 02GV2 
PH Meter 
EDT GP 353 
Water Purification System 
MiRi Q 
Water Baths 
Grant JB 1 and SE 10 
CO, ý Incubator 
GalleAampf ControlledC02 
Nuclear Enterprises, Edinburgh, 
UK. 
Bethesda Research Labs, Trident 
House, Renfrew Rd, Paisley, Scotland. 
LKB Instruments Ltd, Selsdon, 
Croydon, Sussex, UK. 
VA Howe and Co., St. Anne's 
Crescent, London, UK. 
Pentacourt Ltd, Halstead, Essex, UK. 
Waters Millipore, Harrow, Middlesex, 
UK. 
Chemlab Instruments, Homchurch, 
Essex, UK. 
Gallenkampf, Christopher St., London, 
UK. 
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Laminar Flow Cabinet 
Envair MSC Il 
Balances 
Mettler PM 300 
Chan 28 Automatic Electrobalance 
Stanton MC9 
Microscope 
Olympus CK 
Temperature Controlled Incubator 
Leec MkH 
Fraction CoRector 
Ultrorac 2070 
Oil Pump 
High V acuum ED 100 
Gel Dryer 
BioRad 543 
Envair (UK) Ltd, Rossendale, Lancs., 
UK. 
Gallenkampf, Chtistopher St., London, 
UK. 
WT Avery Ltd, Smethwick, 
W. Midlands, UK. 
Stanton Instruments Ltd, London, UK. 
Olympus, Tokyo, Japan. 
Luckhams, Burgess Hill, Sussex, UK. 
LKB Instruments Ltd, Croydon, Sussex, 
UK. 
Edwards High Vac Ltd, Manor Royal, 
Crawley, Sussex, UK. 
BioRad Inc., Hemel Hempstead, Herts., 
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UK. 
Peristaltic Pump 
Chem Lab CPP 15 
Densitometers 
Model 450 microplate reader with 
595nm and 650nm wavelength filters 
LKB Ultrascan XL scanning 
densitometer 
Shimadzu UV- 150-02 spectrophotometer 
2.3. NIHnor Equipment 
Vortex Mixer 
Magnetic Stirrer 
Gas 
95%02 : 5%CO2 
Pipettes 
Chem Lab Instruments, Homchurch, 
Essex, UK. 
BioRad Inc., Hemel Hempstead, Herts., 
UK. 
Pharmacia LKB, Biotechnology, 
Uppsala, Sweden. 
Shimadzu Co., Kyoto, Japan. 
Hook & Tucker Instruments Ltd, New 
Addington, Croydon, UK. 
Jencons Scientific Equipment, Hemel 
Hempstead, Herts. 
British Oxygen Company, London, UK. 
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Finn Pipettes 
Eppendorf Pipettes 
Plastics 
Pipette Tips Rainin S20 and S200 
Trieff Lab Microfuge Tubes 
Siliconized Microfuge Tubes 
Nunc Sterile 50 ml Centrifuge Tubes 
RIA Tubes (2.5 ml) 
Nunc Tissue Culture Flasks 
Cryostat Tubes 
Sterile Pipettes (1,5,10 ml) 
Jencons Scientific Equipment, Hemel 
Hempstead, Herts, UK. 
Andennan & Co., Kingston-on-Thames, 
Surrey, UK. 
Anachern, Luton, Beds., UK. 
Scotlab, Bellshill, Strathclyde, UK. 
Sigma Chemical Co. Ltd, Poole, 
Dorset, UK. 
Gibco, Paisley, Renfrewshire, UK. 
Griffiths & Nielson Ltd. Billingshurst, 
Sussex, UK. 
Gibco, Paisley, Renfrewshire, UK. 
Sterilin Ltd, Alton, Hants., UK. 
Sterilin Ltd, Alton, Hants., UK. 
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Sterile Syringes & Needles 
Glassware 
Glassware, pipettes, measuring 
cylinders, volumetric flasks, 
electrophoresis plates, beakers, 
magnetic stirrers. 
Glass pasteur pipettes 
Laboratory chromatography 
columns 
Size exclusion gels 
Sephadex G25 and G50 
Pharmacia 1.0 x 30 cm Superose 12 
AcA 202 size exclusion gel 
Autoradiography Film 
Kodak XAR5 Film 
Amersham Hyperfilm MP 
Sterilin Ltd, Alton, Hants., UK. 
Jencons Scientific, Hemel Hempstead, 
Herts, UK. 
John Paulten Ltd, Barking, Essex, UK. 
Pharmacia, Milton Keynes, Beds., UK. 
Pharmacia, Milton Keynes, Beds., UK. 
Pharmacia, Milton Keynes, Beds., UK. 
Ultragel IBF, Biotechnics, ViUeneuve, 
France. 
Kodak, Hemel Hempstead, Herts., UK. 
Amersham International PIC., 
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Amersham, Bucks. 
Autoradiography Cassettes Genetic Research Instruments, Bishops 
Stortford, Herts., UK. 
Membranes 
Hybond C+ 
Biotrans 
Amersham International PIC., 
Amersham, Bucks. UK. 
ICN Biomedical Inc., Irvine, CA. USA. 
Filters 
3mm paper 
Sterile 0.2 VM filters 
Whatman International Ltd, Maidstone, 
Kent, UK. 
Schleicher & Schuell, Dassel, Gen-nany. 
Sterile Arodisc 0.2 VM filters 
2.4. Reagents 
Gelman Sciences, Michigan, USA. 
General laboratory chemicals (AnalaR or Molecular Biology Grade) and reagents for 
tissue culture were supplied by: BDH Chemicals Ltd, Poole, Dorset, UK., or Sigma 
Chemical Co. Ltd, Poole, Dorset, UK. 
2.5. Commercially available kits and preparations 
QIAGEN Plasmid Kit QIAGEN Inc., Chatsworth, CA, USA. 
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GENECLEANII 
Oligolabelling kit 
RNAzol B 
BIO 101 Inc., CA, USA 
Pharmacia, Milton Keynes, Beds., UK. 
Biogenesis, BOumemouth, UK. 
68 
CHAPTER 3. 
METHODS 
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3.1. CELL CULTURE 
The fibroblast cells used throughout this thesis, designated Hs68, were obtained from the 
American Type Culture Collection (Rockville, Maryland, USA), number CRL 1635. They 
were first developed at the Naval Biosciences Laboratory (Oakland, California) and are 
derived from the foreskin of a normal, Caucasian newborn infant. Unspecified longevity 
studies carried out at source demonstrated that the cells could be successfully propagated 
for up to 40 passages. For our studies they were routinely used for experiments between 
passages 15 and 30 without noticeable alteration in morphology or IGFBP production. 
a. Cryopreservation 
Stocks of Hs68 cells (2-10 x 106 cells/cryotube) were kept frozen in liquid nitrogen stored 
in 95% fetal calf serum (v/v) plus 5% dimethyl sulphoxide (v/v). Resuscitation involved 
rapid thawing and transfer into pre-warmed 'growth medium', followed by centrifugation 
for 5 minutes at 50g, aspiration and seeding into tissue culture treated flasks in 'growth 
medium'. 
b. Growth medium 
Hs68 cells were routinely grown in a humidified incubator at 37'C, 
5%CO2 in the 
following medium: 
Dulbecco's modified Eagle's medium (DMEM) with 4.5 g1l glucose 
L-glutamine 2 mmols/I 
Fetal bovine serum 10% V/v 
Aspiration of spent medium and subsequent re-feeding was performed every 3-4 days. 
c. Trypsinisation procedure 
Growing adherant cell stocks were passaged every 7 days using the following solution: 
Dulbecco's PBS; 
Sodium chloride 137 mmols/I 
Sodium phosphate 
Potassium chloride 
Potassium phosphate 
95 mmols/I 
2.7 mmols/I 
1.5 mmols/I 
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Trypsin (bovine) 
EDTA 
0.5 gll 
I mmol/I 
Spent growth medium was first aspirated, and then sufficient trypsinising solution added 
such that the monolayers were fully wetted. Following a brief 5 minute incubation at 
37'C, the dispersed cells were placed into a sterile 30 ml universal tube and 10 mls of 
growth medium added to quench excessive trypsinising. The tube was then centrifuged 
(approximately 50g) for 5 minutes, the solution aspirated and the cells resuspended in 5- 
10 mls of growth medium for estimation of cell number using a haemocytometer. Flasks 
of new stock cultures (5 x 10'/ml) or experimental plates and dishes were subsequently 
seeded. 
d. Standard experimental conditions 
All cells committed for experiments were grown in growth medium for 3-4 days until 
approximately 80% confluent prior to placement into serum-free conditions. Essentially, 
this medium consisted of the growth medium described above but with 0.1% bovine 
serum albumin (BSA) replacing the serum component. 
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3.2. WESTERN LIGAND BLOTTING (WLB) 
Early analysis of IGFBPs mostly involved size separation gel chromatography followed 
by radiolabelled IGF binding studies. However, in addition to its laborious nature, the 
presence of saturating endogenous IGFs, particularly in serum samples, presented major 
difficulties. The development of a technique which overcame many of these problems was 
first described by Hossenlopp et al (1986). In this seminal paper, they demonstated a 
methodology, named Western ligand blotting (WLB), that involved the separation of 
IGFBPs by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Crucially, the SDS incubation conditions were seen to reversibly dissociate endogenous 
IGFs from the binding proteins, allowing the binding of 1251_IGF following their transfer 
to nitrocellulose membranes. Visualisation of the IGFBPs, migrating at their molecular 
weights, could thus be achieved with autoradiography. 
In this study we have utilised WLB ourselves for the determination of IGFBPs. It must 
be stressed however that this technique is not necessarily quantitative, as band intensities 
are determined by the combination of both the IGFBP's molecular mass and its binding 
affinities for the radiolabelled IGF ligand. With the discovery of certain proteolytic 
enzymes capable of altering IGFBP affinity this is especially pertinent to interpretation 
of WLB data, as will be seen in the following RESULTS section. 
a. Polyacrylanfide gel electrophoresis (PAGE) 
Size separation of IGFBPs was performed by PAGE, as described by Laemmli (1970), 
using 12.5 % homogenous linear gradient acrylamide gel slabs under non-reducing 
conditions. 
Resolving Gel: 
acrylamide (30% w/v) 
N,, N, -Methylene Bis acrylamide 
(1% w/v) 
Tris base (1.5 mols/l, pH 8.9) 
Distilled H20 
EDTA (0-1 mols/l, pH 7.4) 
SDS 10% w/v 
27 ml 
16.8 ml 
15.6 ml 
5.4 ml 
2.7 ml 
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Ammonium persulphate (10% w/v) 0.6 ml 
N, N, N, N-tetramethylethylenediamine (TEMED) 26 W 
Stacking Gel: 
30% w/v acrylamide +I% w/v Bis 3.75 ml 
Tris-HCI (I. I mols/l, pH 6.8) 1.125 ml 
Distilled H20 16.95 ml 
EDTA (0.1 mols/l, pH 7.4) 0.45 ml 
SDS (10%) 0.22 ml 
Ammonium persulphate (10% w/v) 0.34 ml 
TEMED 22.5 pl 
Electrophoresis Running Buffer, pH 9-6: 
Tris base 6 g/I 
Glycine 29 g1I 
EDTA 1.5 g1I 
SDS 2 g/I 
Distilled H20 II 
Sample Buffer: 
1.1 M Tris HCI pH 6.8 0.7 ml 
Glycerol 1.1 ml 
10 SDS 3.0 ml 
Bromophenol blue (I % solution) 0.2 ml 
Method: 
Two glass plates were first washed with 7X-PF detergent (ICN FLOW) and absolute 
methanol, then rinsed with distilled water. After assembly using 3mm spacers, the 
resolving gel was poured, overlaid with isopropanol to ensure a planar surface, and 
allowed to set for about 30 minutes. Once set, the isopropanol was poured off and 
approximately 2.5 cm of stacking gel added. The spacer comb was inserted and the gel 
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again left for 30 minutes to set. Once set, the comb was removed and wells flushed with 
distilled H20 ready for sample loading. 
The samples (specific details of which are given in the relevant results chapters) were 
diluted with sample buffer and boiled for 5 minutes, before being cooled on ice. A 
maximum of 80[d of each sample was loaded into the lanes of the stacking gel. Pre- 
stained molecular weight markers (Life Technologies Ltd, Strathclyde, U. K. ) were run in 
parallel lanes. Electrophoresis was performed at a constant current of 40 mA for 15 hours 
(70 mA for two gels). 
b. Protein electroblotting of IGFBPs to nitrocellulose 
Two methods were used for transferring and immobilising the IGFBPs from the 
polyacrylamide gel to solid phase nitrocellulose membranes. 
i. Standard electroblotting 
Transfer Buffer; 
Glycine 42.75 g 
Tris-HCI 15.15 
Distilled H20 3L 
Following preparation of the above solution, a further IL of MeOH, followed by 1L of 
distilled H20was added, making a total volume of 5L. Finally, the pH was adjusted to 
8.3. 
Method: 
Slab gels were removed from the glass plates, the stacking gel removed and discarded, 
and then placed on a sheet of 'Hybond-C extra' nitrocellulose (Amersham International, 
Bucks, U. K. ). This was then sandwiched between two sheets of Whatman 3mm filter 
paper, followed by two pieces of foam padding, before being placed in the electro-transfer 
cassette. The cassette was placed into the electro-transfer tank (LKB 2005, Transphor 
unit), ensuring that its alignment allowed the proteins, moving from -ve to +ve, to transfer 
onto the nitrocellulose. Electroblotting was performed under a constant current, 
0.8 - 1.0 
Amps, for 4 hours at 4'C. 
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ii. Semi-dry electroblotting 
An alternative method of electroblotting without the requirement of large buffer volumes 
was also used. Firstly, four pieces of Whatman 3mm filter paper were cut to the same size 
as the gel and soaked in Transfer buffer as detailed above. A similar sized piece of 
nitrocellulose paper was then placed on top of the filter papers, followed by the gel itself, 
and a further four soaked filter papers. This sandwich was then placed onto a Semi-Phor 
electroblotter (Hoefer Scientific Instruments) and run at a constant current of 25 mAmps 
for 2 hours. 
c. Preparation of nitrocellulose for probing 
Following electroblotting, the nitrocellulose sheet required treatment with a series of 
detergent washes and blocking of non-specific binding prior to incubation with 125 I-IGF. 
Solution #1, pH 7.4 
Tris-HCI 0.8 g 
Nonidet P-40 (NP40) 50 pl 
Distilled H20 100 ml 
Solution #2, pH 7.4 
Tris-HCI 0.8 g 
BSA 3.0 g 
Distilled H20 
100 MI 
Solution #3, pH 7.4 
Tris-HCI 0.8 g 
Sodium phosphate 0.8 g 
Tween 20 2000 
Distilled H20 
100 ml 
Method: 
The nitrocellulose filter was air dried for 15 minutes at 
37'C, before being soaked in 
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solution #1 for 30 minutes at 37'C. This was followed by incubation with solution #2, for 
90 minutes, and then solution #3, for 20 minutes, both at 37T. The blot was then allowed 
to dry at room temperature. 
d. 125 I-IGF binding 
The IGFBP bands on the nitrocellulose were visualised by incubation with radiolabelled 
IGF-I. lodination of recombinant human IGF-I was performed using the chloramine-T 
method. This technique relies upon Na 125 1 being oxidised by chloramine-T (N-chloro-p- 
toluenesulphonomide sodium salt) in the presence of the protein to be labelled, thus 
allowing the subsequent incorporation of 1251 into the tyrosine residues of the protein. 
Excess oxidised Na 1251 is quenched with a saturated solution of free tyrosine. After the 
addition of a protein containing buffer, to act as a carrier, the labelled IGF peptide is 
purified from the unincorporated iodide by size exclusion gel chromatography. The 
specific protocol was as follows: 
lodination reaction; 
10 [tg IGF-I, in 10 0 0.05 mols/I phosphate buffered saline (PBS) 
1.0 mCi Na 1251 (Amersham International, Bucks, UK) in 10 VI 
1.25 Vg chloramine-T, in 5W0.05 mols/I NaH2PO4 
The above were mixed together in aI ml centrifuge tube for 15-20 seconds at room 
temperature, and then mixed once more following the addition of; 
5 pl saturated tyrosine 
and then by; 
75 0 0.05 mols/I PBS + 1% bovine serum albumin (BSA) 
Purification 
Sephadex G-25 was first pre-swollen overnight in 0.05 mols/I PBS + 1% BSA, packed 
into a 10 xI cm chromatography column and equilibrated with 
50 ml of the same buffer. 
As the size separation of this gel is in the range 1000 to 
5000 kDa, the radiolabelled IGF 
is fractionated in the initial void volume and is followed by the free 
125 I-tyrosine in later 
fractions. The fractions were collected every 45 seconds, giving volumes of approximately 
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0.25 ml, and the labelled peptide aliquoted and stored frozen at -20'C. A typical profile 
is shown in figure 3J. overleaf. 
Solutions were subsequently made for incubation with the nitrocellulose as follows and 
incubated overnight at 4'C. 
Solution #4; 
Tris-HCI 0.8 g 
BSA 3.0 g 
Distilled H20 100 MI 
1251_labelled IGF (60,000 counts/ I OOVI/min) 
Solution #5; 
Tris-HCI 0.8 g 
Sodium phosphate 0.8 g 
Tween 20 400 gl 
Distilled H20 100 MI 
Solution #6; 
as Solution #5, less Tween 20 
Method: 
The nitrocellulose blot was first incubated with radiolabelled IGF-I, solution #4, for either 
2 hours at room temperature or overnight at 4'C. It was then washed in solution #6 for 
15 minutes at 4'C, and finally washed a further three times in solution #6. The blot was 
then air dried at room temperature. 
e. Autoradiography 
The dried blot was first covered with cling-film to avoid contaminating the photographic 
film. It was then exposed to X-ray film (Kodak X-OMAT RP, 20cm x 25.5cm) at -70'C 
for between 3 and 7 days, before being developed. Certain of the autoradiographs were 
quatitatively analysed by scanning densitometry. 
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Figure 3A. 
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Sephadex G25 size exclusion chromatographic profile 
of IGF-I following radiolabelling with 125 1, as 
described in section 3.2. d. Radiolabelled IGF-l 
eluted in fractions 10 to 15, with free tyrosine in 
fractions 24 to 25. 
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3.3. IGFBP-3 RADIOIMMUNOASSAY 
IGFBP-3 immunoreactivity in cell conditioned medium was determined by RIA, based 
upon that of Cwyfan-Hughes et al (1993) developed in this laboratory using recombinant 
glycosylated IGFBP-3 for standards and tracer (generously provided by Dr C. Maack, 
Celtrix, Santa Clara, CA, U. S. A. ). 
Assay buffer: 
Sodium phosphate 4.6 8 g1l 
Protamine sulphate 0.2 g1l 
EDTA 3.7 2 g/l 
Sodium azide 0.2 g1l 
The buffer was titrated to pH 7.5 and stored at -20'C. Before use in assay, Tween 20 was 
added to a concentration of 0.05%. 
a. IGFBP-3 standards 
Assay standards were prepared from a stock of the CHO cell derived recombinant 
glycosylated IGFBP-3. The dilutions were made in a solution comprising 0.1% formic 
acid, 1% BSA and 0.9% NaCl, giving an analytical range of IGFBP-3 between 5- 500 
gg/I or 0.25 - 25 gg/tube. Standards were stored at -20'c until use. 
b. 1251 IGFBP-3 tracer 
lodination of the peptide was performed using the chloramine-T method. This technique 
relies upon Na 125 1 being oxidised by chloramine-T (N-chloro-p-toluenesulph onamide 
sodium salt) in the presence of the protein to be labelled, thus allowing the subsequent 
incorporation of [1251] iodine into the tyrosine residues of the protein. Excess chloramine-T 
is reduced by the addition of sodium metabisulphite, and the free iodine is reduced to 
iodide. 
After the addition of a protein containing buffer, to act as a carrier, the labelled peptide 
is separated from the unincorporated iodide by gel filtration. The specific protocol adopted 
for iodination of IGFBP-3 was as follows: 
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lodination reaction; 
5 pg glycosylated IGFBP-3, in 10 pl H20 
0.5 mols/I sodium phosphate, 10 [d 
0.5 mCi Na 1251 (Amersham International, Bucks, U. K. ), 5 
5 pg chloramine-T, in 5 pl 0.05 mols/I sodium phosphate 
The above were mixed together in aI ml siliconised tube for 15 - 20 seconds at room 
temperature, followed by the addition of; 
5 gg sodium metabisulphate, in 5W0.05 mols/I sodium phosphate 
This reaction mixture was then mixed for a further 60 seconds at room temperature, 
before finally adding 75 pl of elution buffer, consisting of; 
0.1 % formic acid + 0.5 % Tween 20 +I% BSA + 0.9 % NaCl 
Purification 
Ultrogel AcA 202 (IIBF, Villeneuve-la-Garenne, France) was packed into a 10 xI cm 
column. After being connected to a peristaltic pump, the gel was washed and equilibrated 
overnight with the above degassed elution buffer, at a flow rate of 3 ml/hour. As this 
particular gel has a separation range of between I and 15 kDa, once the iodination 
solution was applied to the column the radiolabelled IGFBP eluted in the void volume, 
that is in the early fraction numbers. The free 1251 , being able to fully enter the gel itself, 
eluted in the later fractions. Fractions were collected every 10 minutes, giving volumes 
of 0.5 ml, and were briefly counted in a gamma counter before being stored at -20'C. 
Specific activities were typically between 50 and 80 gCi/pg. 
c. Antisera 
For the majority of the data described in this study a single rabbit polyclonal antiserum 
was used, designated 1287-2-14 from Celtrix. This antibody was found to be at optimal 
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titre at a dilution of 1: 20,000 in assay buffer (Cwyfan-Hughes et al, 1993). Results 
obtained from 1287-2-14 were affected by the presence of the IGF-I peptide however, 
presumably because the epitope it recognised was near to the IGF binding site on the 
IGFBP-3 molecule. To overcome the problem of fluctuating IGF levels in the assay 
sample all assay tubes were loaded with 2 ng (40 Vg/1) IGF-I. 
Conditioned medium from our Hs68 line was found to dilute in parallel with the IGFBP-3 
standards (figure Iii. ), whilst proteolytic activity from these cells was without effect upon 
the assay (figure Iiii. ). This latter point was demonstrated by similar IGFBP-3 data 
obtained from samples incubated at 37'C for 24 hours in the presence or absence of a 
known inhibitory concentration (20 mmols/1) of EDTA. 
In addition to 1287-2-14, two further IGFBP-3 rabbit antisera were also used for some of 
our studies. The first, SCH 2/5, was raised against the recombinant IGFBP-3 from Celtrix, 
and was used at a final dilution of 1: 8000. Unlike antiserum 1287-2-14, its binding to 1251 
IGFBP-3 was unaffected by the presence of IGF-I. 
The second, (x-BP-3gl, was provided by Dr R. G. Rosenfeld, and has been characterised at 
Stanford University, U. S. A., (Gargosky et al, 1992). It was used at a final dilution of 
1: 50,000 and again its binding to IGFBP-3 was not affected by the presence of IGF-I. 
d. Assay methodology 
A volume of 300 pl of assay buffer was first added to a3 ml polystyrene assay tube. This 
was followed by 50 V1 of the IGF-I solution (40 pg/1) used to overcome sample variation 
in this peptide. 50 pl of sample or IGFBP-3 standard was then added, followed by 50 PI 
1251 IGFBP-3, diluted in assay buffer to give approximately 10,000 counts/minute. Finally, 
50 V1 of diluted antiserurn was added (except to non-specific binding, NSB, tube) and the 
assay tube votexed and incubated overnight at 40C. 
Separation of bound and free antigen was then achieved by adding for 30 minutes at 40C 
a volume of 50 V1 of donkey anti-rabbit IgG coated cellulose (Sac-Cel, IDS, U. K. ). I ml 
of distilled H20was then added to each tube, votexed briefly, and centrifuged at 10OOg 
for 30 minutes at 40C. Supernatants were aspirated and the remaining pellets counted in 
a gamma counter (Nuclear Enterprises, Edinburgh, Scotland) 
for 100 seconds. 
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Figure 3. ii. 
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Figure 3. iii. 
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The effect of Hs68 cell conditioned medium (CM) 
protease on IGFBP-3 immunoreactivity, assessed 
by radioimmunoassay (antiserum 1287-2-14). 24 
hour CM from untreated cells was loaded with 50 
ng/ml exogenous IGFBP-3 and incubated for 24 
hours as outlined above before quantitation. 
CaCl and EDTA were used at 20 mmols/l. 
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3.4. MOLECULAR BIOLOGY 
When analysing the regulation of the secretion of a peptide, such as an IGFBP, it is 
important to establish if the specific mechanism of the regulation occurs at the gene 
expression level or is post-transcriptional. As a number of IGFBPs, including IGFBP-3, 
have been seen to be both 'stored' on cell surfaces and degraded by proteolytic enzymes, 
the potential for such post-transcriptional regulation would seem high, making experiments 
investigating gene expression essential. 
In this study we have utilised the Northern blotting technique to examine regulation of 
Hs68 fibroblast IGFBP-3 gene expression. Essentially, this consists of isolation of total 
RNA from cell monolayers, electrophoresis of denatured RNA through agarose gels, the 
transfer of fractionated RNA to nylon or cellulose membranes and finally the hybridisation 
of the immobilised RNA to highly specific radiolabelled probes. Visualisation of bands 
is made by autoradiography. Our particular protocol was as follows. 
a. DNA Probes 
i. IGFBP-3 cDNA 
The human IGFBP-3 cDNA probe that was used throughout this thesis was a generous 
gift from Dr S. Shimasaki (1989). It consisted of a 475 bp fragment of IGFBP-3 DNA (see 
figure Lifi), coding for approximately 60% of the mature IGFBP-3 protein, and was 
originally prepared by polymerase chain reaction and ligation into the pHBP3-502 plasmid 
vector, as shown in figure 3. iv. 
ii. IGFBP-4 cDNA 
A human IGFBP-4 cDNA was generously supplied by Dr D. R. Clemmons (University of 
North Carolina, NC, USA) having been prepared as previously described (Camacho- 
Hubner et al (1992). Briefly, primers were designed to amplify by polymerase chain 
reaction a 462 bp segment of DNA that was located in the centre of the IGFBP-4 protein 
coding region. The amplified DNA was subsequently ligated into the EcoRl site of the 
PBS vector that had been EcoRl digested. 
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Figure 3. iv. 
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Schematic representation of human IGFBP-3 cDNA 
probe construction. The resultant pHBP3-502 plasmid 
was obtained from Dr. S. Shimasaki and treated as 
described in the Methods. Adapted from Shimasaki et 
al (1988). 
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ii. B-Actin cDNA 
For some of the final Northern blot analyses described in this thesis a control cDNA 
probe was used to hybridise the Northern blot membranes, providing a precise record of 
the quantity of RNA loaded on the gels. B-actin is a widespread structural protein found 
throughout all eucaryotic cells and as such has been established as a useful control cDNA 
probe in a large number of studies. The cDNA used in this study was kindly supplied by 
Dr S. Chew, St. Bartholomew's Hospital, and encoded for a 689 bp section of the 1761 bp 
human B-actin mRNA. It was constructed by polymerase chain reaction using primers at 
bp position 144 and 833, and was labelled as described for the IGFBPs. 
b. Transformation 
Competent E. coli cells (JM 109) were transfected with either IGFBP-3 orIGFBP-4 plasmid. 
Firstly, to 50 VI of cells approximately 10 ng plasmid (in aI [d volume) was added and 
left on ice for 10 minutes. The solution was then heat shocked at 42'C for exactly 47 
seconds before being placed on ice once more. An 800 [d volume of LB broth (Sigma) 
was subsequently added and mixed with the reaction solution by gentle inversion before 
being incubated for I hour at 37'C. A 100 W volume of reaction solution was then 
incubated overnight at 37'C on culture plates prepared with sterile LB broth containing 
1.5% (w/v) bacto agar and 100 mg/ml ampicillin. As IGFBP-3 and IGFBP-4 plasmids 
carried antibiotic resistance, this step allowed simple selection of those cells that had 
undergone successful trasformation. A single colony of these cells was then cultured for 
6 hours at 37'C in a 20 ml solution of LB broth + ampicillin (100 mg / ml). Finally, the 
20 ml solution was mixed with 500 mls of LB broth and cultured overnight at 37'C. 
c. 1GFBP cDNA purification 
Plasmid DNA, containing the IGFBP cDNA, was initially purified from cultured Exo1i 
cells using the QIAGEN Plasmid Kit (QIAGEN Inc., CA, USA). This method involves 
gently lysing the bacteria under alkaline conditions which results in the liberation of the 
plasmid without completely lysing the cell and releasing unwanted chromosomal DNA. 
RNA is removed by the action of exogenous RNAses. Separation of plasmid DNA from 
chromosomal DNA is achieved by the addition of acidic potassium acetate. This high salt 
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concentration causes the denatured proteins, chromosomal DNA, cellular debris and the 
SDS to precipitate, while the shorter plasmid DNA renatures correctly and stays in 
solution. The precipitate is then easily removed by high speed centrifugation, leaving a 
clear supernatant which can then be loaded onto the anion-exchange column provided in 
the kit. The DNA is finally eluted from the column by the addition of a specific salt 
concentration. 
The detailed protocol was as follows: 
i. Cell resuspension 
Bacterial cells were first transfered from culture vessels to 50 ml sterile centrifuge tubes 
and separated from the culture broth by centrifugation at 4'C for 15 minutes at 6000 rpm 
(Sorvall GSA). The pellet was then fully resuspended in 10 mls of buffer designated P1, 
consisting of, 
100 pg/ml RNase A 
50 mM Tris / HCI 
10 mM EDTA 
pH 8.0 
ii. Cell lysis 
DNA and cellular protein was denatured by the addition of 10 ml of buffer designated P2; 
200 mM sodium hydroxide 
1% SDS 
The above cell solution was gently mixed to ensure maximum denaturation by inverting 
the centrifuge tube briefly, and incubated at room temperature for 5 minutes. Vigorous 
mixing was avoided as this results in the shearing of chromosomal DNA, allowing its 
undesirable co-purification with the plasmid DNA. 
iii. Neutralisation and precipitation 
To the above lysate 10 ml of buffer P3 was added, consisting of; 
3M Potassium acetate 
pH 5.5 
The solution was then thoroughly, but gently, mixed to ensure the maximum precipitation 
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of genomic DNA, cellular protein and especially the SDS. Failure to remove fully the 
SDS inhibits the ability of the plasmid DNA to bind to the purification column. The 
solution was incubated for 20 minutes on ice. 
iv. Column purification of plasmid DNA 
The 'QIAGEN-tip' anion exchange column was equilibrated with 10 ml of QBT buffer 
consisting of-, 
750 mM sodium chloride 
50 mM MOPS 
15% ethanol titrated to pH 7.0 
The precipitated lysate from step 3 above was transfered to ultracentrifuge tubes and spun 
at 30,000 g for 30 minutes at 4'C. The supernatant, hopefully containing mostly plasmid 
DNA, was then loaded onto the column at room temperature, followed by 2 washes of 30 
ml of QC buffer consisting of; 
1.0 M sodium chloride 
50 mM MOPS 
15% ethanol 
pH 7.0 
These wash steps effectively remove protein and carbohydrate contaminants from the 
DNA preparation. 
The plasmid DNA is eluted from the column by the addition of 15 ml of buffer QF which 
consisted of; 
1.25 M sodium chloride 
50 mM Tris / HCI 
15% ethanol 
pH 8.5 
DNA was then collected by precipitation with 10.5 ml (0.7 volumes) of isopropanol at 
room temperature and ultracentrifuged at 10,000 rpm or approximately 
15,000 g for 30 
minutes at 4'C. Following careful aspiration of the supernatant, the 
DNA pellet was 
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washed with 2 mls of cold 70% ethanol to remove any precipitated salt and replace the 
isopropanol with the more volatile ethanol, making the DNA easier to redissolve. 
The pellet was subsequently briefly air dried and redissolved in 100 0 of sterile TE 
buffer comprising; 
10 mM Tris / HCI 
I mM EDTA 
pH 8.0 
v. DNA calculation 
The calculation of DNA in the above preparations were made using the following 
equation; 
absorbance 260nm xK (constant) x dilution = gg DNA 
For the 1: 100 diluted IGFBP-3 preparation the absorbance value obtained was 0.067, 
giving the calculation as follows; 
0.067 x 50 x 100 = 335 pg / ml 
equating to a total of 33.5 [tg in 100 VI TE buffer 
A. Isolation of IGFBP-3 cDNA 
Using information derived from the map provided in rigure. 3. iv. the IGFBP-3 cDNA was 
cut from the plasmid. by the use of restriction enzymes EcoRl and HIND 111. The protocol 
was as follows; 
30 pl (approximately 10 gg) IGFBP-3 containing plasmid 
2.5 W EcoRl 
2.5 pl HIND III 
50 NEB (2) buffer 
10 W H20 
The solution was vortexed and the reaction allowed to run for 1 hour at 37'C before being 
stopped by a further incubation at 65'C for 3 minutes. 
Assessment of the efficiency of the above reaction and isolation of the cDNA of interest 
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was performed by size separating the sample through a mini (10 x6 cm) I% (w/v) 
agarose gel, as described in the electrophoresis section of the Northern blotting RNA 
methodology. For these DNA experiments the running buffer was changed however to 
TAE buffer consisting of; 
40 mM Tris base 
1.14 ml glacial acetic acid 
I mM EDTA 
IL H20 
The IGFBP-3 cDNA sample was prepared as follows; 
2 gl restriction enzyme treated IGFBP-3 cDNA plasmid 
30 DNA loading dye 
30% glycerol 
0.25% xylene cyanol 
0.25% bromophenol blue 
69.5 H20 
5W H20 
For estimation of DNA size a single (2 pl) sample containing a commercially available 
Hind III treated lambda phage DNA, with known molecular weight DNA fragments, was 
also included. The electrophoresis unit was ran for approximately 2 hours at 70 mAmps. 
With the aid of intercalated ethidium bromide the bands of DNA were subsequently 
revealed by trans illumination of the gel under UV light and photographed. The results for 
IGFBP-3 are shown in figure 3. v. overleaf. Lane I shows the Hind III treated lambda 
phage DNA, whilst lane 2 shows the EcoRl / Hind 1111 treated IGFBP-3 cDNA plasmid, 
showing one major band migrating at an estimated weight of just below 500 bp. 
vii. DNA purification from gel 
Removal and purification of the IGFBP-3 cDNA band from the agarose gel seen in figure 
3. v. was performed using the GENECLEAN 11 kit (BIO 101 Inc., CA, USA). The procedure 
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Figure 3. v. 
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DNA size assessment of the plasmid containing 
the IGFBP-3 cDNA clone following incubation 
with HIND III and EcoRl restriction enzymes. 
Molecular weight markers from HIND III treated 
lambda phage are shown in Lane 1. The predicted 
size of the IGFBP-3 cDNA is 475 bp (Shimasaki 
et al, 1988). 
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markers IGFBP-3 
plasmid 
was as follows; 
With the aid of UV light the band containing the 500 bp IGFBP-3 cDNA was excised 
from the gel using a sterile surgical scalpel. The weight of the gel slice was determined 
and it was then placed into a sterile 1.5 ml microfuge tube. On the assumption that Ig 
is the equivalent of 1 ml of gel, 3 volumes of a6M sodium iodide (NaI) was added. For 
our IGFBP-3 preparation the gel weight was 0.24 g, making the Nal volume 0.75 ml. The 
gel / Nal solution was then incubated for 5 minutes at 50'C to dissolve the agarose. 
The next step was to reversibly attach the solubilised DNA (approximately 10 pg) to a 
solid phase for purification. This was achieved with the GENECLEAN kit by the use of 
a silica matrix suspension, known as 'Glassmilk'. Based on the premise of a minimum 
recomended volume of 5 [il Glassmilk for 5 gg DNA, a total of 20 [d was added to our 
IGFBP-3 DNA / Nal solution. After thorough vortexing, the tube was incubated for a 
further 5 minutes at room temperature to allow maximal DNA binding. 
The silica matrix bound DNA was pelleted by a brief 5 second spin in a microfuge, and 
the supernatant discarded. It was then washed 3 times each with 500 VI of ice cold 'New 
Wash' buffer, comprising NaCl, Tris, EDTA, ethanol and water, pH 8.0. 
Elution of IGFBP-3 cDNA from the silica matrix was made by the addition of a low salt 
solution. Thus, 10 pJ sterile water was added to the solution, then vortexed and incubated 
for 3 minutes at 50'C. Following a5 second microfugation to pellet the matrix, the 
supernatant, containing the DNA was carefully removed to a new sterile tube and the 
process repeated. The final volume was therefore 20 pl. 
A final check on the integrity of the IGFBP-3 cDNA was made by running 2W of this 
solution on a1% agarose gel as previously described. Results of this are shown 
in figure 
3. vi. overleaf. 
d. 32p labelling of cDNA 
Labelling of IGFBP-3 and IGFBP-4 cDNA for use as hybridisation probes with the 
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Figure 3. vi. 
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Photograph of gel showing in lane 2 the size and 
integrity of IGFBP-3 cDNA (indicated by arrow) 
following purification from plasmid DNA with the 
GENECLEAN kit. Standard molecular weight markers 
from HIND III treated phage DNA are shown in lane 1. 
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Northem blots was made with the 'Oligolabelling kit' supplied by Pharmacia Biotech. The 
IGFBP-3 cDNA to be labelled is first denatured and then mixed with 
hexadeoxyribonucleotides of random sequence. These random hexamers anneal to random 
sites on the DNA (now single stranded) and then serve as primers for new DNA synthesis 
by a polymerase. With the labelled nucleotide 32p-dCTP present during this synthesis, 
highly labelled DNA is generated. The specific protocol was as follows; 
i. An aliqout of the IGFBP cDNA (containing approximately 100 ng in a 15 ýtl volume) 
was first heated in a water bath at 95- 1 OOOC for 5 minutes to denature the DNA. The tube 
was then placed briefly on ice for 1-2 minutes. 
ii. The reaction solution was then added to the denatured DNA. This comprised 25 [tCi 
(25 W) [32p]dCTP, 10 pl of 'reagent mix' containing cold dATP, dGTP, dTTP and random 
hexadeoxyribonucleotides, and 10 of the Klenow fragment of Ecoli DNA polymerase 
1. The tube was vortexed and incubated at 37'C for 1 hour to allow DNA synthesis. The 
above reaction was stopped by the addition of 100 pl TE buffer (see page 86) and a final 
incubation at 65'C for 10 minutes. 
iii. Separation of labelled cDNA from the unincorporated 32 P dCTP nucleotide was made 
using a small column of Sephadex G-50 (Pharmacia, Uppsala, Sweden). This was 
constructed by placing a small amount of glass wool into a glass pipette, and then packing 
approximately 3 mls of pre-swollen G-50 gel such that it left loading space for the sample 
and elution buffer. 
Initially, the gel was washed with approximately 5 mls of TE buffer, and then loaded with 
the 150 gl radiolabelled DNA sample. This was allowed to fully enter the column and 
eluted by successive washes with 200 [d TE buffer. Fractions were collected and 
quantitated in a gamma counter. A typical profile is shown overleaf in fligure 3. vii. 
d. Northern blotting 
i. Isolation of Hs68 fibroblast RNA 
Extraction of RNA, based upon the guanidinium thiocyanate method (Chomcznski and 
Sacchi, 1987) was performed using RNAzol B (Biogenesis, Bournemouth, U. K. ). This 
solution promotes the formation of complexes of 
RNA with guanidinium and water, whilst 
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Figure 3. vii. 
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Size exclusion chromatographic profile of IGFBP-3 
cDNA following radiolabelling with 32 P-dCTP using 
the 'Oligolabelling kit' as described in section 3.4. c. 
The first peak corresponds to the cDNA, and the 
second to the unincorporated 32P nucleotides. 
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"abolishing the hydrophillic interaction of DNA and proteins. The net result 's that 
separation of the RNA, in the aqueous phase, can be made from the DNA and protein 
which can be pelleted and removed. 
Cell homogenisation 
Cell monolayers were first washed briefly with chilled sterile PBS (calcium and 
magnesium free) pH 7.4. To each culture dish 1 ml of RNAzol B solution was added and 
the cells homogenised with a cell scraper. The resultant lysate was transfered to a sterile 
centrifuge tube. 
RNA extraction 
100 0 of chloroform was added to the homogenised cells and mixed thoroughly. The tube 
was then allowed to stand for a few minutes on ice and then microfuged at 13,000 rpm 
for 15 minutes at 4'C. The aqueous phase was subsequently removed and placed into a 
new sterile centrifuge tube. 
RNA precipitation 
An equal volume of isopropanol was added to precipitate the RNA in the aqueous phase. 
The tube was then allowed to stand for 15 minutes at 4'C (or overnight at -20'C) and the 
RNA pelleted by a further 30 minute 13,000 rpm spin at 4'C in a microfuge. 
RNA wash 
Following the above spin, the isopropanol was gently aspirated and a 200 ýtl volume of 
70% EtOH added for a simple wash procedure. After vortexing the tube and another spin 
for 5 minutes at 13,000 rpm and 4'C, the ethanol was carefully aspirated and allowed to 
briefly air dry. 
Calculation of RNA content 
The dried RNA pellet was resuspended in 100 pJ H20 and solubilised. A 1: 100 dilution 
of the resultant solution was made in water and absorbances measured at 
260nm and 
280nm wavelengths in a spectrophotorneter. 
For clean preparations of RNA the 
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absorbance ratio between 260nm and 280nm should be greater than 1.85. 
Typical absobance data obtained from a set of five Hs68 cell samples, each comprising 
pooled lysates from three culture dishes, is given below in Table 2: 
Table 2. 
Sample Absorbance 
260 nm 
Absorbance 
280 nm 
Ratio 
260: 280nm 
Total RNA 
([Lglml)* 
Control 0.030 0.015 2.00 120 
IGF-1 0.037 0.019 1.95 148 
LR3-IGF-I 0.051 0.026 1.96 208 
Insulin 0.049 0.025 1.96 192 
TGFB1 0.045 0.023 1.96 168 
* Total RNA was calculated from : 
Absorbance 260 nm x 100 (dilution) x 40 (Constant) = pg/ml 
Following the calculation of RNA content, the RNA was precipitated once again with a 
volume of sodium acetate (2 mols/l, pH 5) sufficient to give a 10% (v/v) concentration, 
and 2.5 volumes of absolute ethanol. These samples were then stored at -70'C. 
ii. Electrophoresis 
Denaturing the RNA 
Stored precipitated RNA samples were first thawed and microfuged at 13,000 rpm for 15 
minutes at 4'C. The supernatant was aspirated and 50 ýd absolute ethanol added to each 
tube, and the samples microfuged as before. The ethanol was then aspirated and the RNA 
allowed to briefly air dry. For the purpose of denaturing the RNA to allow electrophoretic 
size separation, each 15 gg sample was mixed with 
12 W of 'denaturing buffer' and 
incubated at 55'C for 60 minutes. 
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Denaturing buffer: 
Glyoxal (deionised) 
Dimethyl sulphoxide 
H20(sterile, DEPC treated) 
Sodium phosphate (0.2 mols/1) 
20% (v/v) 
50% (v/v) 
20% (v/v) 
10% (V/V) 
Following the above incubation, the denatured RNA samples were cooled on ice and 
mixed with 3W of gel-loading buffer, consisting of: 
Sucrose (50% solution) 100 PI 
Xylene cyanol (1% solution) 12.5 W 
Bromophenol blue (1% solution) 12.5 VI 
The total sample volume of 15 W was then loaded into each lane of the agarose gel, as 
described below. 
Agarose gel electrophoresis 
A 1% agarose solution was made up in sodium phosphate buffer (10 mmols/1). To fully 
solubilise the agarose it was necessary to first heat the solution fairly vigorously. Whilst 
the solution was cooling, ethidium bromide was then added to give a concentration of 
0.005% (v/v). Once reaching a 'hand hot' temperature the agarose was poured into a 
taped-closed 14cm x 10cm horizontal gel block, all air bubbles removed and the spacer 
comb placed in position. The gel was then allowed to set for approximately 30 minutes 
at room temperature. 
Once this was achieved the spacer comb and tapes were removed and the gel placed into 
the electrophoresis tank submerged in running buffer (10 mmols/l sodium phosphate, pH 
6.8). RNA samples were then loaded into each lane, and the electrophoresis unit ran for 
5 minutes at high power (120v) to quickly move the samples into the gel, simply to avoid 
their dispersion from the wells into the running buffer. The power was subsequently 
reduced to 70v, and recirculation of the buffer at 100 mls/hour began. After 3-4 hours 
at room temperature, the gel was removed, checked and photographed under ultra violet 
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light for assessment of loading in each lane. 
Transfer of RNA 
Following electrophoresis, the RNA was transferred to a nylon membrane (Biotrans, ICN 
Flow, U. K. ) by capillary action. First, a piece of Whatman 3MM filter paper was placed 
on the over-tumed electrophoresis block with its length sufficient to overhang the ends. 
This was then put into a large plastic box, and 20x sterile sodium citrate (SSQ buffer 
added. 
20x SSC buffer: 
Sodium chloride 175.3 g 
Sodium citrate 88.2 g 
H20 II 
titrated to pH. 7.4. 
Once the filter paper was thoroughly wet and all air bubbles removed, the agarose gel 
containing the RNA was carefully placed on top, followed by the wetted nylon membrane 
cut to the exact size of the gel. To avoid 'short-circuits' and uneven transfer, the gel was 
surrounded by Parafilm. Subsequently, three pieces of wetted filter paper were then placed 
onto the nylon membrane and a 15cm high stack of paper towels, also cut like the filter 
paper to the size of the gel, finally added. A glass plate and a heavy weight were then 
placed onto the paper and the transfer allowed to run overnight at room temperature. 
Due to the presence of intercalated ethidium bromide in the RNA, the gel and nylon 
membrane were then briefly checked to see if the transfer had been successful. Under 
ultraviolet light no RNA was seen in the gel, whilst the 18 S ribosomal RNA band just 
visible on the membrane. To fix the RNA to the membrane, it was subsequently air dried 
and baked in a vacuum oven for 2 hours at 80'C. 
iii. cDNA hybridisation 
The nylon membrane containing the RNA was first incubated for 12 hours at 550C with 
a prehybridisation buffer, essentially to block non-specific 
binding of the radiolabelled 
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probe. 
Prehybridisation / Hybridisation buffer: 
Sodium phosphate (pH 7.2) 0.25 mols/I 
EDTA 
SDS 
Herring sperm DNA (denatured) 
I mmols/I 
0.25 mols/I 
0.2 gll 
The radiolabelled IGFBP-3 cDNA was then diluted into 15 mls of the same buffer but 
without the herring sperm DNA, and incubated with the membrane for a further 24 hours 
at 55'C. Following this incubation, the membrane was washed in 2X SSC buffer + 3.5 
mmols/I SDS first for 15 minutes at room temperature, and then in IX SSC + 3.5 mmols/l 
SDS for a further 15 minutes at 50'C. Finally, it was washed in 0. IX SSC buffer + 3.5 
mmols/I SDS for 1 hour at 65'C. 
Autoradiography of the dried blot was performed at -80'C for between 3 and 5 days, and 
quantitation of the IGFBP-3 mRNA band was made using scanning densitometry. 
iv. Rehybridisation 
IGFBP-4 and 6-actin hybridisation was performed on Northern blot membranes following 
initial IGFBP-3 analysis. Membranes were first subjected to a stringent wash procedure 
of 30 minutes at 60'C using a rehybridisation buffer: 
Sodium phosphate (10 mM, pH 6-8) 50% v/v 
Formamide 50% v/v 
Subsequent hybridisation conditions were the same as described for IGFBP-3 above. 
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3.5. IGFBP PROTEASE ANALYSIS 
As outlined in the Introduction, the presence of proteolytic activity directed against the 
IGFBPs has now been described in pregnancy serum and in a number of pathological 
states. Their presence affects the binding affinity of the IGFBPs, particularly IGFBP-3, 
for radiolabelled IGF and has therefore been given as an explanation for the low IGFBP 
values in the serum of these patients when analysed by Western ligand blotting (WLB). 
Initial analysis of such activity was undertaken by incubating the sample of interest with 
a constant volume of normal serum (with little or no IGFBP protease activity) and 
subsequently assessing the IGFBP degradation by WLB (Giudice et al, 1990). Whilst this 
technique had certain advantages in that it was possible to assess the effect of the 
protease(s) on all IGFBP species found in normal serum, it also introduced into the 
incubation sample another source of proteases and associated inhibitors. 
In this thesis an alternative technique first described by Lamson et al (1991) has been 
used which avoids the above problem. Rather than using serum IGFBPs followed by 
WLB, recombinant IGFBP-3 radiolabelled with 125 1 has instead been used as substrate. 
Visualisation of proteolytic activity is achieved by SDS polyacrylamide gel electrophoresis 
and autoradiography. The specific protocol was as follows. 
a. 
125 I-IGFBP-3 substrate 
IGFBP protease activity in fibroblast conditioned media was analysed using radiolabelled 
human non-glycosylated IGFBP-3 (Celtrix, USA). This recombinant peptide is the 28 kDa 
core protein as expressed by E. coli cells and was labelled using the chloromine-T 
methodology exactly as described for the glycosylated IGFBP-3 in the Radioimmunoassay 
section of this Methods chapter. Separation of the 1251_IGFBP-3 from free unincorporated 
1251 was made by size exclusion chromatography using a 10 cm ACA 202 gel (IBF, 
Villeneuve-la-Garenne, France) as described previously. Typical specific activity was 
approximately 0.1 mCi/[tg IGFBP-3. 
b. Digestions 
To a 1.5 ml silicOnised centrifuge tube 90 pl of CM 
from Hs68 fibroblast cultures, or 
unconditioned medium for control, was mixed with 
2-4 pl of 1251_IGFBP-3, giving a final 
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activity in the solution of approximately 10,000 counts / minute. To avoid any possible 
alterations in calcium ions in the CM sample which may alter the activity of the putative 
IGFBP metalloproteinase(s) 4 pJ of 500 mmols/l CaC12, giving a final concentration of 20 
mmols/l, was also added. Samples were then incubated at 37'C for 3- 24 hours 
c. Electrophoresis 
Degradation of the 1251_IGFBP-3 substrate was analysed by SDS Page, using reagents and 
buffers as described in the Western ligand blotting section of this Methods chapter. 
However, to aid later drying of the gel its thickness was reduced to 1.5 mm from the 
usual 3 mm, and the acrylamide content reduced from 12.5 % to 11 % to aid separation of 
possible IGBP-3 fragments. Accordingly, gels were comprised of the following. 
Resolving gel: 
30% acrylamide + 1% Bis solution 16 ml 
1.5 mols/I Tris base (pH 8.9) 11.2 ml 
1 mols/1 EDTA (pH 7.4) 3.6 ml 
10% SDS 1.8 ml 
distilled water 11.9 ml 
10% APS 0.45 ml 
TEMED 20 VI 
Stacking gel: 
30% acrylamide + 1% Bis solution 3.75 ml 
1.5 mols/I Tris / HCI (pH 6.9) 1.125 ml 
0.1 mols/I EDTA (pH 7.4) 0.45 ml 
10% SDS 0.22 ml 
distilled water 16.95 ml 
10% APS 0.34 ml 
TEMED 22.5 pI 
Once the gels were constructed 20 ýtl of incubated sample was mixed with 
40 pI of sample 
buffer, and the proteins denatured by placing them 
into boiling water for 5 minutes. 10 
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0 molecular weight rainbow markers (Amersham International, Bucks, UK) were diluted 
1: 7 with sample buffer and treated in a similar manner. The samples were then cooled and 
30 [tl loaded into each lane. Electrophoresis was performed at a constant current of 40 mA 
for approximately 4 hours. 
d. Autoradiography 
After electrophoresis the gel was taken from the electrophoresis unit and one of the glass 
plates carefully removed. The gel was lifted from the remaining plate by placing it onto 
a similar sized piece of Whatman 3mm filter paper and then transfered with the gel facing 
upwards onto a vacuum slab drier (Bio-Rad, Herts, UK). The gel surface was wetted with 
distilled water and then covered with cellophane membrane backing (Bio-Rad, Herts, UK) 
ensuring all air bubbles were removed by further wetting. The gel was subsequently dried 
under vacuum at 70'C for 90 minutes, and then exposed to X-ray film (Kodak X-OMAT 
RP) at -80'C for 2-3 days. 
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3.6. FAST PHASE LIOUED CHROMATOGRAPHY (FPLC) 
For size estimation of the 1251_IGFBP-3 substrate and its possible proteolytic fragmentation 
in the absence of the harsh biochemical conditions used in the electrophoretic analysis 
described above, neutral FPLC was also performed. 
For these experiments aIx 30 cm pre-packed column of cross-linked agarose with a 
molecular weight separation range of between 1000 and 300,000 kDa (Superose 12) was 
used. It was first equilibrated at a flow rate of 0.5 ml/minute with 2 volumes 
(approximately 75 mls) of degassed and filtered (0.45 pm) running buffer: 
FPLC run buffer 
Sodium phosphate 50 mmols/I 
NaCl 6 g1l 
Sodium azide 100 mg1l 
Tween 20 500 gl1l 
pH 7.4 
100 ýd filtered (0.22 pm) samples containing the radiolabelled IGFBP-3 peptide were 
subsequently loaded onto the column using a glass Hamilton syringe and a 200 [11 HPLC 
loading loop. Fractions were collected every 30 seconds, giving fraction volumes of 
approximately 250 W, and assessed for radioactivity with a gamma counter. 
Due to the unacceptable loss of the non-glycosylated IGFBP-3 peptide on the column, 
presumably a result of its high non-specific adherant properties as described by the 
manufacturers and Conover (1991), it was necessary to use the glycosylated varient in 
these studies. Its radiolabelling, purification and storage was identical to that described in 
the Radioimmunoassay section of this chapter. 
As the predicted molecular weight of the glycosylated IGFBP-3 peptide has been given 
by the manufacturers as 40 kDa, the column was calibrated by running through 1 mg 
quantities (in 100 pl) of unlabelled bovine insulin (5.5 kDa) and ovalburnin (44 kDa) 
followed by analysis of fraction peak distribution by spectrophotometry at a 280 nm 
wavelength. 
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3.7.1GF BINDING STUDIES 
In addition to those IGFBPs secreted into the surrounding culture medium, there is 
increasing evidence that a number of IGFBPs associate in vitro with fibroblast cell 
surfaces and extracellular matrix components. Indeed, a study by Clemmons et al (1986) 
has revealed that up to 90% of IGF-I binding sites on these cells may comprise such 
immobilised IGFBPs, thus forming an important store of binding protein with a high 
potential for modulation of IGF bioactivity. We have therefore performed "'I-IGF-I 
binding studies on Hs68 fibroblast monolayers (adapted from those described by 
Clemmons et al, 1991) to assess possible regulation of these IGFBPs. 
a. Cell culture 
Hs68 fibroblasts were initially seeded into 24-well tissue culture plates at a density of 5 
x 10' cells / cm' and in a volume of 0.5 ml / well DMEM + FCS, as described earlier. 
Following a three day incubation at 37'C the monolayers were placed into serum-free 
medium for a further 24 hours. Cells were then rinsed with fresh serum-free medium, and 
test samples added for another 24 hours before commitment to the binding assay. 
b. 1251_IGF-I binding assay 
i. Total IGF-I binding 
Assays were first performed to assess the binding of 125I_IGF-I to all possible components 
on the cell surface; Type I IGF receptors, insulin receptors, and cell-associated IGFBPs. 
This was designated 'total binding'. Type 11 IGF receptors were not considered to be 
included in this group as very weak binding has only been observed with purified IGF-I 
(possibly contaminated with IGF-H) whilst no significant binding has been seen with 
recombinant IGF-I (Rosenfeld et al, 1987), the peptide used in our study. 
Cells were first gently washed twice with ice cold phosphate buffered saline (PBS, 0.05 
mols/l, pH 7.4) to remove IGFBPs in the culture medium, and then incubated for 2.5 
hours at 10'C (to avoid active cellular uptake of the tracer) with 250 ýd of assay buffer. 
Assay buffer; 
Minimum Essential Medium (MEM) 250 pl 
Bovine serum albumin (BSA) 0.1% W/v 
105 
HEPES 
1251_IGF-I 
pH 7.4 
20 mmols/I 
75,000 cpm 
plus unlabelled IGF-I peptide over a concentration range of 0.1 - 100 nmols/l. 
At the end of the incubation period the above assay buffer was aspirated and the cells 
washed twice with ice cold PBS as before. Following subsequent solubilization with 
sodium hydroxide (0.3 mols/l, 250 W/ well), the radiolabelled IGF-I content of each 
monolayer was assessed with a gamma spectrometer. Results are expressed as counts per 
minute of duplicate wells. 
11. Binding to IGFBPs 
To determine the level and possible modulation of the cell-associated IGFBPs, similar 
experiments to those above were performed in the presence of 10 pmols/I unlabelled 
insulin which effectively abolishes binding of the 1251_IGF-I to both type I IGF and insulin 
cell membrane receptors. 
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3.8. IGF BIOASSAY 
a. Cytochenfical bioassays 
The use of cytochemical techniques for the quantitative measurement of hormone 
bioactivity was first developed by Chayen and Bitensky (1968). These early in vitro 
bioassays involved the exposure of target tissue segments to the chosen hormone followed 
by measurement of certain cytochemical reaction products. After precipitation within the 
cell these highly coloured products are then analysed by scanning and integrating 
densitometry. Such bioassays were developed for adrenocorticotrophin (ACTH), thyroid 
stimulating hormone (TSH), gastrin and luteinising hormone (LH). 
b. Tetrazolium reactions 
Various substrates have been utilised in the development of this type of bioassay, such as 
the the production of ferric ferrocyanide (Prussian blue) from ferricyanide in the ACTH 
assay for example (Alaghband-Zadeh et al, 1974). However, perhaps the most widely used 
set of cytochemical reactions have involved the large group of tetrazolium salts. These 
soluble organic compounds are able to serve as indicators of biological reducing systems 
since they are converted into highly coloured insoluble formazans upon mild reduction 
Altman, 1974). For the purposes of quatifying dehydrogenase activity, the formazan can 
be easily measured at its absorbance maximum using a spectrophotometer. In particular, 
the mono-tetrazole 3-[4,5-dimethyl thiazolyl-2]-2,4-diphenyl tetrazolium bromide (MTT) 
has been used in the study of cellular dehydrogenase activity, and was chosen for the IGF- 
I bioassay described in this study. 
Essentially, dehydrogenase enzymes catalyze the transfer in certain metabolic pathways 
of hydrogen (or electrons) from a substrate which becomes oxidised, to an acceptor 
molecule which is then reduced. These reduced acceptors may be an enzyme prosthetic 
group, such as flavin adenine dinucleotide (FAD) which becomes FADH, or a co-enzyme, 
such as nicotinamide adenine dinucleotide / phosphate which become NADH and 
NADPH, respectively. They are then reoxidised via a number of intracellular hydrogen 
transport pathways which include the mitochondrial respiratory chain, the mitochondrial 
b5 system, and the cytochrome 
P450 system (Altman, 1974). The tetrazolium salt MT'r can 
intercept the passage of the hydrogen ions along these transport chains, become reduced 
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and thus forrn its coloured formazan product. MTT has particular advantages over other 
tetrazoliurn salts, in that it is the most easily reduced, perhaps partly due to its low 
molecular weight (414 daltons) which allows it easier access across cell and subcellular 
membranes. 
An outline of the chemical structure of MTT and its coloured formazan following enzymic 
reduction is shown in figure 3. viii. overleaf. The reaction has been utilised for a number 
of in vitro bioassays. Most of these have not involved measurement of stimulated 
dehydrogenase activity per se, but have used MTT reduction as an indicator of cell 
populations in response to cytotoxic or mitogenic factors, Mosmann (1983). 
c. Development of MTT assay for Hs68 fibroblasts 
Cell culture conditions 
Growing stocks of adherant Hs68 cells were first removed from tissue culture flasks by 
the addition of the trypsin / EDTA solution. They were then seeded into 96-well microtitre 
plates in volumes of 150 gl/well complete medium at densities ranging from Ix IWIml 
(3 x 
103 / CM2) to 5x 104/ml (1.5 x 
104/CM2) 
, and incubated at 370C / 5%C02for 4 days. 
This incubation time was used to allow the cells to recover from passaging, adhere once 
again and begin their exponential growth phase. 
The spent medium was subsequently removed by inverting and vigorously shaking the 
microtitre plate, and blotting the remainder onto sterile paper. Each well then received 
100pl of serum-free DMEM + 0.1% BSA and the plate incubated for another 24 hours at 
37'C / 5% C02, principally to remove any remaining serum. Medium was again removed, 
and replaced by IOOW sample for a further 48 hours at 37'C / 5%CO2* 
MTT assay methodology 
MTIF (5 g1l) was solubilised in Dulbecco's formula phospate buffered saline (see page 70), 
containing both calcium and magnesium salts: 
Calcium chloride 13 mg 
Magnesium chloride 10 mg 
H20 100 MIS 
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Figure 3. viii. 
MTT 
3-[4,5-dimethyl thiazol-21-2,4-diphenyl 
tetrazoliurn bromide 
/N-N 
--0 
N CH 
N 
S --L- CH3 
Enzymic reduction of MTT 
Soluble yellow tetrazolium 
salt 
N-N-R 
R-C 
N=N-R 
Br- 
Crystalline purple 
formazan 
H 
I 
N-N-R 
R-C 
N=N-R 
ch- 
2H 
H+ 
Structure of tetrazolium salt MTT and schematic of 
its reduction to a coloured formazan product. 
Adapted from Altman (1974). 
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Once fully solubilised, the MTT solution was warmed to 37'C and 10W added to each 
well on top of the 10OW sample. Following incubation at 37'C in airl the crystaline 
formazan was eluted into the surrounding medium by the addition of an acidified 
detergent consisting of: 
Triton X100 10% (Vol/Vol) 
Hydrochloric acid (concentrated) 100 mmols/I 
H20 100 MIS 
Microtitre plates were then shaken for 10 minutes to mix each well, and finally the 
absorbances measured using a BioRad microtitre, plate reader with a test wavelength of 
595nm and reference wavelength of 650nm. 
Initial experiments 
Time-course experiments using a final MTT concentration of 0.5 g1l, based upon Ealey 
et al (1988), and a higher dose of 1.0 g1l were first investigated. Cells were exposed to 
serum-free medium only for 48 hours before the addition of the MTT. As shown in figure 
3. ix., both the MTT concentrations resulted in fairly linear formazan production during 
the 20 to 60 minute incubations. 
The relationship between cell number and MTT reduction was also investigated. As shown 
in figure Ix., formazan production was directly proportional to plating cell density, with 
very similar percentage increases seen after each incubation period. 
For all subsequent assays, MTT was used at a concentration of 0.75 g1l over an incubation 
time of 30 minutes. Such conditions were chosen to give a reasonable level of formazan 
production (optical density of 0.1), and a convenient incubation period. Due to certain 
difficulties in solubilising MTT at the high dose of 1.0 g/l, the slightly lower dose of 0.75 
g1l was chosen. 
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Figure 3. ix. 
0.30 
0.25 
0.20 
0 
0.15 
03 C) 
0 
C, f) 0.10 
10 
0.05 
0.00 
010 20 30 40 50 60 70 
Incubation time (mins) 
Time-course of Hs68 cell reduction of MTT 
tetrazolium salt to its coloured formazan. High 
density cells in serum-free media were exposed 
to either 0.5 g1l (m) or 1.0 g/l (11) MTT, and incubated 
for either 20,40 or 60 minutes at 37 'C. The 
reaction was stopped and coloured formazan eluted 
by the addition of acidified detergent Triton X100. 
Absorbances were spectrophotometrically read at 
a wavelength of 590nm. Mean results for duplicate 
wells are shown. 
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Figure 3. x. 
0.30 
0.25 
On 
0 0.20 
0.15 
ý-4 01% 
- -- 0 W) 
C'n -, 
0.10 
0.0 5 
0.00 
1 2.5 5 
Cell density (x 104/Ml) 
The relationship between MTT formazan production 
and plating cell density of Hs68 cells following 48 
hours in serum-free conditions. Results are shown as 
the mean absorbance at 590nm for duplicate cultures 
following MTT (1g1l) incubations of either 20 (0), 
40 (o ) or 60 (0 ) minutes at 37 T. 
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3.9. STATISTICAL ANALYSIS 
i. Values from immunoassays and IGF bioassay were expressed as the means of triplicate 
tests unless otherwise stated. Error bars shown on graphs are standard deviation scores. 
The electrophoresis data shown was representative of duplicated experiments. 
ii. Radioirnmunoassay data of fibroblast IGFBP-3 responses to cytokines were analysed 
by analysis of variance (ANOVA) using the S-PLUS computer package (Statistical 
Sciences Inc., Oxford, UK. ) and Dunnett"s multiple comparison test (Dunnett., 1955). This 
test is similar to a t-test but includes within it a constant term that depends on the residual 
degrees of freedom (given in the ANOVA) and the number of individual treatments being 
compared, including the control. An example is given below, using raw data on the effect 
of six doses of TGF6 on fibroblast IGFBP-3 taken from fligure 7. H. 
ANOVA 
degree 
freedom 
Sums of 
squares 
Means of 
squares 
Frequency P 
Groups 6 1604.49 267.414 47.7672 < 0.0001 
Residuals 15 83.97 5.598 
To calculate Dunnett's constant 
(DO then take: 
residual degrees of freedom = 15 
number of treatments =7 (including control) 
which gives a Dkvalue of 2.89 (taken from published tables) for a2 sided test with 95% 
confidence interval. 
The difference between the six TGFB treatment means (mean IGFBP-3 radioimmunoassay 
values, X2-, ) and the control mean (x. ) is then considered significant at the 5% level if 
(X2-Xc) > Dk 
ý 
MSe (1/n2 + 1/nc) 
since all n2-7 values =3 (triplicate cultures for each dose of TGF6) 
and nc =4 we have : 
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(x2-x,, ) > 2.89 4 5.598 (1/3 + 1/4) = 5.222 
making any treatment mean that differs from the control mean by more than 5.222 
significantly different; 
X2 - Xc = 16.0 - 15.8 = 0.2 
X3 - xc = 27.2 - 15.8 = 11.4 
X4 - xc = 30.6 - 15.8 = 14.8 
Not significant at dose 0.01 [tgll 
Significant at dose 0.05 Rg/l 
Significant at dose 0.1 Vg1l 
X5 - xc = 35.9 - 15.8 = 20.1 Significant at dose 0.5 ggli 
X6 - Xc = 38.0 - 15.8 = 22.2 Significant at dose 1.0 pg/l 
X7 - x,, = 33.0 - 15.8 = 17.2 Significant at dose 10.0 pg/l 
We may conclude therefore that all TGFB doses of 0.05 pg1l and above significantly 
increase Hs68 fibroblast IGFBP-3 production compared to unstimulated controls. 
iii. Analysis of variance (ANOVA) and Duncan's multiple range test (Duncan, 1955) were 
used to assess IGF-I bioactivity either in the presence or absence of cytokines in the MTT 
cytochernical assay. This test was chosen as it allows statistical analysis of both IGF-I 
doses compared to control and also all pairs of IGF-I doses between the cytokine treated 
and untreated cells. As this test controls the overall significance level, both of these two 
comparisons can be analysed all in one test. An example using raw data from figure 
8. viii. showing the effect of I ýtg/l TNF(x on the MTr response to five doses of IGF-I is 
shown below. 
ANOVA for MTT response to 5 doses of IGF-I, plus the untreated control, in the presence 
and absence of TNFoc. 
df SS MS F p 
Treatment 1 145.58 145.58 16.9 < 0.01 
Dose 5 2258.45 451.69 52.5 < 0.01 
Interaction 5 623.45 124.69 14.5 < 0.01 
114 
Residual 24 206.65 8.61 
The ANOVA data therefore suggests strong evidence in terms of MTT response of a 
treatment effect (TNF(x in this example), a dose effect (IGF-1) and an interaction between 
the two. More detailed analysis of each dose of IGF-I in the treated and untreated groups 
is then made using Duncan's multiple range test as follows; 
First calculate standard error of each dose mean by 
Syj =4 MS /n 
in this example 8.61 /3=1.694 
where Ms = residual mean square from ANOVA 
and n= size of each dose group (triplicate cultures in this example) 
Then obtain ranges R(p/f) for our data from Duncan's table of significant ranges using 
a 5% significance level (where p= number of means being compared (2,3 .... 12) and f 
degrees of freedom of residuals (24)) and multiply each by Syj. 
For this data set we calculate R as; 
R2(2,24) = 4.95 
R3(3,24) = 5.20 
R4(4,24) = 5.34 
R5(5,24) = 5.45 
R6(6,24) = 5.57 
R7(7,24) = 5.61 
R8(8,24) = 5.66 
Rg(9,24) = 5.71 
R10(10,24) = 5.73 
R11(l 1,24) = 5.76 
R12(12,24) = 5.78 
Comparisons are then made between the MTT data means obtained 
for the IGF-I dose 
points (designated Y. ) in the presence or absence of 
TNF(x. The notation was as follows; 
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control dose 5 dose 10 dose 25 dose 50 dose 100 
IGF-I 
alone 
Y1 Y2 Y3 Y4 Y5 Y6 
IGF-I + 
TNFcc 
Y7 Y8 Y9 Y10 y1i Y12 
These MTT means at each IGF-I dose are then sorted into decreasing order; 
Y6 Yll Y12 Ylo Y5 Y9 Y8 Y4 Y7 Y, Y2 Y3 
126.48 118.34 114.60 114.60 113.36 108.49 103.23 101.93 100 100 97.03 96.28 
The largest difference is then compared to the largest Duncan range (R,. ) such that in this 
example; 
Y6 against Y, = 126.48 - 100 = 26.48 > R9 = significant at p>0.05 
Y5 against Y, = 113.36 - 100 = 13.36 > 
R5 
= significant at p>0.05 
Y4 against Y, = 101.98 - 100 = 1.98 < 
R2 
= not significant at p>0.05 
Y, againstY2 == 100 - 97.03 = 2.97 < 
R2 
= not significant at p>0.05 
Y, againstY3 == 100 - 96.28 = 3.72 < 
R3 
= not significant at p>0.05 
Yll againstY7 -= 118.34 - 100 = 18.34 > 
R8 
= significant at p>0.05 
Y12 againstY7 = 
114.60 
- 100 = 14.60 > 
R7 
= significant at p>0.05 
Ylo againstY7 -= 114.60 - 100 = 14.60 > 
R7 
= significant at p>0.05 
Yq against Y, = 108-49 - 100 = 8.49 > R4 = significant at p>0.05 
Y,, againstY7 ý 103.23 - 100 = 3.23 > R4 = not significant at p>0.05 
Therefore, in terms of relative change from control the MTT response significantly 
increased by dose 50 pg/l IGF-I (Y, ) in the absence of TNF(x, and by dose 10 Pg1l IGF-I 
(Yg) in the presence of TNF(x. 
Comparisons can also be made between each IGF-I dose level in untreated or TNF(x 
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treated cells; 
Y8 againstY2 103.23 - 97.03 = 6.20 > 
R5 
significant at p>0.05 
Yq againstY3 108.49 - 96.28 = 12.21 > 
R7 
significant at p>0.05 
Y10 againstY4 114.60 - 101-98 = 12.62 > R5 = significant at p>0.05 
Y, j againstY5 118.34 - 113.36 = 4.98 > 
R4 
not significant at p>0.05 
Y6 againsty12 126.48 - 114.60 = 11.88 > 
R3 
= significant at p>0.05 
Therefore from these comparisons we can say that the relative changes in MTT response 
from control were significantly larger when IGF-I was in the presence of TNF(x compared 
with being alone over the IGF-I dose range of 5,10 and 25 Pg/l. At dose 50 [tg/I there 
was no significant difference in in the relative change from control in the two groups, and 
at a dose of 100 Vg/l a higher relative change occurred in the absence of TNF(x. 
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. 
CHAPTER 4. MECHANISMS OF IGF REGULATION 
OF IGFBP-3 IN VITRO.. 
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OVERVIEW 
With the probability that IGF-I stimulated increases in fibroblast IGFBP-3 are not due to 
alterations in de novo synthesis (as discussed in the Introduction), alternative mechanisms 
of regulation have been sought. It appears that a certain proportion of secreted IGFBPs, 
including IGFBP-1, IGFBP-2 and IGFBP-3, remain associated with the cell surface in 
vitro (McCusker et al, 1990), and that these may account for a large majority (up to 90%) 
of potential IGF binding sites (Clemmons et al, 1986). Recent data has now confirmed 
that IGFBP-1, via its RGD amino acid sequence, can bind to the integrin family of cell 
receptors, and also that IGFBP-3 and IGFBP-5 can be localised in the extracellular matrix 
(ECM) compartment (Jones et al, 1993), another possible storage site for secreted 
IGFBPs. Moreover, the relative abundance of basic amino acids in the carboxy-terminal 
region of IGFBP-3 suggests that it has the potential to bind with polyanionic sulfated 
glycosaminoglycans found in fibroblast ECM. 
An attractive hypothesis to explain the non-IGF receptor mediated regulation of IGFBP-3 
by IGF-I has now been proposed involving modulation of the cell-associated binding 
protein fraction (Martin et al, 1992). Following the observation that the IGF-I stimulated 
increase in IGFBP-3 in fibroblast conditioned medium was accompanied by a parallel 
reduction in cell-associated IGFBP-3, it was argued that IGF-I was simply displacing this 
store of binding protein. Clearly, no alteration in IGFBP-3 gene expression would be 
necessary in this mechanism, although no explanation was given to explain how such 
displacement occurs. 
In the following chapter, an investigation has been made on the possible role that the 
recently discovered IGFBP proteases may have in mediating IGF-I regulation of IGFBP-3 
secretion. Our motivation for these studies arose from certain reports over the last few 
years describing significant discrepancies between IGFBP-3 measured by 
radioimmunoassay and Western ligand blotting (Gargosky et al, 1992). It is believed that 
misleading low values in the latter technique result from the induction of proteolytic 
activity causing a reduction in the affinity of IGFBP-3 for the radiolabelled IGF ligand. 
Our initial studies, and those first published by Martin and Baxter (1991), seemed to 
suggest the opposite pattern existed for fibroblast 
IGFBP-3 in conditioned media following 
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IGF-I treatment. Our working hypothesis was therefore, that IGF-I was in some way 
inhibiting the activity of an IGFBP-3 protease produced by these cells leading to large 
exagerated increases of binding protein in Western ligand blots, not dependent upon 
altered peptide secretion. We have therefore analysed the Hs68 CM samples for their 
IGFBP-3 protease activity and have investigated its possible down-regulation by IGF-I. 
4.1. METHODS 
4.1. i. Cell culture 
Newbom human foreskin fibroblasts designated Hs68 were obtained from the American 
Type Tissue Collection, Rockville, USA. Cells were routinely cultured in Dulbecco's 
modified Eagles medium (DMEM) with 4.5 g1l glucose, 2 mmols/I L-glutamine and 10% 
fetal calf serum (FCS), in 5% C02 / 95% air. 
4.1. ii. Conditioned medium (CM) 
CM was collected as follows : Hs68 cells were seeded into 6-well tissue culture plates 
(Nunc, Roskilde, Denmark) at a density of 2x 104/CM2. Cells were allowed to grow in 
DMEM + 10% FCS for 72 hours at 37'C. After this time cells were washed once in 
DMEM + 0.1% bovine serum albumin (BSA) and incubated in the same serum-free 
medium (SFM) for a further 24 hours. After another wash, 2mls SFM containing 
increasing doses of IGF-I was added to each well for 24 hours. CM samples were 
collected and immediately stored at -20'C until analysis of IGFBPs by WLB and IGFBP-3 
RIA. 
4.1. iii. Western ligand blotting (WLB) 
The effect of IGF-I on fibroblast IGFBP-3 protein secretion was assessed by WLB. In 
addition to native IGF-I similar experiments were also performed with the IGF-1 analogue 
LongR3-IGF-I (GroPep Inc., Adelaide, Australia). LongR3-IGF-I is an 83 amino acid 
analogue of human IGF-I comprising the complete human IGF-I sequence with the 
substitution of an Arg for a Glu at position 3 and a 
13 amino acid extension at the N- 
terminus. Whilst these modifications greatly reduce the affinity of the peptide for an 
IGFBPs they minimally affect IGF-I receptor binding. It therefore provides a useful tool 
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to delineate those effects mediated by the IGFs via cell membrane receptors or interaction 
with IGFBPs. 
For all the WLB experiments 250pl pooled CM comprising SFM + IGF-I peptides was 
concentrated 5-fold before loading onto the gels. IGFBPs were visualised by the 
1251_IGF-I 
ligand as described in Methods. 
4.1. iv. 1GFBP-3 radioimmunoassays (RIA) 
CM samples were also analysed by RIA using glycosylated human recombinant IGFBP-3 
as tracer and standards, and three polyclonal IGFBP-3 antisera: SCH2/5,1287-2-14 
(Celltrix Inc., La Jolla, CA., USA), (x-BP-3gl (provided by Dr. R. Rosenfeld, Stamford, 
CA., USA). No concentration of sample was necessary, with 50 pl CM assayed directly. 
4.1. v. IGFBP-3 gene expression 
Hs68 cells were plated in DMEM + 10% FCS into PlOO culture dishes at a density of 
10'cells/dish, 1.3 x 
103/CMI 
. 
After 96 hours at 37T, cells were washed in SFM and 
incubated in same for 24 hours. After a further wash cells were incubated with test 
samples (5 mls/dish) for another 24 hours. Following removal of CM the cell monolayers 
were washed with sterile phosphate buffered saline (PBS) pH 7.4, before extraction of 
total RNA (RNAzol kit, Biogenesis, Bournemouth, U. K. ) and subsequent Northern blotting 
for IGFBP-3 mRNA as described in the Methods chapter. 
4.1. vi. Analysis of protease activity 
IGF-I regulation of Hs68 protease activity capable of degrading radiolabelled 1251 IGFBP-3 
was analysed by electrophoresis, following that of Lamson et al (1991), and as described 
in Materials and Methods. Cell culture and collection of serum-free CM was as described 
above using 24-well plates with the final 24 hour samples consisting of pooled CM from 
triplicate wells. The ability of IGF-I to alter the activity of the IGFBP-3 protease was 
assessed by adding either IGF-I or LongR3-IGF-I to the radiolabelled 1211_IGFBP-3 
substrate foRowed by incubations with 24 hour untreated CM for 3,6, and 24 hours at 
37C. 
Experiments were also performed to investigate whether the degradation of the IGFBP-3 
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substrate by Hs68 CM was artifactual, with fragmentation generated by the chemically 
disruptive SDS and heat (60-100'C) treatment used in both WLB and the electrophoresis 
technique. We therefore analysed 1251-IGFBP-3 following treatment with Hs68 cell 
protease by neutral fast-phase liquid chromatography (FPLQ utilising a 24 ml size- 
exclusion agarose column (Superose 12, Pharmacia, Uppsala, Sweden). Specifically, in a 
1.5 ml siliconised centrifuge tube 200[d of Hs68 24 hour CM was incubated for 24 hours 
at 370C with 150,000 cpm of freshly iodinated (< 7 days at -20'C) glycosylated 
1251_ 
IGFBP-3, in a total volume of 300pl. After this time FPLC was undertaken as described 
in Materials and Methods. 
4.2. RESULTS 
4.2. i. Western ligand blot of Hs68 CM 
The effect of increasing doses of IGF-I upon IGFBPs in Hs68 CM is shown in lanes 1-4 
in the autoradiograph in Figure 4. i. Under basal conditions of 24 hour SFM (lane 1) the 
fibroblasts secreted IGFBPs with apparent molecular weight of 43 kDa, consistent with 
IGFBP-3, a 33 kDa IGFBP, a 28-31 kDa consistent with IGFBP-5, and a 24 kDa IGFBP- 
4. Analysis of IGFBP mRNA species shown subsequently in this thesis confin-ned the 
existence of IGFBP-3 and IGFBP-4, and similar but as yet unpublished experiments on 
these cells by Dr. Camacho-Hubner recorded IGFBP-5 mRNA and protein. 
The addition of native IGF-I during the 24 hour incubation at doses of 10 pg/l (lane 3) 
and 100 Vg11 (lane 4) affected the band intensity of all the aforementioned IGFBPs 
compared to the untreated control (lane 1). IGF-I at a dose of 100 ýtg/l caused an 
approximate 2-fold increase in IGFBP-3 abundance when the autoradiograph was assessed 
by scanning densitometry, and also had a similar although considerably greater effect upon 
the 28 kDa IGFBP-5. In contrast, IGFBP-4 was inhibited with increasing doses of IGF-1. 
The effect of the IGF-I analogue LongR3-IGF-I is shown in lanes 5-8 in Figure 4. i. Basal 
24 hour serum-free CM control from these experiments is shown in lane 5. LongR3-IGF-I 
up to a dose of 100 gg/l, was seen to have little or no effect upon the IGFBP-3 band 
intensity, or indeed IGFBP-4 or the 33 kDa band, despite being reported to be 10-20-fold 
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Figure 4A. 
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Western ligand blot for IGFBPs in Hs68 cell conditioned 
medium following 24 hour treatment with either 
native IGF-I (lane 1-4) or LongR3-IGF-l (lane 5- 
8). Molecular weight markers are indicated. 
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more active in mitogenic bioassays. It had some stimulatory activity on the 28-30 kDa 
bands, although its effect was markedly smaller than that seen in response to native IGF-I. 
4.2. ii. IGFBP-3 radioimmunoassays 
The same Hs68 CM samples analysed by Western ligand blotting above were then subject 
to radioirnmunoassay using a variety of IGFBP-3 antisera, as summarised in Figure 4. fi. 
Despite the increased appearance of IGFBP-3 in response to 100 Vg1l IGF-I described 
above by WLB, only a maximal 7% increase in immunoreactive IGFBP-3 was observed 
using antibody cc-BP-3gl. Moreover, maximal IGFBP-3 increases to 100 Vg/l IGF-I were 
only 14.2% and 23.1% for antisera 1287-2-14 and SCH 2/5, respectively. Antiserum cc- 
BP-3gI detected no increase in IGFBP-3 in response to 100 [tgll LongR3-IGF-1, whilst 
minor increases of 5.5% and 13.8% were seen by antisera 1287-2-14 and SCH 2/5. 
4.2. iii. IGFBP-3 gene expression 
Figure 4. iii. shows the autoradiograph of a Northern blot of Hs68 fibroblast IGFBP-3 
mRNA after 24 h in serum-free medium (lane 1), 50 ggll IGF-I (lane 2), 1 mg/l insulin 
(lane 3) or 1 Vtg/l LongR3- IGF-I (lane 4). In accordance with the immunoassay data, 
native IGF-I did not cause any increase in the single 2.4-kb transcript recognised by the 
human IGFBP-3 cDNA probe, but actually lead to a moderate reduction. A similar effect 
was observed following treatment of the cells with the IGF-I analogue LongR3-IGF-1, but 
no alteration in IGFBP-3 gene expression was seen with insulin. As all of these peptides 
have the ability to interact with the type-I IGF receptors, it would seem that there is little 
or no regulation of IGFBP-3 at the gene transcription through this receptor. Also shown 
in Figure 4. iii. is the ethidium bromide staining of the 28s and 18s components of the 15 
[tg total RNA loaded in each lane, giving an approximation of the integrity of each sample 
and an indication of the accuracy of gel loading. 
4.2. iv. IGF-I regulation of IGFBP-3 protease(s) 
Proteolytic activity capable of leading to the breakdown of radiolabelled IGFBP-3, 
migrating at an approximate molecular weight of 35 kDa, was detected in 24 hour serum- 
free CM taken from Hs68 fibroblasts (Figure 4. iv., lane 4). Whilst its activity was less 
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Figure 4. ii. 
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The effect of IGF-I upon immunoreactive levels of 
IGFBP-3 in Hs68 cell conditioned media, assessed 
by three different antisera. Cells were incubated for 
24 hours in serum-free conditions with the addition 
of either native IGF-I or LongR3-IGF-I as described. 
Pooled samples from duplicate wells were then assayed 
by radioimmunoassay using antiserum (x-BP-3gl (N), 
antiserum 1287-2-14 (RI) and antiserum SCH 2/5 
(a) as described in the Methods. The mean error 
between duplicates was 5.1%. 
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Figure 4. iii. 
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Northern blot showing IGFBP-3 mRNA abundance 
in Hs68 cells following 24 hour treatment with 
IGF-I and related peptides. Results are shown for 
control untreated cells (lane 1), 50gg/l native IGF-I 
(lane 2), lmg/l insulin (lane 3), and lOgg/l LongR3- 
IGF-I (lane 4). Treatment with Igg/l TGFP 1 acted as 
a positive control (lane 5). 
To confirm that similar amounts of total RNA were 
loaded ethidium bromide staining of the gel is shown. 
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potent than the well recognised protease found in late pregnancy serum (lane 2), it too 
was evident following incubations of 3 hours at 37'C and could be abolished by the 
inclusion of the metal ion chelater EDTA (lane 5). The proteolytic effect was also time- 
dependent with further degradation of the radiolabelled IGFBP-3 following 6 hour 
incubations (Figure 4. v., lane 4) and complete breakdown after 24 hours (Figure 4. Vi., 
lane 4). A number of IGFBP-3 fragments were generated by the fibroblast protease and 
migrated at approximate molecular weights of 20 kDa, 15 kDa and 10 kDa. 
When native IGF-I was added to the 1211_IGFBP-3 substrate before the incubation with 
basal Hs68 conditioned media inhibition of protease activity was evident following 3 hour 
incubations (Figure 4. iv. ). A dose-dependency effect was observed, with an IGF-I 
concentration of I pg/l producing visible protease inhibition (lane 6) and 100 ýIg/l IGF-I 
(lane 10) returning the level of intact IGFBP-3 back to that seen in the presence of EDTA 
(lane 11) or in the control (lane 1). This 'protection' of IGFBP-3 by native IGF-I was 
quite short-lived however, and no effect was observed following 6 and 24 hour IGFBP- 
3/protease incubations (Figure 4. v. and Figure 4. vi. ). Similar experiments at 3,6 and 24 
hour incubations with the LongR3-IGF-I analogue which has minimal affinity for the 
IGFBPs, LongR3-IGF-1, failed to detect any inhibitory effect upon the activity of the 
fibroblast-derived protease (Figure 4. iv., Figure 4. v., and Figure 4. vi. ). 
Fractionation of glycosylated 1251_IGFBP-3 by FPLC (50,000 counts in 100 W) produced 
a major peak between fractions 45-50 and a smaller peak at fraction 150+ (Figure 4. vii. ), 
corresponding to the radiolabelled IGFBP-3 peptide at a molecular weight of 
approximately 45 kDa and the considerably smaller non-incorporated 
12'iodide, 
respectively. 
Figure 4. viii. shows the same 1251_IGFBP-3 run through the FPLC column following a 24h 
incubation at 37'C with Hs68 24 hour conditioned media. A large peak was once again 
observed between fraction 45 and 50 corresponding to the intact 
45 kDa IGFBP-3 peptide 
seen in the control experiment above. However, a number of 
different sized peaks were 
also evident. The most abundant of these eluted 
in fractions 65 to 75 indicating a 
molecular weight of approximately 5 kDa. 
Other peaks were detected in fractions 30 to 
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Superose-12 size exclusion chromatographic profile 
of 1251-radiolabelled human glycosylated recombinant 
IGFBP-3. Molecular weight standards of 44 kDa 
(ovalbumin) and 5.5 kDa (insulin) are indicated. 
131 
Figure 4. viii. 
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Superose-12 size exclusion chromatographic profile 
of 121 I-IGFBP-3 following incubation for 24 hours 
at 370C with serum-free conditioned medium from 
untreated Hs68 cells. Molecular weight standards of 
44 kDa (ovalbumin) and 5.5 kDa (insulin) are indicated 
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45, corresponding to one or more large molecular weight complexes in excess of 50 kDa. 
Inclusion of 20 mmols/l EDTA during the incubation lead to the reduction of the 
proportion of the major 5 kDa peak, confirming that this was a product of proteolytic 
cleavage (Figure 4. ix. ). 
4.3. CONCLUSIONS 
The principal aim of these experiments was to clarify the post-translational mechanisms 
involved in IGF-I stimulation of IGFBP-3 secretion by human fibroblasts in vitro. With 
the recent discovery that a number of proteolytic enzymes are capable of degrading the 
IGFBPs, including IGFBP-3, we have attempted to examine if they play a part in this 
effect. 
Firstly, we have established a normal human skin fibroblast model whose appearance of 
IGFBP-3 in conditioned medium responds to IGF-I in the expected manner. Apparent two- 
fold increases in IGFBP-3 were thus recorded in response to sub-maximal doses of IGF-I, 
when measured by Western ligand blot. As reported by others, this effect was not 
dependent upon IGF-I interacting with the type I IGF receptor, highlighted by the lack of 
effect of LongR3-IGF-1, a synthetic analogue with normal affinity for this receptor, but 
minimal affinity for the IGFBPs. 
Further examination of these samples by radioimmunoassay using three specific IGFBP-3 
antisera failed to detect comparable increases however. Although not directly reported 
elsewhere, such data is not totally without precedent. One of the first studies investigating 
IGF-stimulated enhancement of fibroblast IGFBP-3, from the only group using a 
radioimmunoassay (Baxter), reported minor increases of up to 50% only, despite much 
larger increases seen on Western ligand blot. Moreover, these increases were observed 
over an incubation period 3-fold greater than the one employed in our study; 72 hours 
compared to 24 hours. Whilst it is likely that real differences may exist between our 
neonatal Hs68 cell line and the neonatal fibroblasts used by this group, our experience 
with a number of IGFBP-3 antisera indicate that data showing such comparitively small 
increases in immunoreactive IGFBP-3 may also arise when the binding of said antibody 
is affected by IGF-I occupancy of the IGFBP-3. As described 
in the Methods section 
specific binding of one of the IGFBP-3 polyclonal antisera used 
in our study, 1287-2-14, 
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Figure 4. ix. 
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was significantly reduced when in the presence of the IGF peptide. Presumably, this 
occured because the epitope recognised by this antibody was very close to the IGF 
binding site on the IGFBP-3, causing a certain degree of competition. The net effect of 
high doses of IGF-I during the radioimmunoassay was therefore to reduce 1251_IGFBP-3 
tracer binding, resulting in an artifactually increased sample IGFBP-3 value from the 
radioimmunoassay. Such interferance could be overcome by adding a large excess of IGF 
to each assay tube. If the antibody used in the Baxter studies, designated R7, behaved in 
a similar manner this may perhaps explain the apparent dose-dependent increase in 
IGFBP-3 seen in response to IGF-I in their assay. 
Furthermore, such an IGF-mediated reduction in binding affinity of IGFBP-3 for antibody 
could explain the reported concommittant 'displacement' of cell-associated IGFBP-3, 
proposed as the mechanism for IGF regulation of this binding protein. Simply, IGF-I may 
reduce the affinity of IGFBP-3 for antibody rather than its concentration. Notably in our 
study, the two antisera unaffected by the presence of IGF recorded no increase in 
immunoreactive IGFBP-3 in response to IGF-1. 
Major discrepancies between IGFBPs measured by Western ligand blot and 
radioimmunoassay have recently been reported in pregnancy serum, cerebro-spinal fluid, 
seminal plasma, peritoneal. fluid, amniotic fluid (Gargosky et al, 1992) and in the 
conditioned media from pheochromocytorna and anterior pituitary cells (Ocrant et al, 
1992). They appear to describe the presence of one or more proteolytic enzymes capable 
of reducing the affinity of IGFBPs for the IGF molecule leading to low or even absent 
IGFBPs on Western ligand blots, despite non-nal immunoreactive levels of the peptides. 
Such discrepancies thus highlight the Western ligand blot technique as being a measure 
of both the molar concentration and binding affinity of the IGFBP. 
Our data on the regulation of IGFBP-3 in Hs68 fibroblast conditioned medium suggested 
that the affinity of the binding protein, and not peptide concentration, was altered in the 
presence of IGF-I. However, despite recording the presence of IGFBP-3 proteolYtic 
enzymes in the conditioned media taken from these cells, no alteration was seen 
following 
treatment with LongR3-IGF-1, suggesting that the 'stimulation' of 
IGFBP-3 by IGF-I seen 
on Western ligand blot was not due to down-regulated secretion of 
this protease. However, 
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we have subsequently shown that binding of native IGF-I to IGFBP-3, presumably leading 
to the formation of IGF-I/IGFBP-3 complexes, renders the binding protein partly resistant 
to degradation by the proteolytic activity produced by these cells. This was demonstrated 
by the addition of IGF-I to untreated Hs68 conditioned medium after it had been removed 
from the cells, which resulted in the inhibition of IGFBP-3 protease activity and may 
suggest that the protease was active at or near to the IGF binding site on the IGFBP-3 
molecule. Such passive protection of the IGFBP-3 peptide may help explain the 
conflicting immunoassay and Western ligand blotting data presented in this chapter, but 
does not necessarily attach any important functional significance to IGF-I 'stimulation' 
of IGFBP-3 from these cells. 
It does appear however from our neutral size exclusion gel chromatography data that 
proteolytic fragmentation of IGFBP-3 can occur under more physiological conditions than 
those neccesary for electrophoresis. Experiments showed that incubation of glycosylated 
"I-IGFBP-3 with the Hs68 cell conditioned media lead to the appearance of a major 
fragment peak with an approximate molecular weight of 5 kDa, which could be mostly 
abolished with the addition of EDTA. Whilst this may suggest that proteolytic degradation 
of IGFBP-3 is possible under more physiological conditions (pH, absence of SDS and 
heat) we found no evidence of the major fragments of between 10 kDa to 20 kDa 
observed following electrophoretic separation. This may reflect differential migration of 
these fragments due to variation in glycosylation, although equally it may indicate that the 
large fragments are a product of the chemically harsh conditions and high temperature 
used in the SDS polyacrylamide gel electrophoresis and protease analyses. 
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CHAPTER 5. FIBROBLAST IGFBP REGULATION BY, 
TUMOUR NECROSIS FACTOR oc 
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OVERVIEW 
As outlined earlier the inflammatory cytokine TNF(x is explicitly involved in a diverse 
range of effects in cell physiology. Moreover, many of these are involved in controlling 
cellular growth, with both positive and negative signals elicited. Evidence has accumulated 
to suggest some of these actions are mediated via the modulation of other growth factors 
found in serum, such as EGF and insulin (Vilcek et al, 1986). At present there is little 
data on the role this cytokine may have in regulating the IGFs, and it this via investigation 
of its effect upon IGFBP secretion in the Hs68 normal human neonatal fibroblast model 
that has been addressed in the following chapter. 
5.1. METHODS 
5.11 Cell culture. 
The normal human neonatal skin fibroblast cell line, Hs68, was routinely cultured as 
described earlier. 
5.1. ii. Conditioned medium 
Cells were seeded into 24-well tissue culture plates in complete growth medium, (10% 
fetal calf serum), in a volume of 0.5 ml / well and at densities of 2.5,5 x 10' / ml and 
105 / ml. After 96 hours at 37C in 5%CO2, the spent medium was aspirated and replaced 
by serum-free medium (SFM). SFM was essentially the same as growth medium, but 
0.1% bovine serum albumin (BSA) replacing the fetal calf serum. Following a 24 hour 
incubation at 37'C, this medium was once again removed and the cells washed briefly 
with SFM. Test samples containing recombinant human TNF(x in 300 gl were then added 
to each well and incubated for a further 24 hours at 37'C. Triplicate wells were used for 
each sample. Conditioned medium was collected and immediately stored at -20'C until 
analysis. 
5.1. iii. Western ligand blotting 
IGFBPs in the above conditioned medium were analysed by the WLB technique as 
described in the Materials and Methods section, based on that by Hossenlopp et al (1986). 
Specifically for this set of experiments 600 pl of pooled conditioned medium from 
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triplicate wells was Iyophylised dried (4 hours in a GyroVap vacuum drier (Howe Ltd) 
and subsequently resuspended in 80 [d deionised water, thus giving a 6.66-fold 
concentration. A 30 pl volume of each sample was then added to 10 W of 4-fold 
concentrated WLB sample buffer (see Methods page 73) to give a final concentration of 
the CM of 5-fold. After denaturation at 60'C, 25 W was loaded into each lane on the 
polyacrylamide mini-gel and electrophoresed as previously described. After transfer of the 
proteins to nitrocellulose, the membrane was blocked for non-specific binding, incubated 
Withl251_IGF-1, washed and dried. The blot was then subject to autoradiography for 3 days 
at -700C. 
5.1. iv. IGFBP-3 radioimmunoassay 
The effect of TNFa on immunoreactive IGFBP-3 in Hs68 conditioned medium was 
quantified by specific radioimmunassay (RIA). Human recombinant glycosylated IGFBP-3 
(Celtrix, Santa Clara, CA) was used for standards and radiolabelling as described in 
Materials and Methods. For this set of experiments a rabbit polyclonal antiserum, 1287-2- 
14, was used at a final dilution of 1: 20,000, with the additional presence of 2 ng/tube 
recombinant IGF-I for reasons described earlier. Due to the sensitivity of this assay no 
concentration of CM was necessary, with 50 ýtl measured directly. 
5.1. v. Analysis of IGFBP gene expression by Northern blotting 
Hs68 IGFBP-3 gene expression was analysed by Northern blotting, following the 
procedure described by Carnacho-Hubner et al (1992). Hs68 cells were plated into 9.5 cm 
tissue culture petri-dishes in a volume of 10 mls and at a density of 10'/ml. After 96 
hours at 37'C and 5% C02 the spent medium was aspirated and replaced with 5 mls SFM. 
Following 24 hours at 37'C this medium was aspirated and the cells washed briefly with 
SFM. TNF(x samples in 5 mls SFM / dish were then added and incubated for either 1,3, 
6,12 and 24 hours. After this time conditioned medium was collected and 
immediately 
frozen to -20'C for use in IGFBP-3 protease analysis as 
described below. RNA was 
isolated from the remaining cell monolayers and Northern blotting undertaken to 
determine IGFBP-3 and IGFBP-4 gene expression, as described in Materials and 
Methods. 
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5-1-vi. Analysis of IGFBP-3 protease activity 
Conditioned medium from untreated and TNF(x treated Hs68 cells as described above was 
incubated with 1251_IGFBP-3 for analysis of protease activity. Digestion incubations were 
kept at 37'C for 3 to 24 hours and subsequently electrophoresed, as described in the 
Methods chapter. 
5.1. vii. Cell surface-associated IGFBPs 
Initially 125 I-IGF-I binding studies (as described in the Methods chapter) were performed 
on TNF(x treated Hs68 fibroblasts to assess possible regulation of cell membrane IGF-I 
binding sites, potentially comprising type 1, type 11, insulin receptors and also cell-bound 
IGFBPs. The cell culture protocol was as described above, with cells treated with I Vg/l 
TNF(x for 24 hours in serum-free conditions. 
5.2. RESULTS 
5.21 Western ligand blot 
As shown in rigure 51, incubation of Hs68 fibroblasts for 24 hours in the presence of 1 
Vg1I TNF(x resulted in the reduction of conditioned media IGFBP band intensities on 
WLB. Scanning densitometric analysis of the autoradiograph revealed there to be 
decreases of 66.8% in the IGFBP-3 band (35 kDa), 81.1% in IGFBP-5 (28 kDa) and 
81.7% in IGFBP-4 (24 kDa) compared with serum-free control values. Analysis of 
fibroblast cell number using both cell counting and our MTT cytochemical bioassay 
(described in Chapter 8. of this thesis) suggested that these effects were not simply due 
to TNF(x induced cytotoxicity. 
5.2. ii. IGFBP-3 immunoreactivity 
Analysis of Hs68 24 hour conditioned medium by specific IGFBP-3 radioimmunoassay, 
shown in figure 5M, demonstrated that TNFoc reduced the binding protein in a dose- 
dependent manner with significant effects seen at concentrations above 0.1 Pg1l. Variation 
in the absolute values of IGFBP-3 reduction were observed between experiments 
however, 
ranging from 25% to 60% inhibition at I Vg1l TNF(x, although this 
did not appear to be 
correlated with cell passage number. Inhibition of 
IGFBP-3 by TNF(x was not affected by 
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Figure 5A. 
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30 IGFBP-5 
2 1.5 IGFBP-4 
c TNFoc 
(I gg/1) 
Western ligand blot showing the effect of TNF(x (Igg/1) 
on IGFBP secretion from Hs68 fibroblasts. Cells were 
treated for 24 hours in serum-free conditions. Lane I 
shows the untreated control, Lane 2 shows TNF(x 
treatment. Molecular weight standards are indicated. 
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Figure 5. ii. 
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Dose-dependent TNF(x-mediated inhibition of 
immunoreactive IGFBP-3 produced by Hs68 cells. 
Results are expressed as the percentage IGFBP-3, 
assessed by radioimmunoassay, of that found in 24 
hour serum-free conditioned medium control ± S. D. 
* P<0.05 compared to control. 
142 
cell density, with similar responses of 40.5% ± 15.8,36.9% ± 6.5, and 39.1% ± 6.4 
recorded in sparse (2.5 x 10'/ml), semi-confluent (5 x 104/ml) and confluent (I x 105/Ml) 
cultures. 
There are reports in the literature of the ability of TNF(x to stimulate the synthesis and 
secretion of prostaglandin E2 (PGE2) from fibroblasts, and certain physiological effects of 
TNF(x have now been attributed to the secondary effects of PGE2. Although the inhibitory 
action of TNF(x on IGFBP-3 secretion was observed within 24 hours, perhaps suggesting 
it to be mediated directly by the cytokine, experiments were performed to investigate the 
possible role of PGE2 in this effect. 
As shown in figure 5. in., following a 24 hour incubation with recombinant PGE2 
immunoreactive Hs68 IGFBP-3 in conditioned medium was inhibited in a dose-dependent 
manner. Significant inhibition, similar to that caused by TNF(x, was observed at doses of 
I mg/I and above. However, the cyclo-oxygenase inhibitor indomethacin, which blocks 
the synthesis of the prostaglandins, had no effect on either the TNF(x effect or basal 
IGFBP-3 secretion over a dose range of 0.1 - 10 VM. This would suggest that IGFBP-3 
inhibition by TNF(x is not due to enhanced PGE2 synthesis. 
Interferon- gamma (IFN-g) is a cytokine often closely associated with TNF(x in vivo. It was 
perhaps not surprising therefore in our in vitro model IFN-g also inhibited IGFBP-3 
secretion from Hs68 fibroblasts, as seen in fligure 5. iv. This effect was dose-dependent, 
with significant inhibitory activity observed at doses of I ýtg/l or more, some ten-fold less 
potent than TNFoc. A number of in vitro studies have also shown that IFN-g can modulate 
the function of TNFoc, possibly via its ability to up-regulate cell membrane TNF(x 
receptors. The co-incubation of IFN-g with I ýtg/l TNF(x resulted in attenuated inhibition 
of Hs68 IGFBP-3 secretion, with 10 pg/l EFN-g fully reversing the TNF(x effect. 
5.2. iii. IGFBP gene expression 
IGFBP-3 
Despite the significant decrease in IGFBP-3 peptide levels in Hs68 conditioned media as 
measured above by both WLB and RIA, no parallel reduction 
in IGFBP-3 mRNA was 
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Figure 5. iii. 
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The inhibitory effect of prostaglandin E2 (PGE2) 
on IGFBP-3 secretion from Hs68 fibroblasts. The 
cyclo-oxygenase inhibitor indomethacin was without 
significant effect upon basal IGFBP-3 levels or 
upon the inhibitory effect of 1gg/l TNFa. 
IGFBP-3 collected over 24 hours was assessed by 
radioimmunoassay, and results are expressed as the 
percentage of the serum-free control. 
P<0.05 compared to control 
** P>0.05 compared to TNF(x alone. 
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Figure 5. iv. 
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The effect of interferon-gamma on immunoreactive 
IGFBP-3 secretion from Hs68 fibroblasts, and its 
reversal of the inhibitory effect of TNF(x. IGFBP-3 
collected over 24 hours was assessed by 
radioimmunoassay, and results expressed as 
percentage of the serum-free control ± S. D. 
* P<0.05 compared to control 
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observed following a 24 hour incubation with I pg/l TNF(x (figure 5. v. a. ). Indeed, 
scanning densitometric analysis revealed a small increase of approximately 1.5-fold in the 
2.4 kb transcript identified by our 32p_labelled IGFBP-3 cDNA probe. This effect could 
not be explained by variable gel loading of the total RNA (15 Pg/lane) with minimal 
differences seen between the control and TNF(x samples (5. v. b. ). 
Time-course studies also suggested there to be no consistent reduction in IGFBP-3 mRNA 
abundance in response to TNF(x treatments of 2,4,6,8 or 12 hours, figure 5M. Due to 
problems of RNA loading in these particular experiments, B-actin mRNA levels are 
shown for comparison. These time-course studies were however also repeated on three 
seperate occasions with cells at different passages, and with similar results. This would 
seem to confirm that TNF(x mediated inhibition of Hs68 cell IGFBP-3 peptide was not 
a consequence of a parallel reduction in IGFBP-3 gene expression. 
IGFBP-4 
The membranes used in the analysis of IGFBP-3 gene expression regulation by TNFOC 
above were re-hybridised with a 32p_labelled IGFBP-4 cDNA probe. As shown in figure 
5. v., the intensity of the single 2.2 kb IGFBP-4 mRNA transcript was also increased 
following 24 hour treatment with 1 gg/ml TNF(x. 
5.2. iv. IGFBP protease 
The close agreement in data between WLB and RIA would suggest that the TNFOC 
mediated reduction in IGFBP-3 involved real changes in peptide 
levels and was not via 
stimulation of proteolytic activity. However, as this cytokine 
is widely known to enhance 
the production of various fibroblast metalloproteinases, whilst concommitantly reducing 
associated inhibitors, experiments were performed to 
firmly establish the relevance of this 
function of TNF(x on its ability to modulate IGFBP-3. As is illustrated 
in Figure 5. vu., 
24 hour treatment with I gg/l TNF(x was seen to have no effect upon the activity of 
IGFBP-3 protease secreted by Hs68 cells, with no alteration 
in the degradation in 
1251_ 
IGFBP-3 substrate compared to untreated cells. 
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Figure 5. v. 
A. Northern blots 
IGFBP-3 IGFBP-4 
mRNA mRNA 
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B. Ethidium bromide staining 
lanes I&32&4 
- 28s 
- 18S 
c TNFoc 
Regulation of IGFBP-3 and IGFBP-4 gene expression 
in Hs68 fibroblasts by Igg/l TNF(x. Shown in panel (A) 
are IGFBP-3 and -4 mRNA levels following 24 hours 
of treatment at 370C. In panel (B) the ethidium 
bromide staining of the 28s and 18s RNA is shown 
to indicate the accuracy of loading 15gg total RNA 
per lane. 
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Figure 5. vi. 
Northern blots. 
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246812 
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Analysis of IGFBP-3 mRNA levels in Hs68 fibroblasts 
following incubations for 2,4,6,8 or 12 hours with either 
serum-free media (C) or l[tg/l TNF(x (T). Corresponding 
P-actin mRNA levels are shown to accurately indicate 
loading variations bewteen lanes. 
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Figure 5. vii. 
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The effect of TNF(x on IGFBP-3 protease activity 
produced by Hs68 fibroblasts. 24 hour conditioned 
medium from untreated or TNF(x (Igg/1) treated cells 
was incubated for 4 hours at 37'C with "'I-IGFBP-3 
and subjected to electrophoresis. Lane I shows control 
IGFBP-3; lanes 2 and 3 show untreated CM; lanes 4 
and 5 show TNF(x treated CM; lanes 6 and 7 show 
untreated CM + EDTA (25 mM); lanes 8 and 9 show 
TNFcc treated CM + EDTA. 
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5.2. v. Cell-associated 1GFBPs 
It is becoming increasingly apparent that in cell culture systems a potential mechanism 
for IGFBP regulation concerns the existence of cell-associated IGFBPs. A change in the 
levels of IGFBPs secreted into the surrounding medium, such as that elicited by TNFoc, 
may arise through an alteration in the proportion of IGFBPs attached to the cell membrane 
or located in the extracellular matrix for example. 1251_IGF-I cell-binding studies were 
undertaken therefore to address this point. 
Figure 5. viii. shows the effect of a 24 hour incubation with I pgll TNF(x on the number 
and affinity of IGF-I binding sites in Hs68 fibroblasts. Specific total binding of the 1251_ 
IGF-I tracer, that is its binding to membrane receptors and cell-associated IGFBPs in 
absence of additional non-radiolabelled IGF-I peptide, was reduced from 7000 cpm to 
5370 cpm, a decrease of some 30%. Competitive binding with non-radiolabelled IGF-I 
revealed this effect to be due to a decrease in IGF binding site number, and not due to 
alterations in their affinity. 
To ascertain whether this effect of TNF(x was due to modulation of membrane IGF 
receptors or cell-associated IGFBPs the 125 I-IGF-I binding assay was then performed in 
the presence of 10 Mols1I human insulin, effectively acting to block both its own 
receptors and the type I IGF receptors (Clemmons et al, 1986). Moreover, in view of the 
minimal affinity that recombinant IGF-I has for the type Id IGF membrane receptor 
(Rosenfeld et al, 1987. ) it follows that the remaining available 1251_IGF binding sites must 
be the cell-associated IGFBPs. As described in figure 5. ix., 24 hour TNF(x treatment once 
again resulted in the reduction in 1251_IGF-I binding under the conditions just described. 
Specific binding of the tracer to IGFBPs was decreased some 30%, from the control 5260 
cpm to 4350 cpm. Non-radiolabelled IGF-I displacement curves in both TNF(x treated and 
untreated cultures were once again similar, suggesting a reduction in cell-associated 
IGFBP number, rather than affinity. 
5.3. CONCLUSIONS 
From the data described above it would seem that the inflammatory cytokine TNF(x is 
capable of modulating IGFBP production by the Hs68 human skin fibroblast in vitro. 
Treatment with TNF(x for 24 hours in serum-free conditions caused the apparent reduction 
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Figure 5. viii. 
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The effect of TNF(x on radiolabelled IGF-l binding 
to Hs68 fibroblast monolayers. Cells were incubated 
for 24 hours in the absence (E) or presence ([ý]) of 
TNF(x (Igg/1) and then IGF-I binding assessed as 
described in Methods. 
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Figure 5. ix. 
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The effect of TNF(x on radiolabelled IGF-I binding to 
Hs68 cell associated IGFBPs. Cells were incubated at 
37 'C for 24 hours in the absence (9) or presence (0) 
of TNFcc (lgg/1) before binding of IGF-I was assessed 
with type-1 IGF and insulin receptors blocked with the 
addition of 10 gmols/I insulin. 
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of all IGFBPs secreted by these cells, IGFBP-3, IGFBP-4 and IGFBP-5, as determined 
by WLB. Confirmation that at least one of these alterations in IGFBP abundance involved 
changes in molar quantities of the peptide was provided by analysis of IGFBP-3 in 
conditioned media by specific radioimmunoassay (RIA) unaffected by proteolytic activity. 
In a similar fashion to the WLB data, IGFBP-3 was seen in the RIA to be typically 
reduced by approximately 35% following TNF(x treatment. 
This effect may not however be a direct one as TNF(x can stimulate the synthesis of 
prostaglandins from a number of cultured cells, including adipocytes (Hardarddottir et al, 
1992) and fibroblasts (Hori et al, 199 1). Exogenous PGE2 in our Hs68 fibroblasts was 
seen to inhibit IGFBP-3 secretion, suggesting therefore that the TNF(x effect may indeed 
act via this pathway. However, addition of the cyclo-oxygenase inhibitor indomethacin, 
at doses at and above those found effective in blocking prostaglandin synthesis by others 
(Goss et al, 1993), was without effect on either basal or TNF(x inhibited IGFBP-3 
secretion, suggesting this not to be the case. It may be that either TNRX did not affect 
prostaglandin synthesis in Hs68 fibroblasts (data unavailable) or that after 24 hours in the 
presence of the cytokine insufficient PGE has been secreted to match the high doses of 
prostaglandin E2 (>I mg/1) found effective at inhibiting IGFBP-3 when added 
exogenously. Data supporting the latter explanation has been reported for TNF(x mediation 
of lipolysis in cultured 3T3-F442A fat cells (Hardardottir et al, 1992). The importance of 
TNF(x-stimulated PGE2 synthesis in contributing to the inhibitory effect on IGFBP-3 may 
increase over longer time periods than we have examined however. 
Interferons have a number of physiological functions, in addition to their inhibitory action 
on virus replication, and these often involve the alteration in cellular growth. Interferon- 
gamma (IFN-g) has the capacity to modulate the activity of TNF(x, enhancing its 
cytotoxicity in HeLa carcinoma cells (Stone-Wolff et A 1984) and conversely inhibiting 
its mitogenic action in FS-4 normal foreskin fibroblasts (Vilcek et al, 1986). Taken 
together with the observation that IFN-g could completely block the TNF(x-mediated 
reduction in IGFBP-3 secretion from Hs68 cells an attractive hypothesis would be that 
IFN-g acts as a negative growth signal. However, this is based on the assumption that 
IGFBP-3 is inhibitory to the mitogenic effects of IGF and also fails to account for the 
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inhibition of IGFBP-3 elicited by EFN-9 when incubated alone. 
Analysis of IGFBP-3 and IGFBP-4 gene expression in these cells following incubation 
with TNF(x demonstrated that this effect was more complex than straightforward alteration 
in transcription of the respective mRNAs. Both the single transcripts for IGFBP-3 (2.4 kb) 
and IGFBP-4 (2.2 kb) were increased at the end of the 24 hour TNFOC treatment, and no 
consistent down regulation of mRNAs was seen at earlier time-points in the incubation 
period. This apparent novel regulation of the IGFBPs therefore lead us to examine 
possible TNF(x regulation Of POst-transcriptional mechanisms. 
Data from others has shown that cultured fibroblast monolayers secrete one or more 
binding proteins that alter the cellular binding of IGF-l (Clemmons et al, 1986) and Jones 
et al (1993) has revealed that certain IGFBPs, including IGFBP-5 and IGFBP-3, can be 
found closely located with the fibroblast cell membrane or in the extraceflular matrix. As 
described in the previous chapter, regulation of this immobilised store of IGFBPs has now 
been given as a mechanism to explain the increase in IGFBP-3 in fibroblast conditioned 
medium following IGF-I treatment (Martin and Baxter, 1992). One possible mechanism 
employed by TNF(x may be via changes in the compartmentalisation of the IGFBPs 
therefore, that is the alteration in the proportion of cell-associated IGFBPs in comparison 
with that found in the conditioned medium. Rather than TNF(x increasing the amount of 
cell-bound IGFBPs however, which would have perhaps explained our WLB and RIA 
data, a decrease was observed suggesting once again therefore reduced IGFBP secretion. 
An increase in IGFBP clearance by the fibroblasts is a possible alternative explanation but 
at this moment in time is purely speculative. 
Even though the IGFBP-3 RIA used in these experiments was unaffected by the presence 
of IGFBP proteolytic activity produced by untreated Hs68 cells (see Methods section) the 
possibilty existed that TNFoc was stimulating separate distinct enzymic activity that 
affected our interpretation of the RIA data. Evidence that this cytokine can indeed 
upregulate a number of metalloproteinases, as outlined in the Introduction, gave a certain 
degree of support to this hypothesis. Analysis was therefore made of such proteolytic 
activity in Hs68 conditioned media following TNF(x treatment using 
1251_IGFBP-3 as 
substrate. Despite time-courses and various assay incubation periods no alteration 
in 
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IGFBP-3 degradation was observed however, suggesting that TNFOc regulation of IGFBP-3 
was not through mediation of a protease or associated inhibitor. In view of the well 
established role that TNF(x has in mediating metalloproteinase activity, particularly in 
fibroblasts, such data was disappointing as regards ascribing a physiological role for the 
IGFBP-3 protease produced by our cells. 
In conclusion, it would seem from the above data that perhaps the most likely mechanism 
to explain the apparent post-transcriptional regulation of IGFBP-3, and possibly IGFBP-4 
by TNFoc involves an effect upon the translation of the IGFBPs mRNA transcripts. 
Although not studied in the course of this thesis it follows that a decrease or inhibited rate 
of translation could result in a corresponding reduced rate of peptide secretion as we have 
observed. Moreover, it may also help explain the increases in IGFBP mRNA abundance 
seen following exposure to the cytokine, as this mechanism would perhaps cause an 
accumulation of untranslated mRNAs. Further studies will be necessary to address such 
a hypothesis and establish the precise mechanism of TNF(x mediated down-regulation of 
fibroblast IGFBP secretion. 
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CHAPTER 6. REGULATION OF FIBROBLAST IGFBPs 
BY INTERLEUKIN I AND 6. 
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OVERVIEW 
Although both interleukin loc (IL-10c) and IB (IL-IB) are biochemically and 
immunologically distinct from TNF(x, and bind to different cell surface receptors, there 
is striking similarity in their biological activities, many of which are important in the 
acute inflammatory response. In fibroblasts, the cell type under investigation in this study, 
these shared actions include the stimulation of mitogenesis, and synthesis of procollagen, 
collagenase and tissue inhibitor of metalloproteinases (TIMP). As well as sharing many 
functions in cellular immune responses, both IL-1 and TNF-CC can also induce the 
production of each other in certain other cell types, whilst the cellular signal transduction 
by these cytokines is also closely related, often involving certain novel serine/threonine 
protein kinases and cAMP, or via intermediaries such as prostaglandin E2. 
Some studies have also described an interaction between IL-I and the lGFs; such as 
Linkhart and MacCharles (1992) who found increased IGF-l mRNA synthesis in mouse 
bone calvaria in response to both IL- I (x and IL- I B. However, such action by IL- 1 appears 
to be cell type specific, as Lin et al (1992) found the opposite effect on IGF-l mRNA in 
Leydig cells. The effect of these cytokines on the IGFBPs has not been investigated. In 
view of the functional similarities of IL-I with TNF(x, and the apparent modulatory role 
of TNF(x in regulating fibroblast IGFBP secretion described in the previous chapter, we 
have investigated the effects of IL-l(x and IL-lB in this model system. Experiments were 
also undertaken to establish the effects of interleukin 6, a cytokine with rather more 
independent function. 
6.1. METHODS 
6.11 Cell culture 
The normal human neonatal skin fibroblast cell line, Hs68, was used for these experiments 
and was routinely cultured as previously described. 
6.1. ii. Conditioned medium 
Collection of conditioned medium from Hs68 fibroblasts followed the protocol as 
described in the previous chapter. For these experiments cells were seeded into 24-well 
tissue culture plates in complete growth medium at a density of 
1x 10' / ml, or 2.5 x 10' 
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/ CM2 
, and incubated at 37'C for 96h. Following a further 24h in SFM, the cells were 
washed and the interleukin samples added for 24h. 
6.1. iii. Western ligand blotting (WLB) 
IGFBPs in the above CM were analysed by WLB, as described in the Methods section. 
For these experiments, pooled CM from triplicate wells was lyophyhsed under vacuum 
and concentrated five-fold before being loaded onto the gel. 
6.1. iv. 1GFBP-3 radioimmunoassay 
IGFBP-3 in the conditioned medium was quantified by specific RIA, as described 
previously, using the rabbit polyclonal antiserum designated SCH 2/5 raised against the 
recombinant glycosylated IGFBP-3 peptide supplied by Celtrix Inc., Santa Clara, USA. 
A 50 pl volume of CM was assayed directly. 
6.1. v. Analysis of IGFBP gene expression by Northern blotting 
Hs68 fibroblast IGFBP-3 and IGFBP-4 gene expression in response to 24 hour incubations 
with I [tg/I IL- 1B or IL-6 was analysed by Northern blotting. Cells were plated into 9.5cm 
diameter culture dishes in a volume of 10ml and at a density of 1x 10'/ml, or 1.3 x 
104/CM2 
. 
Following 96 hours in complete medium the cells, now approximately 80% 
confluent, were incubated with serum-free medium for 24 hours, washed, and 
finally 
incubated with IL-16 or IL-6. RNA isolation and Northern blotting was performed as 
described in the Methods section. 
6.2. RESULTS - Interleukin 1 
6.2. i. Western ligand blotting 
The effects of interleukin 16 on the appearance of IGFBPs 
in Hs68 fibroblast conditioned 
medium is shown in r1gure 61 At a dose of 
I Vg1l IIL-lB, changes to IGFBP-3 were 
observed, with a reduction in its band intensity 
(lane 2) compared to that of the control 
(lane 1). Scanning densitometric analysis of the blot revealed the IGFBP-3 
level to be 
some 29.2% lower than control. 
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Figure 6A. 
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The effect of IL-1p (Igg/1) and IL-6 (Igg/1) on IGFBP 
abundance in 24 hour serum-free conditioned medium 
taken from Hs68 fibroblasts, as assessed by Western 
ligand blotting. Lane I shows control, Lane 2 shows 
IL-1 P, Lane 3 shows control and Lane 4 shows IL-6 
treatment. Molecular weight standards are indicated. 
-. 
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6.2. ii. IGFBP-3 immunoreactivity 
IGFBP-3 radioirnmunoassay analysis of Hs68 cell conditioned medium following IL-IB 
treatment, as shown in figure CH., demonstated that the cytokine inhibited the secretion 
of the binding protein in a dose-dependent manner. The effective doses and degree of 
IGFBP-3 response to IIL-113 were similar to TNFoc, with significant inhibition at levels of 
IL-16 of 0.1 [tg/I and 1 Vg/l causing a 31.8% reduction in IGFBP-3 compared with 27.6% 
for the same dose of TNFoc in this set of experiments. 
Due to the close functional association of IL-113 and TNFoc in many other systems, 
coincubation experiments were also performed. As can be seen in figure 6. M., the 
addition of I [tg/l IIL-16 to the effective dose-range of TNF(x (0.1 - 10 Vg1l) resulted in 
slight enhancement of IGFBP-3 inhibition. Significant alteration in the level of IGFBP-3 
from that seen in response to IL-lB alone was observed in the presence of 10 gg/l TNF(X 
only, the highest dose tested, but was less than additive. This may suggest perhaps that 
a common exhaustable pathway was being utilised by the two cytokines, although as we 
have also seen the effect of TNF(x to plateau between I and 10 gg/I we cannot discount 
that IOL-lB may be in part operating via an alternative mechanism. Unfortunately, 
constraints of available recombinant TNFoc made further experiments with higher TNF(x 
doses impossible. 
The effects of IIL-1(x on IGFBP-3 secretion were also assessed by radioimmunoassay. As 
shown in figure 6. iv., this cytokine was equally effective at inhibiting Hs68 cell IGFBP-3 
secretion as the functionally identical IL-IB, with similar effective doses and degree of 
response. 
6.2. iii. IGFBP gene expression 
IGFBP-3 
Despite the close similarity in IGFBP-3 peptide secretion 
following treatment with IIL-IB 
or TNFoc, differences were observed in their effect upon 
IGFBP-3 gene expression. Unlike 
TNF(x, which had no inhibitory effect on IGFBP-3 mRNA abundance after 
24 hours of 
treatment, I [tg/l IIL-16 caused a reduction in the single 
2.4 kb transcript, as shown in 
figure 6. v. Scanning densitometry showed the 
decrease to be a 30% reduction from the 
unstimulated control. These data suggest therefore 
that IL-16 mediated inhibition of 
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Dose-dependent inhibition of immunoreactive IGFBP-3 
secretion from Hs68 fibroblasts by interleukin-1p. 
Results are expressed as the percentage IGFBP-3 in 
24 hour conditioned medium compared to the basal 
serum-free control ± S. D. 
* P<0.05 compared to control. 
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Figure 6. iii. 
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The eff ect of IL- IP(I gg/1) on the inhibition by 
TNFa of immunoreactive IGFBP-3 in 24 hour serum- 
free conditioned medium from Hs68 fibroblasts. 
Results from triplicate cultures are expressed as the 
percentage IGFBP-3 compared to the untreated control 
value ± S. D. 
*- P<0.05 compared to IL-1P alone. 
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Figure 6. iv. 
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Dose-dependent inhibition of immunoreactive IGFBP-3 
secretion from Hs68 fibroblasts by interleukin-l(x. Results 
are expressed as the percentage IGFBP-3 in 24 hour 
conditioned medium compared to the basal serum-free 
control ± S. D. 
* P<0.05 compared to control. 
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Figure 6. v. 
A. Northern blot 
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Regulation of IGFBP-3 and IGFBP-4 gene expression 
in Hs68 fibroblasts by Igg/l IL-lp and Igg/l IL-6. 
Shown in panel A are IGFBP-3 and -4 mRNA levels 
following 24 hours of treatment. In panel B ethidium 
bromide staining of the gel is shown to confirm that 
similar amounts of total RNA were loaded into each 
lane. 
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IGFBP-3 peptide may occur via down-regulated gene expression. 
IGFBP-4 
The effect of IL-lB (1 ýig/l) upon Hs68 cell IGFBP-4 gene expression at the end of the 
24 hour treatment period was however, similar to that shown by TNFCC. Despite a 
reduction in in IGFBP-4 peptide in response to IL-lB by Western ligand blotting, levels 
of its 2.2 kb transcript were increased some 4.4 fold above the unstimulated control, as 
seen in figure 6. v. 
6.3. RESULTS - Interleukin 6 
6.31 Western figand blotting 
Twenty four hour treatment of Hs68 fibroblasts with I gg/I EL-6 resulted in minimal 
changes in IGFBP secretion from these cells, as shown in the WLB in figure 6. i. In 
contrast to both TNF(x and IL-16, levels of IGFBP-3 were not inhibited by IL-6, being 
135% of the control value when assessed by scanning densitometry. The IGFBP-5 band 
also showed similar differential regulation by IL-6 with its band 204.4% of control, rather 
than being inhibited. However, the IGFBP-4 band was decreased, as it was in response 
to TNF(x and IIL-16, some 37.6% lower than the unstimulated control. 
6.3. H. IGFBP-3 immunoreactivity 
Analysis of the effect of IIL-6 on IGFBP-3 secretion by radioimmunoassay failed to show 
any significant effect of the cytokine on this binding protein over a similar dose-range as 
IL-16; figure 6M. 
3.3. vi. IGFBP gene expression 
IGFBP-3 
As shown in figure 6. v., a dose of 1 Vg1l IL-6 had minimal effect upon IGFBP-3 mRNA 
abundance at the end of the 24 hour treatment period. 
IGFBP-4 
In a similar manner to both TNFoc and 11L- 16, EL-6 (I [tg/1) lead to a small increase in the 
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abundance of the 2.2 kb IGFBP-4 mRNA transcript after 24 hours of treatment. Scanning 
densitometry of the autoradiograph shown in figure 6. v. gave this increase as 152% above 
the control value. 
6.4. CONCLUSIONS 
A high degree of functional similarity between TNF(x and IL- I has been described in a 
number of biological systems, and it would appear from our data that this relationship also 
extends to their effects upon IGFBP secretion in vitro. The inhibitory nature seen by WLB 
analyses of IL- 113 on IGFBP-3, IGFBP-4 and IGFBP-5 levels in 24 hour conditioned 
media from Hs68 fibroblasts parallels that seen in response to TNF(X. Further investigation 
of IGFBP-3 secretion from these cells by RIA demonstrated that the two cytokines were 
active over the same concentration range and inhibited the binding protein to a similar 
degree. The functionally identical, but structurally distinct IL-I species, IL-W, also 
similarly inhibited immunoreactive IGFBP-3 levels. 
Although TNF(x and IL- I share many biological properties, the precise mechanisms 
involved in this relationship are unclear. The activation of common signal transduction 
pathways, possibly involving novel protein kinases (Guy et al, 1991), in both of the 
respective receptors may provide some explanation, although there are other studies that 
suggest some of the precise molecular actions of IIL- I and TNF(x may in fact be different. 
Evidence for such differential mechanisms of action has been given as the often observed 
synergistic relationship between the two cytokines (Ruggiero and Baglioni, 1987), and 
from IL-1 antagonism of TNF(x cytotoxicity seen in some cells (Holtman and Wallach, 
1987). Co-incubation of IOL- 16 with TNF(x in our model produced no synergistic effect and 
was not antagonistic, perhaps suggesting the use of a common mechanism in their 
regulation of IGFBP-3- 
Unlike TNF(x however, the abundance of IGFBP-3 mRNA in Hs68 fibroblasts was 
reduced at the end of the 24 hour treatment period with IL-IB, suggesting that altered 
gene expression may be at least partly involved in mediating the inhibition of IGFBP-3 
peptide. The similar discordant IGFBP-4 mRNA response to both IL- 16 and TNFoc, where 
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the reduction in IGFBP-4 peptide was accompanied by increased gene expression at the 
end of the incubation period, may indicate a common mechanism of action between the 
cytokines in modulating this particular IGFBP species. 
In contrast to the effects of the two closely related cytokines IL-1 and TNF(x, we found 
no evidence that IL-6 had any impact on IGFBP secretion from Hs68 fibroblasts. The lack 
of an effect of IL-6 on IGFBP production suggests cytokine specificity in the IGFBP 
response, with alteration in IGFBPs only occuring during inflammatory episodes involving 
IL-1 and TNF(x. 
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CHAPTER 7. REGULATION OF FIBROBLAST IGFBPs 
BY TRANSFORMING GROWTH FACTOR 13, 
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OVERVIEW 
The IGFs have been widely recognised as having a major role in the processes of wound 
tissue repair. At sites of injury platelets rapidly congregate, adhere to exposed collagen 
and release their secretory alpha-granules, containing numerous growth factors, such as 
the IGFs. Other IGFs from plasma and those secreted from invading macrophages are 
also present, resulting in typical wound site levels reaching approximately two thirds of 
that found in serum. The physiological importance of these high IGF levels has been 
demonstrated experimentally (Sommer et al, 1991) with their inhibition resulting in a 40% 
reduction in wound collagen production. 
Another cytokine or growth factor to be implicitly involved in the repair of wound tissue 
is transforming growth factor 6 (TGFB). Many of its recognised functions seem 
particularly directed towards the wound response, such as its regulation of mitogenesis, 
the stimulation of extracellular matrix (both directly and by inhibiting destructive 
metalloproteinases) and induction of chemotactic migration. A recent study by Baxter et 
al (1991) has also shown this cytokine to be capable of enhancing IGFBP-3 secretion by 
human skin fibroblasts, and therefore may have the potential to mediate IGF bioactivity. 
In view of the data presented in the previous chapters concerning the apparent down- 
regulation of Hs68 cell IGFBPs, including IGFBP-3, by TNF(X and certain of the 
interleukins, we have further investigated TGFf3 in our model. By comparing and 
contrasting the effects and mechanisms of TGFf3 with the inflammatory cytokines we 
hoped some insight into their respective functions as mediators of cellular growth would 
be gained. 
7.1. METHODS 
7.1. i. Cell culture 
The normal human neonatal skin fibroblast cell line, Hs68, was routinely cultured as 
previously described. 
MAL Conditioned medium 
Cells were seeded into 24-well tissue culture plates in complete growth medium (10% 
foetal calf serum) in a volume of 0.5 ml / well, and at densities of 0.5,1,2.5 and 10 x 
170 
IW / ml or 0.125,0.250,0.625 and 2.5 x 104 / CM2 , respectively. This range of densities 
allowed analysis of the effects of TGF9I on fibroblast cultures from sparse to confluent 
populations. 
Following the culture protocol described in the previous chapter, conditioned medium 
(CM) from these cells was collected after 24 hour incubations with human recombinant 
TGFBj over a dose range of 0.01 to 10 Vg1l. 
7.1. iii. Western ligand blotting (WLB) 
IGFBPs in the above CM were analysed by WLB, based upon that of Hossenlopp et al 
(1986) and as described in the Methods chapter. Specifically for these set of experiments, 
pooled CM from triplicate wells was dried under vacuum and concentrated five-fold 
before being loaded onto the gel. 
7.1. iv. IGFBP-3 radioimmunoassay 
IGFBP-3 in the CM was quantified by specific RIA, as described previously, using the 
rabbit polyclonal antiserurn designated 1287-2-14 from Celtrix Inc., Santa Clara, USA. 
Due to the sensitivity of this RIA no concentration of CM was necessary, with 50 pl 
measured directly. 
The effect of fibronectin upon the TGFf3j enhancement of IGFBP-3 was also studied by 
radioimmunoassay. Reasoning behind this was due to a study by Ignotz and Massague 
(1987) that had previously shown that the effect of TGFB on inducing anchorage- 
independent growth of fibroblasts was due to increased synthesis of this extracellular 
matrix component and could be mimicked by the addition of exogenous fibronectin. Both 
could be blocked by the addition of short synthetic peptides containing RGD (Arg-Gly- 
Asp) amino acid sequences, which inhibit binding of the fibronectin to cell membrane 
integrin receptors. 
7.1. v. Northern blotting 
Hs68 IGFBP-3 gene expression in response to 24h incubations with I [Ig/l TGFB, was 
analysed by Northern blotting. Cells were plated into 9.5cm tissue culture dishes in a 
volume of 10ml and at a density of Ix 
105/Ml, or 1.3 x 104/Cm 
2. Such an initial density 
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meant that cultures were sub-confluent (approximately 75%) after 96 hours in complete 
growth medium. They were then incubated for 24h in SFM, washed and finally incubated 
with TGFBj. RNA isolation and Northern blotting was undertaken as detailed in the 
Methods chapter. 
M. A. 1GFBP protease analysis 
In view of the well documented role that TGF6 has in modulating the activity of certain 
metalloproteinases in vitro, experiments were performed to examine its effect upon the 
recently identified IGFBP protease(s). Conditioned medium was taken from Hs68 
fibroblast cells following either serum-free treatment alone or treatment with 1 Vg1l TGFBI 
for 24 hours, and incubated with 1251_IGFBP-3 for 4 hours at 37'C. Alteration in 
proteolytic activity directed against this peptide was assessed by subsequent 
polyacrylamide gel electrophoresis as described in the Methods section. 
7.2. RESULTS 
7.2. i. Western ligand blotting 
As described in figure 71,24 hour treatment of Hs68 fibroblasts with I [tg/l TGFBI 
resulted in changes to all the IGFBPs produced by these cells when assessed by WLB. 
Scanning densitometric analysis of the autoradiograph revealed IGFBP-3 band to be 341% 
of the serum-free control, whilst IGFBP-4 and IGFBP-5 were in contrast reduced by 61% 
and 49.8%, respectively. 
7.2. H. IGFBP-3 immunoreactivity 
The stimulating effect of TGFBj upon the concentration of IGFBP-3 in the conditioned 
medium from Hs68 cells was further assessed by radioimmunoassay as described in figure 
7. H. Significant stimulation of IGFBP-3 was observed at TGFBj doses of 0.05 ýtg/l and 
above, and whilst a dose-dependent effect was generally observed a small hook effect was 
seen at the highest dose tested of 10 [tg/l. 
Further investigation of the effect highlighted its dependency upon cell density, as shown 
in figure 7. M. The degree of IGFBP-3 stimulation was greatest, 260.8 ± 22.4% of control, 
in the most sparsely plated cultures (0.5 x 1WIml) whilst in fully confluent monolayers 
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Figure 7. iii. 
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(I x 10'/ml) significant stimulation of IGFBP-3 was only observed at a TGFO, dose of I 
ýtg/l or more, achieving a modest increase of 32.6 ± 4.9% above control at 10 [tg/l. 
To establish whether enhanced IGFBP-3 secretion by TGFBI was a direct function or 
secondary to stimulation of Hs68 cell fibronectin, experiments were performed to study 
in this model the effects of exogenous recombinant bovine fibronectin and synthetic RGD 
sequences. Using doses comparable with those found effective in the Ignotz and Massague 
study, 24 hour treatment of cells with fibronectin alone (50 mg/1) or in combination with 
TGFBI (I pg/1) had no significant effects upon IGFBP-3 secretion, when assessed by RIA 
(figure 7. iv. ). In addition, the presence of the RGD sequence peptide (400 mg/1) had no 
inhibitory effect on either basal or TGFBj enhanced IGFBP-3 secretion in these cells. 
7.2. iii. IGFBP gene expression 
IGFBP-3 
Northern blotting of total RNA from Hs68 cells following 24 hour treatment with TGFBj 
(1 [tg/1) revealed that enhancement of IGFBP-3 peptide secretion was associated with 
increased IGFBP-3 gene expression, as shown in figure 7. v. Scanning densitometric 
analysis of the autoradiograph showed the single 2.4kb IGFBP-3 mRNA transcript to be 
increased 12.7 fold over the serum-free control value. Initial loading of the RNA into the 
control and TGFBj treatment lanes of the gel appeared similar under ultra violet light. 
IGFBP-4 
Following stringent washing, the nylon Northern blot membrane probed with the IGFBP-3 
cDNA was rehybridised with a cDNA for IGFBP-4. Despite TGFf3j causing a reduction 
in IGFBP-4 peptide on WLB, no significant alteration in its gene expression was seen at 
the end of the 24 hour treatment period, figure 7. v. Scanning 
densitometric analysis of 
the TGFBj treatment lane showed the single 2.2 kb transcript to be 109% of the control 
value. 
4.2. iv. IGFBP-3 protease 
The effect of TGFB, on proteolytic activity produced by Hs68 
fibroblasts and directed 
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Figure 7. v. 
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against IGFBP-3 is shown in figure 7M. Despite being a wen recognised mediator of 
fibroblast metalloproteinases, proteolytic degradation of 125I_IGFBP-3 following 4 hour 
incubations remained constant in conditioned media samples taken from cells treated for 
24 hours with TGFB, (I ýig/l) compared to those in serum-free conditions only. 
7.3. CONCLUSIONS 
The in vitro stimulating effect of TGFBI on IGFBP-3 secretion by normal neonatal human 
fibroblasts was first described by Martin and Baxter (1991). In this study they detected 
significant increases of this binding protein in conditioned media taken from cells treated 
with TGFBj for 24 hours or more, and found a maximal effect at a dose of 1 [1g1l. 
Although Camacho-Hubner and co-workers (1992) failed to observe by Western ligand 
blotting a similar stimulatory response in fetal derived fibroblasts, our results with Hs68 
neonatal fibroblasts confirm many of the observations made by Martin and Baxter. 
In our model TGFB1 was seen to enhance IGFBP-3 production over 24 hours both by 
Western ligand blotting and radioimmunoassay, reaching a maximum increase of 
approximately 2.5 fold at a dose of I pg/l. The degree and sensitivity of response were 
both negatively correlated with cell density, with little effect seen in confluent cultures 
and the stimulating effect of TGF61 appeared to be due to up-regulation of IGFBP-3 gene 
expression. Analysis of total RNA from Hs68 cells revealed major increases in the 
IGFBP-3 mRNA transcript, being some 12-fold more abundent in cultures treated for 24 
hours with I ggll TGFf31 than in control samples. Such gene regulation by TGFB1 has also 
been reported by Martin et al (1992). 
As TGFBj is widely recognised as having an inhibitory role in cellular protease synthesis, 
as detailed in the Introduction, it seemed an attractive and somewhat likely mechanism 
to help explain its enhancing effect upon IGFBP-3, in addition perhaps to the molecular 
events described above. A down-regulation of collagenase synthesis, an enzyme known 
to be affected by TGF13, (Edwards et al, 1987) and effective against IGFBP-3 (Frost V. J. 
Ph. D. thesis, 1994) could result in a greater abundance of intact IGFBP-3 on Western 
ligand blot. However, analysis of proteolytic activity affecting IGFBP-3 in TGFBj treated 
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Hs68 cell conditioned media failed to record any change compared to that taken from 
untreated controls. It appears therefore, that whilst we cannot discount a possible role for 
such a mechanism in regulating IGFBP-3 either associated with the cell surface or in more 
chronic TGFBI treatments, it does not seem to be even partly responsible for our observed 
effect in 24 hour conditioned medium. 
Another major function of TGF81, in parallel with its negative effect on proteases, is to 
enhance the synthesis of extracellular matrix components, and some functional aspects of 
TGFB1 have been ascribed to such secondary effects. The ability of TGFB1 to stimulate 
growth of normal cells in semi-solid media is accompanied by enhanced fibronectin 
secretion and can be inhibited by the addition of synthetic peptides which block 
subsequent interaction of the fibronectin with cell surface integrin receptors. The 
interesting aspect from an IGFBP standpoint is that the integrin receptor binding domains 
act through recognition of RGD (Arg-Gly-Asp) amino acid sequences, found repeatedly 
throughout the fibronectin molecule. As I have described in the Introduction, a single such 
sequence can also be found in both IGFBP- I and IGFBP-2, thus raising the exciting 
possibility, albeit somewhat remote, of IGFBP-3 being regulated by other IGFBPs. 
Unfortunately, our experimental data found that exogenous fibronectin had no effect upon 
IGFBP-3 abundance in fibroblast conditioned medium, and the response to TGFB, was not 
affected by co-incubation with the RGD sequence peptide. This would strongly suggest 
that the integrin receptor / fibronectin is not a novel pathway of IGFBP-3 regulation and 
the functional significance, if any, of the RGD sequence in IGFBP- I and -2, still remains 
to be deduced. 
In addition to its effect on IGFBP-3, TGFBj also had an effect upon the appearance of 
IGFBP-4 and IGFBP-5 in Hs68 conditioned medium. By Western ligand blotting both of 
these binding proteins were reduced some 50 - 60 % in response to I [IgIl TGFB,. 
However, analysis of IGFBP-4 mRNA abundance suggested that the TGFBj induced 
change in this IGFBP was not due to altered gene expression in contrast to the apparent 
mechanism involved in IGFBP-3 mediation. A similar post-transcriptional pattern of 
IGFBP-4 regulation has been observed in fetal skin fibroblasts following treatment with 
IGF-I (Camacho-Hubner et al, 1992) apparently involving the enhancement of a specific 
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protease. Although we cannot dismiss the possibility that TGFBj may act in a similar 
manner this may seem somewhat unlikely given the generally negative effect of TGFBI 
on proteolytic enzymes. 
Alternatively, a reduction in IGFBP-4 levels in conditioned media may theoretically result 
from an increase in the proportion of cell-associated IGFBP-4. Although the latter would 
seem an attractive hypothesis in view of the stimulating effect of TGFB, on extracellular 
matrix production, a recent study by Jones et al (1993) failed to detect any IGFBP-4 in 
the matrix from fetal fibroblasts. Other possible mechanisms to explain the negative effect 
of TGFf3j on IGFBP-4 peptide include altered mRNA translation or peptide secretion, 
although we have no data on these. 
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CHAPTER 8. THE EFFECT OF ENDOGENOUS IGFBP 
REGULATION UPON IGF-I BIOACTIVITY 
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OVERVIEW 
As we have seen in the previous chapters a number of growth factors and cytokines have 
the ability to regulate IGFBPs in vitro, via a number of mechanisms. Moreover, these 
effects can be elicited at peptide levels consistent with their physiological concentrations, 
suggesting they may have important consequences in controlling IGF bioactivity in vivo. 
The precise functions of the IGFBPs have not been defined however, although various 
effects of exogenously added IGFBPs have been reported in a number of in vitro IGF 
bioassays. Several forms of IGFBPs have been shown to have IGF binding affinity 
constants greater than those of the IGF receptors, resulting in the inhibition in vitro of IGF 
mitogenesis and metabolic processes such as glucose and amino acid transport. 
Conversely, enhancement of IGF actions by IGFBP- 1 and IGFBP-3 has also been 
observed. Even though such opposing effects are often dependent upon the specific 
incubation conditions of the bioassay, they may reflect problems in reproducing the effects 
of endogenously secreted IGFBPs with purified or recombinant peptides. 
The aim of this chapter was therefore to examine the consequences on IGF-l bioactivity 
of altered endogenous IGFBP secretion, induced in our Hs68 fibroblast cells by TNF(X and 
TGFBj. This was undertaken by the development of a precise cytochemical bioassay, 
measuring IGF-I mitogenesis in these cells. To delineate the effects of the IGFBPs we 
compared native IGF-I with the IGF-I analogue with minimal IGFBP affinity, LongR3- 
IGF-I. 
8.1. METHODS 
8.11 Cell culture 
Hs68 fibroblasts were plated into 96-well microtitre tissue culture plates at a density of 
3.75 x 103 / well (2.5 x 10' / ml) in a volume of 150 [d DMEM + 10% fetal calf serum. 
After 96 hours at 37T and 5%CO2, the spent medium was aspirated and replaced with 
DMEM + 0.1 % BSA and incubated for a further 24 hours. Following aspiration of this 
medium, samples were added for 48 hours before measurement of cell number with the 
MTT assay, as described in Materials and Methods. 
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8.2. RESULTS 
8.2. i. Effects of IGF-I 
Addition of IGF-I to Hs68 human fibroblasts resulted in a demonstrable increase in 
cellular MTT reduction after 48 hour incubations. No effect was seen after 24 hours. 
Corresponding haemocytometer analysis of similarly treated fibroblasts grown in larger 
6-well culture plates showed good correlation of cell number with the MTT response 
(rigure 81), although the latter bioassay was considerably more precise. Sensitivity of the 
cells to IGF-I was relatively low, with activity observed at doses above 10 Pg1l and an 
effective range from 25 to 100 pg/I (3.3 - 13 nmoVI) (Figure 8. ii. ). Maximal responses 
to IGF-I were typically observed in a number of similar experiments at between 30 - 40% 
above serum-free controls. 
LongR3-IGF-I is an IGF-I analogue that consists of the complete human IGF-I sequence 
with a substitution of Arg for Glu at position 3, and a 13 amino acid extension at the N- 
terminus (Ballard et al, 1986). These structural alterations result in greatly reduced 
binding affinities for all IGFBPs, whilst minimally affecting its type I IGF receptor 
affinity. Consequently its ability to stimulate Hs68 fibroblast proliferation was 
considerably greater than that of the native peptide (fligure 8A. ). Significant activity was 
observed at LongR3-IGF-I doses above 0.1 Vg1l (0.013 nmol/1), some 20 - 25 fold lower 
than IGF-I. In a number of experiments its effective dose range was between 0.25 and 10 
ýtg/l (0.033 - 1.3 nmol/1). 
8.2. ii. Exogenous IGFBP-3 
The effects of human recombinant IGFBP-3 (non-glycosylated) on the mitogenic activities 
of the two IGF-I peptides was investigated using the MTT assay. 
Co-incubation 
The inclusion of large doses of IGFBP-3 (5 mg/1) during the 48 hour cell incubation with 
IGF-I resulted in the complete inhibition of its mitogenic response up to doses of 50 ýIg/l 
(figure. &Hi. a. ). Lower levels of IGFBP-3 were not as effective, indicating a non- 
equimolar relationship in this response. 
The co-incubation of this high IGFBP-3 concentration with the IGF-I analogue, LongR3- 
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Figure 8. ii. 
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Figure 8. iii. 
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IGF-I, was without effect on its mitogenic activity (fligureAni. b. ) thus demonstrating its 
nominal affinity for the IGFBPs. 
Pre-incubation 
The confusion that exists at present concerning the functional role of IGFBP-3 has largely 
arisen from a number of studies describing the ability of exogenous IGFBP-3 to enhance 
IGF activity in vitro. Both enhancement and inhibition of IGF-I can occur within the same 
cell line and appears to depend upon the prior incubation of IGFBP-3 with the cells before 
the addition of IGF-I. To clarify the function of IGFBPs by examining the effects of 
endogenous rather than exogenous IGFBP-3 it was therefore important that our particular 
cell line had the capacity to exibit both these effects. 
The effect of a 48 hour pre-incubation of exogenous IGFBP-3 on the mitogenic activity 
of 50 pg/1 IGF-I in Hs68 fibroblasts is shown in figure 8. iv. Enhancement of IGF-I 
activity was observed and was dose-dependent with a maximal increase of 25.3 %±5.4 
at 100 [tg/1 IGFBP-3, largely in agreement with Baxter et al (1988). No further effects 
were seen at higher doses of IGFBP-3. 
Interestingly, IGFBP-3 pre-incubation also enhanced the mitogenic action of LongR3-IGF- 
I in Hs68 fibroblasts. Maximal increases of 18.6 %±1.5 (figure 8. iv. ) were again evident 
at 100 Vg11 IGFBP-3 with reduced values at higher doses thereafter. 
8.2. iii. Endogenous IGFBP regulation 
Satisfied that exogenous IGFBP-3 could both inhibit and enhance IGF-I in our Hs68 
fibroblast cell line, we then investigated the effects on IGF-l mitogenesis of endogenous 
IGFBP-3 regulation by TNF(x and TGFf3j- 
TNF(x 
As described in Chapter 5 of this thesis the inflammatory cytokine TNF(x inhibits the 
presence of Hs68 fibroblast IGFBPs in serum-free conditioned medium. 
However as this 
factor can be cytotoxic in a number of cell types it was important that 
its direct growth 
regulatory effects were investigated. When assessed using the 
MTT cytochemical assay, 
TNF(x caused a dose-dependent increase in cell proliferation after 
48 hour incubations, 
with maximum increases of between 50 - 60% above the control 
(figure 8. v. ). No effect 
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Figure 8. iv. 
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The effect of pre-incubating a dose-range of exogenous 
IGFBP-3 on the mitogenic activity of native IGF-I and 
LongR3-IGF-I in Hs68 cells. IGFBP-3 was incubated 
with the cells for 48 hours, aspirated and replaced for 
a further 48 hours with either serum-free media (+), 
50 gg/I native IGF-I (0) or 5 gg/l LongR3-IGF-I (L]). 
Cell number was then assessed by the MTT assay. Results 
are means of triplicate wells ± S. D. expressed as the 
percentage MTT of the serum-free controls. 
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Figure 8. v. 
160 
150 
0 
140 
4--4 
0130 
120 
110 
100 
90 
0 0.01 0.1 0.5 1 2.5 10 
TNFa or TGFP 1 (gg/1) 
Dose-dependent stimulation of Hs68 cell proliferation 
by tumour necrosis factor (x (TNF(x) and transforming 
growth factor P1 (TGFP 1), assessed by the MTT assay. 
Cells were cultured in serum-free conditions for 48 
hours with either TNFec (+) or TGFP 1 (0) before the 
addition of MTT as described in the Methods. Results 
are means ± S. D. of triplicate wells expressed as the 
percentage optical density of serum-free controls. 
191 
was observed after 24 hours. Its effective range was between 0.01 - 10 Vg1l (0.6 - 600 
pmol/1), some one hundred-fold less than the native IGF-I. This would strongly suggest 
therefore that the apparent reduction in IGFBP secretion over 24 hours by TNF(x was not 
due to cytotoxicity. 
The TNF(x dose (I [tg/1) seen to maximally decrease IGFBP-3 secretion was susequently 
co-incubated with a dose range of IGF-I and cell proliferation assessed by the MTT 
bioassay. As seen in figure 8M., fibroblast sensitivity to IGF-I was increased 
approximately five-fold, with responses above that of TNF(X alone observed at IGF-I 
concentrations of 10 [tg/l. Interestingly however, the response to the highest IGF-I dose 
examined, 100 Vg1l, was significantly (p<0.05) reduced in the presence of TNFOC. 
Similar experiments were then performed with a range of LongR3-IGF-I concentrations 
co-incubated with 1ýtg/l TNF(x to assess the role of IGFBPs in the above response. No 
such increase in fibroblast sensitivity to the analogue by TNFcc was seen (figure 8. vii. ). 
Indeed, although sensitivity remained unaltered in the presence of TNFoc, the degree of 
response to LongR3-IGF-I was significantly reduced (p<0.05), perhaps indicating some 
form of IGF-I resistance. 
TGFBI 
As described in Chapter 7 of this thesis, TGFBI is a potent stimulator of Hs68 fibroblast 
IGFBP-3 secretion, with its effect mediated via enhanced gene expression. As such, it 
would seem to provide a good model to investigate the effects of increased endogenous 
IGFBP-3 secretion upon IGF-I bioactivity. Moreover, as the secretion of other IGFBPs 
produced by this cell line (IGFBP-4 and IGFBP-5) appeared to be reduced in response to 
this factor, in a similar manner to TNF(x, it could be argued that any divergence in the 
effect of the two peptides on IGF activity is likely to be due to IGFBP-3. 
TGFBj, in the absence of serum, was found to cause a dose-dependent increase in MTT 
response over a 48 hour incubation period (figure 8. v. ). In a similar fashion to the 
response observed to TNF(x, no effect was seen after 24 hours, the incubation period used 
for analysis of IGFBP modulation. Typically, maximal responses reached 50 - 60% above 
control values, and its effective concentration ranged from 0.05 - 10 [tg/I (2 - 400 pmoVI). 
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Figure 8. vi. 
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The effect on Hs68 cell proliferation of co-incubating 
native IGF-l with tumour necrosis factor oc (TNFec). 
Cells were incubated with a dose-range of IGF-I in the 
presence or absence of 1gg/l TNF(x for 48 hours before 
the addition of MTT, as descibed in the Methods. The 
results are expressed as the percentage optical density 
of either serum-free controls for IGF-I alone (0), or of 
TNF(x for IGF-l + TNF(x (0). Each point is the mean of 
triplicate wells ± S. D. 
P<0.05 compared with control; 
P<0.05 compared with the same dose of IGF-l in the 
absence of TNF(x. 
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Figure 8. vii. 
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The effect on Hs68 cell proliferation of co-incubating 
LongR3-IGF-I with tumour necrosis factor oc (TNF(x). 
Cells were incubated with a dose-range of LongR3-IGF-I 
in the presence or absence of 1gg/l TNF(x for 48 hours 
before the addition of MTT, as descibed in the Methods. 
Results are expressed as the percentage optical density 
of serum-free controls for LongR3-IGF-I alone ([: ]), or 
of TNFcc for LongR3-IGF-I + TNFcc (0). Each point is 
the mean of triplicate wells ± S. D. 
P<0.05 compared with control; 
P<0.05 compared with the same dose of LongR3-IGF-I 
in the presence of TNF(X. 
194 
A single dose of TGFBI (I [tg/1), seen to maximally stimulate IGFBP-3 secretion in Hs68 
fibroblasts was then co-incubated with the effective dose range of IGF-I. Assessment of 
mitogenic activity over 48 hours was again made using the MTI` assay. As can be seen 
in figure 8. viii., IGF-I bioactivity above that of 1 Vg1l TGFBI alone was inhibited, with 
a significant response (P<0.05) observed only at the highest IGF-I dose tested, 100 ggll. 
This represented an apparent four-fold loss in sensitivity to the IGF peptide, and suggested 
that the increase in endogenous IGFBP-3 in response to TGFBI was inhibitory. 
To confirm the involvement of the IGFBPs in this effect similar experiments were 
conducted, but with the replacement of the native IGF-I with a dose-range of the LongR3- 
IGF-I analogue. Due to the negligible affinity for the IGFBPs, those effects on IGF-I 
bioactivity mediated through the IGFBPs by TGFf3, should be absent. Indeed, co- 
incubation of TGFB, (1 [tg/1) with LongR3-IGF-I was seen to be without consequence on 
the mitogenic activity the IGF-I analogue (figure 8. ix. ) with no alteration in cell 
sensitivity or absolute response. This would strongly suggest that the inhibitory effect of 
TGFB, on native IGF-I was mediated via alteration in IGFBPs. 
8.3. CONCLUSIONS 
1GF-1 activity 
This chapter has demonstrated that certain factors capable of regulating endogenous 
IGFBP secretion, at least in vitro, can elicit marked effects upon IGF-I bioactivity. The 
most frequently used bioassay to measure the mitogenic activity of the IGFs has been the 
cellular uptake and incorporation of radiolabelled [3 H]-thymidine. However, these assays 
have a number of disadvantages (see Introduction) and were not used to assess IGF 
activity in this study. Instead, we have developed a precise serum-free cytochemical 
bioassay, based upon that by Ealey et al (1988), capable of analysing numerous low 
volume samples within a single microtitre. The assay utilised the Hs68 fibroblast cell line, 
as used for the IGFBP secretion experiments, and did not require the use of isotopes or 
time-consuming extraction techniques. Briefly, the assay was able to measure cell 
proliferation, as the reduction by cellular dehydrogenase enzymes of the yellow 
tetrazolium MTT to its purple formazan was, in this particular model, a function of cell 
number. Moreover, cell counts of stimulated cells positively correlated with reduction of 
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The effect on Hs68 cell proliferation of co-incubating 
native IGF-I with transforming growth factor P, (TGFPI). 
Cells were incubated with a dose-range of IGF-I in the 
presence or absence of lttg/l TGFP, for 48 hours before 
the addition of MTT, as descibed in the Methods. The 
results are expressed as the percentage optical density 
of either serum-free controls for IGF-I alone (0), or of 
TGFP, for IGF-l + TGFPI (0). Each point is the mean of 
triplicate wells ± S. D. 
P<0.05 compared with control; 
P<0.05 compared with the same dose of IGF-I in the 
presence of TGFPI. 
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Figure 8. ix. 
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The effect on Hs68 cell proliferation of co-incubating 
LongR3-IGF-I with transforming growth factor PI(TGFPI). 
Cells were incubated with a dose-range of LongR3-IGF-I 
in the presence or absence of Igg/I TGFPi for 48 hours 
before the addition of MTT, as described in the Methods. 
Results are expressed as the percentage optical density 
of serum-free controls for LongR3-IGF-I alone (E]), or 
of TGFP, for LongR3-IGF-I + TGFP, (N). Each point is 
the mean of triplicate wells ± S. D. 
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MT17, in a similar fashion to that seen in an IGF bioassay recently published using 
BALB/c 3T3 fibroblasts (Okajima et al. 1992). 
Despite numerous data on the need for certain 'competence factors' to render cells 
sensitive to the mitogenic actions of IGF-I, there was no such requirement in our Hs68 
cells using the MTT assay. Dose-dependent IGF-I mediated increases in cell number were 
observed in serum-free medium after 48 hour incubations. This however, is not without 
precedent (Campisi and Pardee, 1984) and has been observed in exponentially growing 
cells when they have not entered into quiescence or Go of the cell cycle. Presumably, the 
24 hour serum-free pre-incubation that our cells receive before the addition of the IGF-l 
is not sufficient to take them into Go. Thus, cells in the GI resting phase of the cell cycle 
can be induced by IGF-I to progress into the S phase, resulting in increased cell number. 
Modulating effects of IGFBPs 
IGF-I sensitivity in our human Hs68 cells was relatively low, with effective doses only 
observed above 10 Vg1l, compared with 0.5 pg/l seen in the BALB/c 3T3 assay (Okajima 
et al, 1992). As these mouse cells were reported to produce little or no IGFBPs, an 
attractive hypothesis would be that the endogenous IGFBPs produced by our Hs68 cells 
were acting in an inhibitory manner. This function of the binding proteins was 
subsequently demonstrated by the activity of an IGF-I analogue with negligible affinity 
for all IGFBPs, LongR3-IGF-1, which was twenty-fold more potent in the MTT assay. 
This would appear to be in agreement with a number of previous studies using fibroblast 
cell culture models that have shown that purified and recombinant IGFBP-3, when co- 
incubated with IGF-L inhibits subsequent IGF actions (DeMellow and Baxter, 1988; 
Conover, 199 1). However, these same IGFBP-3 preparations can also enhance IGF-I when 
they are pre-incubated with the cells before the addition of the IGF, thus casting doubt 
onto its precise function. As both of these apparently opposing effects were observed in 
our fibroblast cell line, it was felt these cells represented a valid model to investigate the 
effect on IGF-I activity of alterations in endogenous IGFBP secretion, specifically by 
TNF(x and TGFBI. Delineation of those effects on IGF-I bioactivity mediated via alteration 
in JGFBP secretion was achieved by comparing native IGF-I and LongR3-IGF-1, the 
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analogue with little affinity for the IGFBPs. 
We have subsequently observed that TNF(X enhanced IGF-I bioactivity in Hs68 fibroblasts 
and that this appeared to be due to its ability to inhibit the secretion of IGFBPs produced 
by these cells. Specifically, this cytokine lead to an approximate five-fold increase in 
sensitivity to native IGF-I, a consequence presumably created by greater access of the 
IGF-I peptide to cell receptors. Confirmation of IGFBP involvement was provided by data 
showing no such increase in sensitivity to the LongR3-IGF-I analogue. The lack of a 
TNF(x-induced enhancement of 100ggll IGF-I may perhaps be explained by the IGF 
receptors being fully saturated at this maximally effective dose even in the absence of 
TNF(x, and is thus consistent with a central role for IGFBP modulation in the sensitizing 
effect. 
In addition to TNF(x affecting IGF-I bioactivity via IGFBP regulation, a more complex 
relationship appears to exist however. In the presence of TNF(X, mitogenic responses to 
LongR3-IGF-I (I - 10 ggll) and the highest dose of the native peptide (100 [tg/1) were 
reduced, perhaps indicating some form of receptor-mediated IGF-I resistance. There is 
some indirect evidence that TNF(x may induce IGF-I receptor resistance in rat muscle and 
skin (Lang et al, 1992) with hyperinsuhnaemia failing to increase glucose uptake to that 
seen in non-TNF(x infused animals. In this in vivo model, it was proposed that due to 
cross-reactivity of such high insulin levels at least some of its activity would be directed 
through the IGF-I receptors. Presumably, in our Hs68 fibroblasts TNF(x enhancement of 
low levels of native IGF-I results from increased access of IGF-I to its receptors following 
inhibition of IGFBP secretion outweighing the moderate attenuation of receptor function. 
The TGFB group of regulatory molecules are, like other cytokines and growth factors, 
multifunctional regulators of cellular activity. They can stimulate cell proliferation, growth 
and differentiation, but are also able to inhibit such processes, depending on cell type and 
incubation conditions. In contrast to the effect of TNF(x, TGFBj was seen to inhibit IGF-I 
mitogenesis through its modulation of IGFBPs. This would appear to result from an 
increase in IGFBP-3 secretion, as other IGFBPs were reduced on ligand blot in a similar 
manner to TNF(x. However, since a number of these 'minor' IGFBPs can be localized 
in 
the extracellular matrix (ECM), we could speculate that an increase in ECM in response 
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to TGFBI (Ignotz and Massague, 1986) could effectively remove them from the conditioned 
medium. This would effectively provide additional inactive binding sites for localization 
of the IGF-I peptide, thus reducing its bioactivity further. Without this data we are left to 
conclude that the contrasting actions of TNF(x and TGFB, on IGF-I bioactivity seem to 
result from their discordant effects upon endogenous IGFBP-3 secretion, the function of 
which appears to be inhibitory. 
1 
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CHAPTER 9. 
DISCUSSION 
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SECTION A. IGF-I rep-ulation of fibroblast IGFBP-3 
9.1. A function of protease modulation? 
Factors that may regulate IGF activity are varied and complex, and may include alteration 
in IGF gene expression, peptide secretion and receptor modulation. In addition, the 
existence of at least six molecularly distinct IGFBPs, often secreted in a tissue-specific 
manner, has seemingly produced a further dimension in the control of the IGF peptide. 
IGFBPs have high affinity for the IGFs and thus can both greatly stabilise the IGFs in the 
circulation and also directly affect the ability of the IGF peptide to interact with its tissue 
receptors. Consequently it is easy to imagine a concept of the IGFBPs acting as rather 
inert inhibitors of IGF bioactivity, simply buffering the growth factor as and when 
required for homeostatic control of cellular growth. Such a simplistic hypothesis has its 
drawbacks however, as it fails to explain how the IGFs are liberated to target tissues from 
either the circulating IGFBPs or from local IGFBPs at the tissues themselves. Clearly, to 
accomodate such a mechanism requires the existence of a more fluid or dynamic IGFBP 
system than that of simple IGF inhibition. 
It was Clemmons and co-workers (1983) who first suggested the possibility that proteases 
could provide an effective mechanism that may lead to transfer of the IGFs from the 
IGFBPs to tissues. They described experimentally, the ability of human serum proteases 
and heparin to disrupt the high molecular weight ternary IGF/IGFBP-3 complex, resulting 
in an increase in the free form of the growth factor, presumably due to a reduction in 
IGFBP affinity. Despite the attraction and widespread potential of enzymic control of 
IGFBP function, it was not until two papers concerning the appearance of serum IGFBPs 
in pregnancy were published seven years later that major interest was generated in the 
possibility of such a system having a physiological role. Both studies, by Hossenlopp et 
al (1990) and Giudice (1990) described the appearance of proteolytic activity in term 
pregnancy serum, which affected IGFBP-3 such that it was largely absent on ligand blots 
despite reported two-fold elevations in its immunoreactivity (Baxter and Martin,, 1986). 
The Hossenlopp study revealed that the pregnancy protease could be inhibited 
experimentally by the addition of either the divalent metal cheleter EDTA, aprotinin or 
high concentrations of phenylmethylsulfonyl-fluoride, suggesting the presence of a serine 
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type enzyme. It was these studies therefore that appeared to provide the first evidence in 
a physiological situation of protease regulation of IGFBPs, thus supporting the original 
findings of Clernmons et al (1983). 
Since this initial description of IGFBP-proteases, serum from a wide range of pathological 
conditions has been investigated in a similar manner, and it now appears that such activity 
is not restricted to pregnancy alone. Proteases principally affecting IGFBP-3 have now 
been described in catabolic patients suffering injury or post-operative stress, in various 
cancers (lung, breast, head and neck), poorly controlled diabetics, some subjects with 
severe GH hormone deficency and in some GH-insensitivity syndrome (Laron) patients 
(Holly et al, 1993). In addition, IGFBP-protease activity has also been recorded in the 
conditioned medium from a number of cell types in vitro, including human breast cancer 
cells (Oh et al, 1993), rhabdomyosarcomas, cervical and bladder cancer cells, 
choriocarcinoma, and squamous cell carcinoma of the tongue (Holly et al, 1993). More 
detailed analysis has suggested the enzymes responsible for IGFBP degradation may 
include plasmin from osteosarcoma cells (Campbell et al, 1992), prostate-specific antigen 
(PSA) in seminal plasma (Cohen et al, 1992) and gelatinase-like enzymes in the 
circulation of non-human primates. Experimentally, a wide range of purified proteases also 
have the ability to degrade IGFBPs, such as collagenase, trypsin, cathepsin D, urokinase 
and plasminogen, leading to the suspicion that IGFBP proteolysis is widespread 
throughout the tissues and could be a common regulatory mechanism of IGF action in 
vivo. It would appear that the relatively large molecular size of the IGFBPs coupled with 
the functional importance of their complex folding pattern (most have at least 18 cysteine 
residues involved in forming disulphide bonds) may help explain why they seem 
somewhat vulnerable to proteolytic degradation. 
In this thesis we have described the presence of IGFBP-3 protease in 24-hour serum-free 
conditioned media taken from a normal human dermal fibroblast cell line, Hs68, which 
in addition to that observed in numerous transformed tissues outlined above, further 
suggests the broad nature of this mechanism. Its activity, which could be inhibited by 
EDTA, was evident following sodium dodecyl sulphate (SDS) gel electrophoresis by 
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increased fragmentation of a "'I radiolabelled recombinant non-glycosylated form of the 
binding protein. Moreover, as this technique does not rely upon serum as a source of 
IGFBP-3, we can be assured that the activity originated from the fibroblasts and was not 
due to activation of serum proteases. 
Detection of IGFBP protease has often relied upon observing descrepancies between 
IGFBP immunoassay data and ligand blot analyses. As the latter technique provides a 
measure of 125 I-IGF-I binding affinity of the IGFBP the presence of protease is signalled 
by abnormally low values compared with immunoassay. In our fibroblast model the 
opposite was observed, with apparent IGF-I stimulation of IGFBP-3 seen on ligand blot 
only. As this effect was non-receptor mediated, suggesting the involvement of post- 
transcriptional processes such as protease modulation, we proposed that IGF-I was having 
a negative effect upon protease activity. Subsequently, IGF-I mediated protection of the 
IGFBP peptide from proteolytic degradation was observed, perhaps indicating the 
existance of a simple negative feedback system whereby increasing concentrations of IGF 
peptide lead to more effective inhibitory control by the IGFBPs. Similar IGF-I diminution 
of IGFBP protease activity, as opposed to inhibition of secretion, has now also been 
described in cultured human fibroblast cells for IGFBP-5 (Camacho-Hubner et al, 1992) 
and human breast cancer cells for IGFBP-3 (Oh et al, 1993). 
The physiological role of IGFBP-proteases, which are not necessarily specific to the 
IGFBPs, is somewhat controversial in view of a number of data described by Baxter and 
colleagues. Following neutral size exclusion chromatography of human serum the 
molecular weight distribution of the IGFBP-3 peptide was found to be identical in 
pregnancy and non-pregnancy sera, with approximately 90% in the 150 kDa ternary 
complex (Suikkari and Baxter, 1992). Since the formation of this complex cannot occur 
unless IGFBP-3 binds IGF and u-subunit normally, it was concluded that the IGFBP-3, 
supposedly proteolytically modified in the pregnancy serum, was functionally normal. The 
normal to elevated IGF levels seen in pregnancy serum (Hall et al, 1984) also suggested 
that the IGFBP-3 retained its capacity to bind IGF. It was argued that perhaps partial 
proteolytic hydrolysis lead to a reduction in the stability of the IGFBP, revealed only 
during the harsh biochemical treatment (sodium dodecyl sulphate and high temperatures) 
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used in the ligand blot electrophoresis. ' The necessity in the ligand blot technique for 
IGFBPs to be correctly refolded after their transfer onto nitrocellulose for them to 
recognise "'I-IGF (Binoux et al, 1991) provides indirect support for such a hypothesis. 
Questions concerning the validity of IGFBP-protease analysis were also raised by 
experiments that showed IGFBP-3 in pregnancy serum bound native IGF-I quite normally, 
but failed to bind the 1251_IGF-I used in ligand blotting (Suikkari and Baxter, 1991). 
Although our assay for analysing putative IGFBP-proteases does not rely upon the use of 
serum or assessment of the binding capacity of IGFBP-3, it still relies upon SDS 
polyacrylamide gel electrophoresis. However, we have also shown that fragmentation of 
the recombinant IGFBP-3 peptide (albeit of dissimilar size to that evident after 
electrophoresis) can occur following incubation with fibroblast conditioned medium and 
separation under neutral conditions by size exclusion column chromatography. IGFBP-3 
fragments have also now been recorded by sophisticated antisera in human serum samples 
(Blum 1993, personal communication), suggesting that such a process may reflect a 
physiological mechanism. 
In conclusion, the involvement of proteolytic enzymes in regulating IGF release from 
inhibitory IGFBPs is an attractive concept, particular as it may provide us with an insight 
into the accelerated growth of transformed tissues. It is well recognised for example, that 
an important factor in tumour development and angiogenesis is the increased secretion of 
a wide variety of proteolytic enzymes. From our simple working hypothesis, we could 
speculate that high local protease concentrations may in effect activate 
IGFs, further 
contributing to tumour proliferation. However, the functional significance of these 
enzymes is still largely speculative and demands much greater clarification, not 
least 
because their proposed role is based upon the premise that IGFBPs are 
inhibitory to IGF 
action, which is not always the case. 
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SECTION B. Cytokine regulation of IGFBPs 
9.2. The relationship of TNF(x and IL-I to the IGFs 
With the great interest that now surrounds the existence of possible IGFBP proteases, we 
have investigated the effect on IGFBPs of a major group of signalling peptides, 
collectively known as cytokines, whose pleitrophy of fuctions include the regulation of 
established cell derived proteases and inhibitors. Even without consideration of their 
effects upon proteases the cytokines may be likely candidates to be IGFBP regulators as 
they are often intrinsically involved with alterations in cellular growth and metabolism, 
either directly or through mediation of secondary factors. 
In Chapter 2 of this thesis we have demonstrated that the major inflammatory cytokine 
tumour necrosis factor cc (TNFa) is indeed capable of regulating the secretion of IGFBP- 
3, IGFBP-4 and IGFBP-5 from the normal human dermal fibroblast cell line Hs68. By 
Western ligand blotting TNF(x appeared to be inhibitory to all these IGFBPs, and a dose- 
dependent effect on IGFBP-3 was subsequently confirmed by radioimmunoassay. The 
effective TNFa doses of 0.25 [tg/l and above appear to be physiologically relevant, being 
consistent with those found pathologically in the plasma of sepsis patients (Casey et al, 
1993), and with those that have been observed in the synovial fluid of arthritic joints 
infiltrated with activated macrophages and monocytes (Saez-Llorens et al, 1990). 
Although the immunoassay data strongly suggested that TNF(X was inhibiting the molar 
concentration of IGFBP-3 by altering its secretion, rather than enhancing protease activity, 
investigation of IGFBP-3 (and IGFBP-4) gene expression revealed that there was no 
parallel reduction in mRNA abundance during the 24 
hour incubation period. This 
therefore consequently suggested the existence of some form of post-transcriptional 
mechanism in this effect. 
In agreement with the immunoassay results, we could find no 
direct evidence to implicate 
TNF(x-induction of IGFBP proteases in conditioned medium. However, it now appears that 
IGFBP proteolysis can be restricted to the cell surface, as demonstrated 
by the activation 
of cell-bound plasminogen by cell surface urokinase plasminogen activator 
(uPA) in 
osteosarcoma cells (Campbell et al, 1993). Although 
in our study there was a reduction 
in cell-bound IGFBPs following the TNF(x treatment, perhaps resulting 
from enhancement 
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of such cell membrane proteases, this could equally result from down-regulated IGFBP 
secretion. Further studies investigating the role of TNF(x in mediating IGFBP gene 
translation and / or secretory mechanisms will therefore be required to fully clarify the 
inhibitory effect of TNF(x. 
In addition to TNF(x, the functionally closely related inflammatory cytokines IL-la and 
IL-16 were also capable of inhibiting IGFBP secretion from our normal fibroblast cells. 
Analysis of IGFBP-3 gene expression showed however, that IL-IB lead to a reduced 
abundance of this mRNA at the end of the 24 hour incubation period, in contrast to 
TNF(x. This was unexpected in view of the many data reporting common second 
messenger systems and regulatory mechanisms employed by the two cytokines, such as 
activation of novel serine / threonine protein kinases and prostaglandin synthesis 
modulation (as reviewed in the Introduction). 
It was found that exogenous prostaglandin E2 (PGE2) could lead to similar inhibition of 
Hs68 cell IGFBP-3, but the addition of a cyclo-oxygenase inhibitor, indomethacin, which 
blocks its synthesis, had no impact upon the TNFa effect. This may be a reflection of the 
high effective doses of PGE2 (some I mg/1) which simply may not be achieved from 
endogenous fibroblast secretion during the 24 hour TNRX incubation. 
The differential effect of TNF(x and IL-IB observed in our model at the molecular level 
is not without precedent however. For example, it has been demonstrated that protein 
synthesis is only required for TNF(x, and not IL- 1 B, mediated up-regulation of low density 
lipoprotein receptor gene transcription in the human hepatoma cell line HEPG2, suggesting 
the activation of distinct signal transduction pathways (Stopeck et al, 1993). Additionally, 
the induction of IIL-16 in human fibroblasts has been observed by Elias et al (1989) to be 
controlled at the gene level by IL- I itself but involves post-transcriptional mechanisms 
for 
TNF(x. 
Not withstanding the apparent divergence in the mechanisms used 
by TNF(x and EL-IB to 
inhibit fibroblasts IGFBP-3 secretion, their effects may have quite wide ranging 
significance on IGF action in vivo. However, to interpret the role that such 
IGFBP 
modulation may have in regulating the IGFs we have to consider 
both their function as 
a buffer or reservoir for the IGF peptide, thus greatly 
increasing its stability, and also their 
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direct regulatory effects upon IGF / IGF receptor interaction at the tissue level. The latter 
point has been addressed by the development of a precise IGF bioassay in this thesis 
using the Hs68 fibroblast cell line. 
The use of various bioassays has previously shown that exogenous IGFBPs, particulary 
IGFBP-3, can act to both inhibit and potentiate IGF-I activity, usually depending on the 
incubation protocol (summarised in the Introduction). By comparing the effect of TNF(x, 
which as we have shown inhibits IGFBP secretion, upon the mitogenic responses to either 
native IGF-I or to a synthetic IGF-I analogue with minimal affinity for the IGFBPs, we 
have now shown that endogenous IGFBPs appear to act in an inhibitory manner at the 
tissue level. Sensitivity of the cells to native IGF-I was increased approximately five-fold 
in the presence of TNFoc, an effect not observed with the IGF-I analogue, confirming it 
as one involving IGFBPs. Recent data from Cohen et al (1993) are in agreement with this 
conclusion, as they demonstrated similar inhibitory activity of an endogenous IGFBP to 
IGF-I mitogenesis in mouse Balb/c fibroblasts transfected with the human IGFBP-3 gene. 
The sensitising effect of TNF(x, and potentially IL-lB also, may have implications in 
determining the metabolic disruption seen associated with these inflammatory cytokines 
in cachetic patients suffering from cancer or chronic infection. Both of these conditions 
produce well characterised changes in carbohydrate metabolism, typically including an 
enhanced rate of glucose utilisation by a number of tissues, that can be mimicked 
by 
intravenous administation of exogenous TNF(x (Lopez-Soriano et al, 1993). As it has also 
been demonstated, experimentally at least, that TNF(x can lead to an impairment or 
resistance of insulin action on glucose disposal in peripheral tissues 
(Lang et al, 1992) it 
seems that another candidate for this effect other than 
insulin must exist. Although TNFoc 
itself may have some function in regulating glucose metabolism, perhaps 
its enhancement 
of IGF-I activity that we have observed in such isolated peripheral tissue 
(skin fibroblasts) 
via alterations in IGFBP secretion may contibute to this phenomenon. 
Caution must be taken however in the interpretation of IGF bioactivity 
data recorded from 
simple in vitro bioassays such as that presented 
in this thesis, as due to their enclosed 
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undynamic nature they fail to take account of the aforementioned stability and trapping 
properties of the IGFBPs which may serve to enhance IGF action. Data gained from such 
assays may therefore be pertinent only to locally derived autocrine or paracrine IGFs, 
whose significance to whole body metabolism and growth is unclear. We must also 
consider the possible degree of cell-type specificity to the effect of TNF(x and IL-IB, 
particularly as in a number of cell systems the IGFs seem to act in an opposing fashion 
to these cytokines. For example, a great deal of data now exists on the ability of TNFoc 
and IL- I to induce or aggravate the tissue destructive processes commonly associated with 
rheumatoid arthritis (Brennan et al, 1992). High concentrations of these inflammatory 
cytokines in the affected limb joints, resulting from infiltrating activated monocytes and 
macrophages, can lead to both local protease synthesis and the inhibition of essential 
connective matrix components, such as proteoglycans and hyaluronan, thus contributing 
greatly to the pathogenesis of the disease. The effect of IGF-I on these proteins is often 
quite the reverse, even antagonising some of the effects of the cytokines, and thus makes 
any extrapolation of our in vitro bioassay data to in vivo pathologies somewhat 
speculative. However, one could argue that if sensitisation to IGF-I by TNFoc modulation 
of IGFBPs is highly restricted to fibroblasts then perhaps this may contribute to increased 
proliferation of this cell-type and the development of fibrosis often observed in the 
arthritic joint. 
Although we cannot quantify the contribution that fibroblast-derived IGFBPs make to the 
circulating concentration of these proteins, the assumption that a cytokine-mediated fall 
in their secretion may lead to a parallel reduction in the serum component must bring with 
it a different interpretation of its effect upon IGF-I bioactivity than that given 
by our 
bioassay. As most (approximately 99%) of the IGFs in serum associate with IGFBPs, and 
most of these in the ternary IGFBP-3 complex, it may be particularly significant that the 
secretion of this IGFBP species is inhibited by TNF(x and 
IL-I. The close correlation 
between IGFBP-3 and the IGFs may mean that the overall effect of these cytokines could 
be to lower the circulating IGF level, thus reducing its overall endocrine potential. 
Further studies are obviously required to investigate the effect of 
TNF(x and IIL- I on 
hepatic IGFBP output, thought to be the primary source of circulating IGFBPs, although 
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it is tempting to hypothesize that a negative effect in serum may be at least partly 
responsible for some of the growth abnormalities and metabolic alterations often observed 
in a number of chronic inflammatory conditions. In juvenile chronic arthritis, for example, 
growth retardation is a common feature (Svantesson 1991). This is especially so in severe 
cases of the disease such as the systemic form with associated polyarthritis, where there 
is an acceleration of epyphysis formation in the active inflammatory joints infiltrated with 
cytokine-releasing macrophages and monocytes. Whilst there are a host of hormonal 
changes which may contribute towards the disruption of growth in these patients, such as 
elevated plasma levels of glucagon, epinephrine, glucocorticoids, adrenocorticotrophic 
hormone, and not least the use of corticosteroid therapy, recent evidence has reported that 
despite normal growth hormone secretory profiles the mean plasma IGF-I levels were 
abnormally low (Allen et al, 1991). This may be the result of course from altered hepatic 
gene expression of the growth factor, as has been observed in response to IL-IB in Leydig 
cell in vitro (Lin et al, 1992), but may also possibly be due to reduced IGFBP secretion. 
Further clinical studies will be required to establish the potential role that the 
inflammatory cytokines have in this effect. 
Another clinical condition which has been associated with elevated cytokine production 
is in the development of graft-versus-host disease (GVHD) following bone marrow 
transplants in recipients with leukaernia (Holler et al, 1990). Excessive release of TNF(x 
and IIL-16 is thought to cause the induction of a shock-like state with consequent tissue 
injury, and an exaggerated and prolonged acute phase protein response (APPR) which 
involves redirecting body protein metabolism away from peripheral tissues towards the 
liver. Achieving positive nitrogen accretion in these patients, or indeed in others suffering 
critical surgical illness or cancer induced cachexia, 
is often not possible by the simple 
provision of calories and nitrogen. Recently, interest 
has arisen in the potential therapeutic 
use of IGFs in view of their well known ubiquitous protein sparing and anabolic actions 
and also from studies that have shown that IGF-I 
infusion into TNFOc treated animals 
results in a marked reduction in protein loss 
(Douglas et al, 1991). High doses of insulin, 
perhaps operating through the type-I IGF receptors, 
have also been reported to reverse the 
toxic effects of this cytokine in a rat model (Fraker et al, 
1989). Data showing 
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considerable reductions in serum IGFs and IGFBPs in human cachetic patients (Davies 
et al, 1991) may suggest that treatment in these animal models was successful because 
they simply replaced the 'lost' IGF fraction. Whether the low IGF concentration is due 
to cytokine mediated alterations in IGFBP abundance, or just follows the disruption of 
nutrient intake (known to inhibit IGF-I gene expression) remains to be established. 
Whilst it is easier from a practical level to consider hormone, growth factor or cytokine 
activity on an isolated basis, it is almost certain that any pathological condition concerning 
TNF(x and IL- I involves a complex interaction between many of these components. For 
example, it is well recognised that signals leading to the release of TNF(X and IL- I may 
also stimulate the secretion of other cytokines, and even the IGFs themselves, from certain 
haernatopoeitic cells. One of these closely related peptides is interferon- gamma (IFN-g), 
which as we have shown in this thesis has the ability individually to inhibit IGFBP-3 
secretion from our Hs68 fibroblasts. However, co-incubation of IFN-g with TNF(x on 
these cells can result in the complete abolition of any IGFBP-3 response. Although this 
may add further confusion to the significance of the TNF(x response, perhaps it may 
indicate that IFN-g acts as part of a homeostatic negative feedback mechanism, whereby 
IGFBP-3 secretion is brought back to normal levels. The fact that these particular 
cytokines appear to have developed such a counter-regulatory mechanism gives support 
to the hypothesis that their mediation of IGFBP-3 inhibition has some physiological and 
perhaps pathological significance. 
9.3. The relationship of TGFB to the IGFs 
The physiological role of TGFB in regulating cell proliferation is generally 
held to be 
inhibitory, although it was first discovered as the factor produced by retrovirus- 
transformed fibroblasts which could support the anchorage-independent growth of normal 
cells. Since this initial discovery however, TGFB has been shown to 
be a potent growth 
inhibitor of epithelial, endothelial, and lymphocyte cells, and may also antagonise platelet 
derived growth factor (PDGF) stimulation of fibroblasts. Following this 
logic, the 
stimulatory effect of TGFO, on Hs68 fibroblast IGFBP-3 secretion, via enhanced gene 
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expression, seems to fit with the view that this binding protein is inhibitory to IGF 
activity. 
The involvement of TGF6 in modulating IGF-I mediated mitogenesis has been reported 
previously, with proliferation of T-47D human breast cancer cells being abolished by 
somewhat large doses (>10 pg/1) of TGFBI and TGFB2 (Zugmeier et al, 1989). Although 
IGFBP-3 was not measured in this study, such retardation of IGF activity could be 
consistent with an increase in IGFBPs. In our study, we have shown that TGFBj reduces 
the sensitivity of our normal human fibroblast cells to stimulation by IGF-I approximately 
ten-fold. No effect of TGFBj was seen on the activity of the LongR3-IGF-I analogue, 
which confirmed its inhibition of the native form as involving IGFBPs. 
It was notable that only IGFBP-3 secretion was increased following TGFBI treatment, with 
similar reductions in IGFBP-4 and IGFBP-5 to that seen in response to TNF(X. The 
opposing action of the two cytokines upon IGF-I activity in these cells suggests the 
importance of IGFBP-3 in these effects, although the TGFBI-induced reduction in the 
conditioned media levels of other IGFBPs may reflect their compartmentalisation into 
additional extracellular matrix (ECM) synthesised in response to TGFB. This would 
provide additional inactive sites for localisation of IGF-I thus reducing its bioactivity 
further, although it should be noted that Jones et al (1993) failed to detect IGFBP-4 in 
foetal. fibroblast ECM. 
The opposing actions of TGFB, and TNF(X (and IL-1) in regulating IGFBP-3 and 
consequently their modulating effects on IGF activity, were not wholly unexpected. 
Many 
actions of TGFB appear to be diametrically opposed to those of 
TNF(X and IIL-I, and 
include positive effects upon bone formation, a general increase 
in the production and 
deposition of ECM components and the stimulation of connective tissue 
formation. 
Perhaps what is surprising in view of the negative effect of 
TGFBj on IGF-I bioactivity, 
is that these effects appear to parallel many of those shown by the 
IGFs themselves. 
TGFB and IGF-I have been detected in significant quantities 
in wound sites and both have 
been shown to aid the healing process. Although one may suspect that 
locally increased 
IGFBP-3, in response to TGFf3, may be detrimental to IGF-I mediated wound 
healing 
there are reports that it may actually enhance the IGF effect. 
Recombinant IGFBP-3, for 
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example, has been shown to slightly increase wound healing when injected alone into the 
site of injury in rat tissue (Mueller et al, 1991), possibly by locally trapping IGFs. In 
addition, treatment with IGF-I together with equimolar ammounts of IGFBP-3 was found 
to be twice as effective as the same dose of IGF-I alone in enhancing all aspects of 
wound healing. Although our bioactivity data seems to suggest that TGFBI can inhibit 
IGF-I activity via increased IGFBP-3 secretion, this may not necessarily be an accurate 
reflection of conditions in vivo therefore. 
213 
SECTION C. Future Obiectives 
Perhaps the overiding message to be gained from the data presented in this thesis is the 
diversity and complexity of IGF / IGFBP physiology. Within a single cell type, in this 
instance human skin fibroblasts, at least three IGFBP species are produced and each may 
be stimulated or inhibited by a variety of factors such as the IGFs themselves and a 
number of cytokines. Regulation of IGFBPs may occur via one or more of a multitude of 
mechanisms, including alterations at the gene expression level or modulation of specific 
IGFBP protease activity. Additionally, the cytokine studies presented in this thesis do not 
take into account the complex interactions between these molecules themselves and their 
associated binding proteins, making the picture even more complex. Clearly then in vitro 
studies of this nature, although providing valuable information, are still very much in their 
infancy and a large number of questions remain as to their physiological implications. 
Although in this thesis we have tried to address the question as to the effect of altering 
IGFBP secretion on subsequent IGF bioactivity, the use of a simple in vitro bioassay may 
be somewhat invalid. We do not know, for example, what is the relationship between 
circulating IGFBPs and those produced at the tissue level, although it is likely that hepatic 
IGF peptide, accounting for the vast majority in the vasculature, arrives at the cell already 
bound to IGFBPs. Obviously, our bioassay model cannot account for this. It may be that 
the action of autocrine / paracrine derived IGFs may be influenced more by variations in 
locally produced IGFBPs (such as that caused by cytokines for example), but we are 
unsure at present as to the overall importance of this source of IGF. 
To answer some of these questions we now therefore plan to extend our studies to include 
some clinical models. In particular, we hope to establish the relationships between the 
cytokines and IGF / IGFBPs in pauciarticular Juvenile Chronic Arthritis patients. 
This 
model seems ideal to take our in vitro work further as 
it is characterised by the 
localisation of inflammatory cytokines to isolated joints, associated growth abnormalities., 
and compartmentalisation of the IGFs and IGFBPs 
between the circulation and synovial 
fluid. We eventually aim to investigate the regulation of local 
IGFBPs within the joints 
by in situ hybridisation and immunohistochemistry and to establish whether 
the cytokine 
effects described in this thesis occur in vivo and are pathologically 
implicated. 
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